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ABSTRACT OF THE THESIS
A DOSIMETRY AND RADIOBIOLOGICAL MODEL FOR INTRAVASCULAR
BRACHYTHERAPY TREATMENT PLANNING
WITH RADIOISOTOPE EMITTING STENTS
by
Maria Alejandra Caceres
Florida International University, 2003
Miami, Florida
Professor Juan Franquiz, Major Professor
The aim of this study was to develop a practical, versatile and fast dosimetry and
radiobiological model for calculation of the 3D dose distribution and radiobiological
effectiveness of radioactive stents. The algorithm was written in Matlab 6.5 programming
language and is based on the dose point kernel convolution. The dosimetry and
radiobiological model was applied for evaluation of the 3D dose distribution of 32P, 90Y,
Re and 177Lu stents. Of the four, 32P delivers the highest dose, while 90Y, "'Re and
"7Lu require high levels of activity to deliver a significant therapeutic dose in the range
of 15-30 Gy. Results of the radiobiological model demonstrated that the same physical
dose delivered by different radioisotopes produces significantly different radiobiological
effects. This type of theoretical dose calculation can be useful in the development of new
stent designs, the planning of animal studies and clinical trials, and clinical decisions
involving individualized treatment plans.
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CHAPTER 1
INTRODUCTION
Coronary artery disease (CAD) is the major cause of death in most western
countries. Approximately 12,800,000 Americans suffer from CAD and nearly 500,000
die from heart attacks caused by CAD (2003 Heart and Stroke Statistical Update,
American Heart Association). Therefore its treatment and prevention is of great interest
to the cardiology community. CAD has been successfully treated with percutaneous
transluminal coronary angioplasty (PTCA). However, restenosis, or re-narrowing of the
artery, remains the major limitation of this technique with rates of approximately 30-50%
(Fischell et al., 2000; Fox, 2002; King, 2002). The use of coronary stents in conjunction
with balloon angioplasty has reduced restenosis rates by 20-30% as a result of their
positive effect on elastic recoil and constrictive remodeling (Fox, 2002; King, 2002).
Despite their success, in-stent restenosis is still a significant problem with stents, and the
stent presence may in fact aggravate neointima formation. High in-stent restenosis rates
represent a major impediment to the success of PTCA (Hehrlein and Kubler, 1997;
Fischell, 1998; Nath et al., 1999; Fox, 2002).
Vascular irradiation, otherwise known as intravascular brachytherapy (IVBT) has
emerged as a prophylaxis for the prevention of restenosis after angioplasty, and is
considered a very promising anti-restenosis therapy (Kuntz and Baim, 2000; Serruys and
Kay, 2000; Sims et al., 2002; Fox, 2002). A radiation delivery platform such as a
radioactive stent provides a mechanism in which mechanical and irradiation benefits can
be combined. The three main components of restenosis identified as early recoil,
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remodeling and neointimal hyperplasia, can all be successfully treated with a radioactive
stent. The stent itself serves as a scaffold, thus maintaining the lumen of the artery open,
even after early recoil soon after the angioplasty procedure. In addition, the ionizing
radiation emitted from the stent has been shown to have positive effects on the reduction
of neointimal growth and negative vascular remodeling (Mintz et al., 1996; Schwartz and
Holmes, 2002).
The safety and efficacy of radioactive stents has been well demonstrated in
several animal studies (Hehrlein et al., 1995; Carter and Laird, 1996; Fischell, 1998;
Carter et al., 1999; John et al., 2000), yet experimental results are inconsistent and
restenosis at stent edges, otherwise known as the "candy wrapper effect", remains a
major problem with this treatment modality (Albeiro et al., 2000b; Fischell et al., 2000;
Serruys and Kay, 2000; Fox, 2002). This can be attributed to geographic miss, excessive
barotrauma during the stent implantation procedure, or inadequate irradiation at the stent
edges due to the rapid dose falloff of the radiation source (Fischell et al., 2000; Serruys
and Kay, 2000; Fox, 2002). It is clear that for radioactive stents to be successful, the
problem of edge restenosis must be overcome. This requires an in-depth evaluation of
different candidate radioisotopes and possibly a combined dose delivery strategy to
maximize radiation at stent edges.
The planning of any radiotherapy treatment is a crucial step in the overall success
of the treatment. Dosimetric analysis is a first and necessary step as it is important to
characterize and optimize the dose that will be delivered to the arterial wall tissue. While
the overall benefits of intravascular brachytherapy are well documented, uncertainties
still remain with uniform radiation delivery, optimal radioisotope, radiation dose, dose
2
rate, initial activity and target tissue (Fischell et al., 2000; Fox, 2002). Ultimately, the
goal of a radioactive stent is to deliver an appropriate dose and dose rate to prevent
restenosis with an acceptable level of toxicity.
In addition to an in-depth dosimetric analysis, an intravascular brachytherapy
treatment planning system should include an a priori evaluation of the radiobiological
effect of the treatment. In IVBT, the dose values reported are those of physically
absorbed dose. However, the real therapeutic effect depends on the radiobiology of the
tissue being irradiated, and therefore other parameters should be considered, such as the
initial dose rate, half-life of the radioisotope being used, repair capability of the tissue,
and the type of tissue being irradiated (Dale, 1985, 1993; Brenner et al., 1996; Hall et al.,
1988, 1999; Brenner and Hall, 2001; Mitchell, 2002). The concept of BED, or biological
equivalent dose, takes these parameters into account for dose calculation. This
comparison of physical absorbed dose and biological equivalent dose is very important,
particularly when comparing the effectiveness of different radioisotopes and could be a
significant factor in dose prescription. Thus far, there is no treatment planning system in
intravascular brachytherapy specifically designed for radioactive stents that takes into
account both the physical dose and the biologically equivalent dose.
1.1 Objectives and Specific Aims
The main objectives and specific aims of this work are as follows:
1. To develop a practical and fast algorithm based on the dose point kernel (DPK)
convolution for calculation of the 3D dose distribution of radioactive stents. This
3
dosimetry model will be equipped to accommodate variations in stent geometry
and dimension, radioisotope(s) and initial activity. Results will be shown as
depth-dose profiles in the longitudinal and axial directions.
2. To develop an algorithm that calculates the 3D radiobiological effectiveness of
the dose distribution of radioactive stents in the form of BED (Biological
equivalent dose).
3. To apply the dosimetry and radiobiological models to stents with the following
radioisotopes: 3P, 90y, 18Re and 17 Lu, and combinations of these, to characterize
the 3D dosimetry of each and demonstrate the potential for use in intravascular
brachytherapy.
4. To validate the dosimetry model by comparing the results of the dose point kernel
convolution with those of Monte Carlo simulations in a 32P cylinder.
1.2 Significance of this Study
This is a development work in which we have implemented an algorithm based
on the DPK convolution that calculates both the physical absorbed dose and BED of
radioactive stents. This model offers the advantage of fast computation times and
versatility in radioisotope selection, stent geometry and dimensions, and initial activity. It
allows the evaluation of different radioisotopes, or combinations of such, for addressing
the problem of edge restenosis and as well as to improve the overall dose distribution of a
radioactive stent. The intention of this model is twofold. It serves as a dosimetry tool to
calculate the three-dimensional dose distribution of the radiation emitted from a
4
radioactive stent, and functions as a radiotherapy treatment planning system by
evaluating the radiobiological damage to the tissue. The model's final results can be used
to aid in the development of industrial designs of a radioactive stents, the planning of
animal and clinical trials, and possibly in the planning of an individualized intravascular
brachytherapy treatment with a radioactive stent.
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CHAPTER 2
BACKGROUND AND RATIONALE
2.1 Angioplasty and Stenting
Atherosclerotic artery disease is primarily caused by accumulation of fatty debris
from the blood in the arteries resulting in a narrowing or stenosis of the arterial lumen,
which consequently compromises blood flow (Nath et al., 1999). Many arteries are
subject to this condition, particularly the coronary arteries, which supply blood to the
heart muscle itself. Stenosis in the coronary arteries can cause much damage to heart as a
result of poor oxygenation of tissues as well as by impairing the heart's electrical
conduction system, which can potentially lead to a life-threatening arrhythmia, ischemia
and myocardial infarction (Fox, 2002).
Aorta
Left Coronary
Artery
Right
Coronary
Artery ! Circumflex
Artery
-\ Left
Arterior
Descending
Artery
Figure 2-1. The heart and its arteries
The late 1950's witnessed the advent of bypass surgery for treatment of diseased
coronary arteries. In 1977, the method of coronary artery bypass graft was introduced and
consisted of taking a segment of a vein from the patient's leg and inserting the graft into
the diseased artery (Fox, 2002). However, these two methods are very invasive since they
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require a major operation that involves opening the patient's chest. In 1977, Andreas
Gruentzig introduced PTCA, or percutaneous transluminal coronary angioplasty, which
consists of the inflation of a balloon catheter in the narrowed area of the coronary artery,
thereby restoring a stable lumen with a diameter similar to that of a normal artery (Figure
2-2) (Fox, 2002; King, 2002).
Paten I ralacd Adventia
Iun~,- 
- - - - - - - - e itito
lumen estrucion *Cwuet Medicine
Figure 2-2. Overview of PTCA procedure
(from: http:I/www.incirculationimagebank.net/O3/).
PTCA, a less invasive and more affordable procedure, proved to be an attractive
alternative to bypass surgery. When compared with coronary bypass graft surgery,
patients treated with PTCA have lower initial costs and fewer complications. However,
restenosis is angioplasty's major setback, limiting the long-term success of the procedure
often requiring repeat revascularization in approximately 30% of patients within six
months (Wurdeman et al., 1998). Of the more than 400,000 angioplasties performed
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every year in the United States, 30 to 40% of them result in a post-angioplasty restenotic
lesion (King, 2002).
The use of intracoronary stenting has revolutionized catheter-based
revascularization of stenosed vessels. Stents are hollow mesh-wire tubes made of
stainless steel or a nickel-titanium alloy that are delivered via the angioplasty balloon or
can be self-expandable and serve as scaffolding to hold the artery open, thereby restoring
blood flow (Fox, 2002). They account for approximately 70-90% of all interventional
cardiology procedures and in conjunction with balloon angioplasty have been found to
significantly reduce restenosis rates as shown by two major trials reported by Serruys et
al. (1994) and Fischman et al. (1994). Stents are purely a mechanical means of preventing
early recoil of the artery, thus creating a larger lumen than PTCA alone. They have
proven effective in treating the first two components of restenosis: elastic recoil and
remodeling. Nevertheless, stents have not been entirely successful in eliminating
restenosis due to tissue proliferation, and have actually been found to stimulate
neointimal hyperplasia in 20-30% of the cases within six to twelve months following
angioplasty (Fox, 2002). In-stent restenosis remains problematic, particularly in smaller
vessels and longer lesions (Janicki et al., 1999) with rates ranging anywhere from 31-
50% as reported by several animal and clinical studies (Fischell et al., 2000).
As a result of these findings, the interventional cardiology community has come
up with a variety of techniques in an attempt to treat or prevent restenosis. Such
techniques include balloon angioplasty, additional stenting or supplementing repeat
balloon angioplasty with excimer laser, high-speed rotational atherectomy and directional
atherectomy (King, 2002). Numerous pharmacological agents with antiproliferative
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properties have been tested for their potential to inhibit restenosis with mostly
disappointing results (Serruys et al., 2001). Strategies consisting of local delivery of
cytotoxic drugs and suicide gene therapy have been unsuccessful because of the risk of
undesired toxicity to surrounding healthy tissues (King, 2002). These genetic and
pharmacological interventions have great potential for success but mechanisms of drug
delivery need much improvement before they can be considered the standard treatment
modality. The use of ionizing radiation in intravascular brachytherapy has significantly
reduced restenosis rates in several randomized trials (Sims, 2002; Kuntz, 2002), and is
therefore considered to be one of the most promising methods for treatment and
prevention of coronary artery restenosis.
2.2 Restenosis
Restenosis is clinically defined as a narrowing of the arterial lumen that is equal
to or exceeds 50% of the lumen diameter in adjacent normal segments of that artery
(King, 2002). The expanding angioplasty balloon can apply pressures of up to 20
atmospheres for time periods ranging from seconds to minutes. Not only does this expand
the lesion site narrowed by plaque, but it can also disrupt and injure the tunicae intima
and media and even the tunica adventitia of the arterial wall (Figure 2-3). Restenosis is
the result of the overstretch injury and exaggerated wound healing response of the
damaged artery wall stimulated by the application of these pressures during the
angioplasty procedure. It is a complex problem, although three main mechanisms are
identified as leading causes (King, 2002).
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A A: Tunica intima
- B: Internal elastic lamina
C: Tunica media
D: External elastic lamina
E: Tunica adventitia
Figure 2-3. Anatomy of the artery wall
The first and most immediate mechanism is elastic recoil, which occurs promptly after
the initial overstretch of the artery and does not seem to progress much beyond the first
few minutes after the deflation of the angioplasty balloon (King, 2002). It represents the
slow return of the overstretched tissue from the expansion of the balloon to its initial
diameter. On average, this has been quantified at 50% of the artery cross-sectional area or
one-third of the lumen diameter (King, 2002).
A second mechanism of restenosis has been identified as that of wound
contracture or remodeling, which occurs in subsequent weeks following PTCA. The
entire artery can become contracted so that the external elastic lamina occupies a much
smaller circumference compared to what it did immediately following the procedure
(Fox, 2002; King, 2002; Wilcox, 2002). Remodeling is in essence the change in artery
diameter following coronary angioplasty, which can either be favorable or unfavorable. A
favorable remodeling occurs when the artery is partially enlargened to compensate for
neointimal growth and plaque. On the contrary, an unfavorable or negative remodeling
occurs when the artery contracts, that is, the diameter decreases in addition to lumen loss
caused by neointimal thickening (Pasterkamp et al., 2000; Schwartz and Holmes, 2002).
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It has been concluded through animal studies that the tunica adventitia plays an extremely
important role in vascular remodeling, because it is this outermost layer that forms a ring
of connective tissue around the artery (Rubin, 2002). The adventitia contributes to
remodeling through a constriction of the external elastic lamina and an accumulation of
myofibroblasts (Wilcox et al., 1996). Furthermore, several animal studies, as well as
some clinical studies supported by intravascular ultrasound indicate that remodeling may
be even more important than neointimal growth in the onset of restenosis (Mintz et al.,
1996).
The third and last mechanism associated with restenosis is that of neointimal
hyperplasia, which normally occurs within the first six months after stent implantation.
Neointimal hyperplasia is characterized by an active and aggressive migration of smooth
muscle cells from the outer layers of the artery and into the lumen, which can cause a
very severe obstruction of the artery (Figure 2-4). It is mainly a proliferative response to
overstretch balloon injury, which causes cracks and tears in the vessel wall (Fox, 2002;
King, 2002). This injury leads to a series of immunological responses in which
monocytes, macrophages and lymphocytes infiltrate the site of injury.
Figure 2-4. Restenosis as a result of neointimal hyperplasia
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Platelet aggregation follows, stimulating the release of certain cytokines such as PDGF,
or platelet derived growth factor, which ultimately results in the proliferation of smooth
muscle cells and myofibroblasts (King, 2002; Sims, 2002). This cascade of events
eventually ends in the migration of smooth muscle cells from their usual location in the
media and/or adventitia, to the intima. In a matter of weeks to months, this healing site
begins to resemble a fibrous plaque as neointimal growth extends in to the arterial lumen
resulting in restenosis.
2.3 Radiation to Treat Restenosis
Intravascular brachytherapy has emerged as an attractive candidate therapy for the
treatment of restenosis and is considered a promising anti-restenosis technology (Kuntz
and Baim, 2000; Serruys and Kay, 2000; Fox, 2002). It involves treating restenosis with a
radioactive source within the arterial lumen. "Brachy" which means "short" in Greek,
implies that a highly localized radiation is applied within short distances in the artery.
Preclinical and clinical studies have generally shown that applying ionizing radiation in
the dose range of 15-30 Gy can significantly reduce the incidence of restenosis in patients
who have undergone angioplasty (Nath et al., 1999). The effects of ionizing radiation
have been thoroughly studied for the past half-century, and its effects on cell death can be
attributed to DNA damage in the form of single-stranded or more importantly, double-
stranded breaks that ultimately result in chromosomal aberrations that prove to be lethal
when the cell attempts division (Mitchell, 2002). This concept has been successfJiy,
adopted by radiation oncologists for the treatment of cancer, and has also been applied
for the treatment of restenosis. The rationale for use of intravascular irradiation to inhibit
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restenosis is based on the increased radiosensitivity of actively proliferating cells to the
lethal effects of ionizing radiation. In intravascular brachytherapy, the most important
mechanistic endpoint is the inability of a cell to clonogenically divide, thereby preventing
restenosis due to neointimal hyperplasia and remodeling (Mitchell, 2002).
2.4 Radiation Delivery Systems
One method of irradiation is that of external beam treatments. Major advantages
of this type of treatment include an extremely uniform dose delivery to the arterial wall as
well as greater accuracy of dose calculations (Fox, 2002). However, because of the nature
of this treatment, it is almost impossible to avoid radioactively treating significant
portions of the heart and other tissues beyond it (Fox, 2002). This presents an undesired
risk since it is well documented that irradiation can potentially induce coronary artery
disease (Stewart et al., 1995). Furthermore, it has been documented that a late effect of
external beam irradiation, when applied at a high rate can result in a fibrosis, leading to
severe carotid or coronary artery restenosis (Silverberg at al, 1978).
2.4.1 Catheter-based systems
Brachytherapy of an intravascular nature for treatment of arterial restenosis can be
delivered via two main platforms: temporary catheter-based systems such as radioactive
ribbons and balloons and permanent implants in the form of radioactive stents. In
catheter-based systems, high-intensity radioactive sources in the form of thin wires,
seeds, or ribbons attached to the end of a specially designed catheter are introduced to the
site of angioplasty (Fox, 2002; Sims, 2002). For example, in a catheter-based y-
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irradiation system, a ribbon containing sealed sources of 19 2Iridium is inserted into a
catheter. An angiogram confirms that the region is in place, covering in entirety the
region of interest, and after 10-20 minutes, the ribbon is removed. The Cordis Checkmate
IRT ois one such system involving 192Ir that consists of an array of cylindrical-shaped
seeds contained in a nylon ribbon (Jani et al., 2002). Alternatively, a catheter-based f3-
irradiation system delivers O-emitting radioisotopes such as 3p or 90Y to the treatment
area for a period of 2-5 minutes. The Guidant GalileoTM Intravascular Radiotherapy
System is an example of a catheter-based system that uses a 32P wire as the radiation
source (Raizner et al., 2002). Radioactive sources are also encased to form a "seed train"
that can be delivered to the lesion site using a manual or hydraulic system. The Novoste
Beta-CathTM is one another device that uses a hydraulic system to deliver the beta-
emitting 90Sr/90Y radioactive seeds to the lesion site using a closed catheter (Jani et al.,
2002). The Cordis CheckmateTM system and Novoste's Beta-CathTM system were FDA
approved in 2000, and the Guidant GalileoTM system was approved in 2001. All of these
systems are currently implemented in a clinical setting. These methods have given
satisfactory results, although centering and geographic miss pose some problems.
Since the angioplasty procedure entails the insertion of saline-filled balloon into
the artery, this suggests that a balloon filled with a radioactive liquid, such as liquid 186Re
can be a feasible method of delivering radiation to the artery wall. The main advantage of
radioactive liquid-filled balloons, perhaps over all of the other types of brachytherapy, is
that it can be applied to all arteries, regardless of size, degree of calcification and
tortuosity (Fox, 2002; Weinberger and Knapp, 2002). In addition, a radioactive liquid-
filled balloon guarantees adequate centering in the arterial lumen, feat that is not as easily
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achieved in catheter-based systems. However, there are some concerns about balloon
rupture, which could deliver high doses of radiation directly into the patient's blood
stream. Because there is such risk in spillage of radioactive liquid, and the potential
damage to the patient and lab personnel, as well as the logistics involved in filling,
handling and disposing of radioactive solutions, radioactive liquid-filled balloons proves
to be a cumbersome technique and not the method of choice of many clinicians (Fox,
2002).
The use of gas-filled balloons in intravascular brachytherapy has also been
explored. This approach is similar to the liquid-filled balloon approach but with the
radioactive material in a gaseous state. 13Xenon has been investigated as a candidate for
this type of radiation delivery system (Apple and Waksman, 2002). The balloon dilation
catheter is filled with the radioactive gas and dilated at the lesion site so as to deliver the
radiation dose to the arterial wall. The inert chemical property of 133Xe offers enormous
safety and limits radiation exposure to the medical staff. Other novel approaches being
tested for intravascular brachytherapy include the catheter-based soft x-ray generator and
the 99mTc injecting system (Fox, 2002; Apple and Waksman, 2002).
2.4.2 Radioactive Stents
Permanent implants in the form of radioactive stents have been a very attractive
proposal since their foundation (Hehrlein and Kubler, 1997; Fischell, 1888;2000; Fox,
2002). A radioactive stent eliminates the need of a repeat revascularization, as the
angioplasty/stenting procedure is done in concurrence with the irradiation procedure.
Furthermore, procedures in the catheterization lab are identical to those already
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performed, as radioactive stents are delivered via the femoral artery to the target site in
the same manner as non-radioactive stents. Radioactive beta-emitting stents offer the
advantage of uniform dosimetry, safety for laboratory personnel, as well as easy storage
(Fox, 2002). Because it is a permanent implant, problems with adequate disposal of
radioactive materials are eliminated. Adequate centering of the radioactive source, which
is a problem with radioactive wires and seeds, is not an issue with radioactive stents
because of the direct contact with the vessel circumference (Fischell, 1998; Fox, 2002).
Artery wall irradiation after radioactive stent implantation is maintained in the days and
weeks following the procedure, thereby covering the whole period of cell proliferation
(Fischell, 1998; John et al., 2001).
The activity of a radioactive stent is up to 10,000 times lower than the activity
levels of other sources used in catheter-based vascular brachytherapy (Hehrlein and
Kubler, 1997; Fischell, 1998). Although stent activities are much lower, the total dose
delivered by a permanently implanted stent is similar to that of a high activity radioactive
seed. The main distinction between the two is the time sequence in which the radiation is
delivered. For example, a 1pCi 32P stent, which has a half-life of 14 days, delivers the
same total dose as a 5-minute exposure of a 6 mCi 32P wire (Amols, 1999). Furthermore,
this low level of activities allows manual handling and eliminates the need for
radioisotope licensing in the catheterization lab. Radioactive stents have an inherent
dosimetry advantage in that the radioactive source is in intimate contact with the artery
wall. However, the dose distribution is extremely nonuniform due to the gridded nature
of stent geometry.
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Radioactive stents combine both mechanical and therapeutical benefits for
restenosis prevention. The stent itself, due to its scaffolding action, supports the artery
wall, while radiation prevents growth of smooth muscle cells that can occlude the lumen
of the artery. In addition, it has been observed that ionizing radiation, or vascular
brachytherapy can have some favorable effects on treating the remodeling aspect of
restenosis by inhibiting the proliferation of the adventitial myofibroblast (Rubin, 2002).
When looking at the post-angioplasty artery as a wound undergoing a process analogous
to wound contraction, the adventitial myofibroblast is believed to occupy a pivotal role in
constricting the blood vessel, thus leading to a lumen narrowing in the case of a negative
remodeling (Scott et al., 1996; Wilcox et al., 1996; Rubin, 2002). In consequence, it can
be postulated that a radioactive stent, with proper usage, radioisotope selection and initial
activity, can be extremely promising in treating the three mechanisms associated with
restenosis: early recoil, due to the scaffolding action, and constrictive remodeling and
neointimal hyperplasia as a consequence of ionizing radiation.
2.4.2.1 Preclinical Studies (Animal Studies)
Stent-based coronary brachytherapy to prevent restenosis has been studied in
preclinical and clinical trials for almost a decade. Several animal models have given
testimony to the fact that radioactive stents are capable of reducing or even eliminating
neointimal hyperplasia. In 1994, Fischell et al. demonstrated that a 32P impregnated stent
wire with an activity of 0.006 pCi inhibited smooth muscle cell proliferation in cell
culture. Hehrlein et al. (1995) were the first to describe the use of radioactive stents,
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which they implanted in non-diseased rabbit iliac arteries. The results of their study,
using radioactive stents with low doses (max. 35 pCi) potently inhibited smooth muscle
cell proliferation and neointimal hyperplasia in the rabbit model (Hehrlein et al., 1995).
They found that neointima formation was markedly reduced by the implantation of the
radioactive stent in a dose-dependent fashion. In the control model, in which a non-
radioactive stent was implanted, there was a 30 2% neointimal growth compared to the
0.5 0.1% seen in the model with the radioactive stent implanted (Hehrlein et al., 1995).
Carter and Laird (1996) reported studies in swine models using low-dose
irradiation from n-particle emitting stents. The initial stent activity was 0.14 pCi and the
dose delivered to the arterial wall was approximately 3 Gy over the 4-week study period.
A 37% reduction in neointimal area and a 32% reduction in stenosis for 0 -particle
emitting stents were observed when compared to non-radioactive control stents at the end
of the 4-week period. In another set of experiments by Carter et al. (1999), the effects of
beta particle-emitting stents with activities ranging from 3-23 Ci were evaluated in
normal pig coronary arteries. At 28 days from implantation a reduction in the medial and
neointimal cell density was observed which inversely correlated with the radiation dose.
Neointimal proliferation was also lower for the radioactive stent as compared to the
nonradioactive stent. Several other studies have been performed in different animal
models such as the porcine and canine model with overall inconsistent results (Carter and
Fischell, 1998; Virmani et al., 2002).
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2.4.2.2 Clinical Studies
Animal models can only partially mimic the restenosis process after angioplasty
and stent implantation in humans. In 1996, IRIS (Isostent for Restenosis Intervention
Study) was the first study done on patients using the 32P Palmaz-Schatz stent. In this
study, 30 patients underwent successful stent placement with an activity between 0.5 and
1.5 pCi (Hehrlein and Fischell, 2002). Thirty days post-treatment, there were no adverse
effects, and in fact a considerable expansion of the arterial lumen was observed.
However, a 6-month follow-up revealed a 31% restenosis rate.
The Milan dose-response study (Albeiro et al., 2000a), which ran from October
1997 to October 1998, explored the short and intermediate term results of the 32P stent in
patients with coronary artery disease. Eighty-one patients were used for this study, and
they were divided into three groups depending on the activity level of the stent: 0.75-3.0
pCi (Group 1), 3.0-6.0 gCi (Group 2) and 6.0-12.0 Ci (Group 3). This trial demonstrated
the safety of using these ranges of activity levels. The low incidence of late thrombosis
was also observed. After a 6-month follow-up, no deaths occurred and intra-stent
neointimal hyperplasia was reduced in a dose-related manner, but intra-lesion restenosis
rates were 52% in Group 1, 41% in Group 2 and 50% in Group 3 (Albeiro et al., 2000a).
This trial generated disappointing results in that they identified the "candy wrapper
effect", or edge restenosis. It is hypothesized that decreased radiation doses at the edges
of the stent might actually stimulate restenosis, while higher doses in the middle inhibit it
(van der Giessen et al., 2001). Barotrauma at stent edges during the implantation
procedure might be a factor as well. A second phase of this trial was initiated using
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higher activity levels, but yielded similar results despite less aggressive implantation
techniques using pressures of only 8 to 10 atm (Albeiro et al., 2000b).
Other European clinical studies involving the implantation of 32P radioactive
stents were conducted in Vienna and Rotterdam. The Rotterdam group did not observe
cases of edge restenosis in 32P radioactive stents of 0.75 to 1.5 pCi (Hehrlein and
Fischell, 2002). However, they reported a restenosis rate of 43% occurring only at stent
edges in an additional group of lesions treated by 32P radioactive stents of higher
activities in the range of 6 to 12 pCi. The Vienna group treated 36 patients with 32P
radioactive stents with activities between 5.36 and 20.77 pCi. At a 6-month follow-up, 15
patients showed signs of edge restenosis (Hehrlein and Fischell, 2002).
2.4.2.3 Edge Restenosis or "Candy Wrapper Effect"
Despite much hope and hype and an overall initial success in reduction of
neointimal area, some clinical and animal trials have exposed several pitfalls pertaining
to the radioactive stent. Most notably, the biggest hindrance of radioactive stents, is that
of edge restenosis, nicknamed the "candy-wrapper effect" because of its appearance in an
angiogram. Figure 2-5 shows the tight stenosis at the stent edges, which are marked by
arrows. This phenomenon has generally been observed 2 to 3 mm distal and proximal to
the stent (Albeiro et al., 2000b; Serruys and Kay, 2000; van der Giessen et al., 2001).
This is believed to be the cause of inadequate dose delivery to target tissues after they
have been injured by the angioplasty procedure. The angioplasty balloon that delivers the
radioactive stent is usually longer than the stent itself resulting in barotrauma at the edges
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to which there is no radiation and therefore no inhibition of cellular growth. Experimental
results from animal models have also suggested that low doses of radiation might in fact
A B C
1 ,.
Figure 2-5. Edge restenosis as seen in an angiogram (Circulation, Albeiro et al., 2000b).
stimulate neointimal growth (Amols, 1999a). Another cause is geographic miss, or failure
of completely irradiating the target lesion. Finally, edge restenosis can also be a result of
the basic physics of a radioactive stent. At the ends of the stent, the dose will be very
close to 50% of its value at the center due to steep dose gradients, especially in the case
of beta emitters (Amols, 199 9a; Serruys and Kay, 2000; van der Giessen et al., 2001).
2.5 Beta and Gamma Emitters: Radioisotopes in Intravascular Brachytherapy
The radioisotopes used in intravascular brachytherapy include both beta and
gamma emitters. Radiation energy from beta emitters in characterized by high energy
with low tissue penetration applied in short time periods, which diminishes rapidly with
distance from the source. Nevertheless, beta particle emitters in contact with the arterial
wall are for the most part sufficient to induce cell death of superficial smooth muscle cell
layers in the intima and media, but not the adventitia (Amols, 1999a; Fox, 2002).
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However, the limited depth of penetration of beta emitters poses the advantage of
minimal exposure to adjacent tissues.
Yet, despite the fact that beta emitters are practical for use in the catheterization
lab because of minimal exposure to remote tissues and staff, they can also present some
challenges for effective delivery of radiation to the arterial wall in the case of large,
highly calcified vessels, and the rapid fall-off dose may also be problematic. Gamma
emitters, on the other hand, offer the advantage of higher tissue penetration, making it
ideal for larger vessels with highly calcified plaques. Gamma radiation generally has
lower energy, but it must be applied for larger periods of time for maximum effectiveness
(Amols, 1999a; Fox, 2002). As a result, much more precaution must be taken to shield
the surrounding tissues as well as the catheterization lab personnel. Beta emitters also
yield higher doses per emission than y-sources and hence the specific activities required
for f3-emitters are at least an order of magnitude lower than for y-sources. It is also
important to note that the dose rate for a given activity of a beta-emitter is much greater
than for a similar activity of a gamma-emitter (Fox, 2002). Therefore, a beta-emitting
source has a much lower activity than a gamma-emitting source. Table 2-1 shows the
properties of some the radioisotopes used in IVBT.
In IVBT, particularly in the case of a permanent implant such as a radioactive
stent, the selection of the radioisotope in critical. A compromise between an acceptable
half-life, energy, range and ease of production is necessary for a cost-efficient and
feasible production of a radioactive stent. The ideal radioactive source would be one that
displays a low energy gamma emission, which would provide a uniform dose distribution
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Table 2-1. Properties of Radioisotopes used in IVBT (animal trials, clinical trials,
theoretical calculations).
Isotope Emission Half-life Average Maximum
Type Energy Energy
(MeV) (MeV)
P Pure - 14.28 d 0.695 1.709
91Y 3- 2.67 d 0.76 1 2.282
192 73.8d 0.224 0.672
NA 0.317
133Xe 5.243 d 0.115 0.346
73 NA 0.081
188Re 16.94 hr 0.706 2.118
7 1NA 0.155
103Pd x-rays 16.99 d NA 0.040
12 I x-rays 59.4 d NA 0.046
48V 16 d 0.230 0.690
V -NA 0.511
_ _Cs 7 9.7 d NA 0.030
and negligible doses to surrounding healthy tissues. Similar dose characteristics could
also be obtained with a very high-energy beta emitter (Amols, 1999a). Unfortunately,
these ideal sources do not exist as most commonly available gamma sources are of too
high an energy, or too low an activity and dose rate. Similarly, most beta sources have
too low an energy, too short a half-life, or excessive amounts of gamma contamination
(Amols, 1999a). In addition, half-life considerations are extremely important. It should be
long enough to cover the period of cell proliferation after the onset of restenosis, yet short
enough to not cause any detrimental effects as a result of permanently remaining in the
body.
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2.6 Treatment Planning for Radioactive Stents
Unlike the situation with a cancerous tumor, where one is interested in killing all
cells, intravascular brachytherapy does not set out to completely liquidate all the cells
responsible for causing artery obstruction. Doing so would mean application of higher
than wanted doses which would inevitable lead to injury to unwanted tissues, leading to a
number of complications and adverse effects. Instead, the inherent focus of this treatment
is to limit the proliferative potential of a group of clonogenic cells, whether they are
smooth muscle cells from the media or adventitia (Brenner et al., 1996; Hall et al., 1999).
Because smooth muscle cells are somatic cells, they have limited cycles of cell division
before they naturally senesce, and therefore do not require the high doses of radiation that
cancerous cells for effective treatment of the problem. It is only necessary to inhibit the
proliferation of a considerable portion of the cell population so that the surviving fraction
of cells runs out of reproductive ability before sufficient progeny are produced to cause
restenosis (Brenner et al., 1996; Hall et al., 1999). This presents the notion of a
therapeutic window, a rather narrow margin between the radiation dose required to
effectively treat the problem, and that which can result in undesirable damage to the
artery wall. A very low dose, such as 10-12 Gy might not be enough to effectively treat
the problem, or might delay rather than prevent restenosis, while a dose near 30 Gy might
be excessive, causing unwanted injury to healthy tissues. It is believed that a dose
somewhere between 15-30 Gy might be enough to inhibit restenosis (Hall et al., 1999;
Nath et al., 1999).
The use of a treatment planning system in vascular brachytherapy can provide the
interventional cardiologist with a tool for prescribing, evaluating and reporting the dose
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given to a patient, or an animal in the case of animal studies. It can provide a means of
documenting the treatment given, as well as further customizing the radiation dose for an
individualized treatment plan (Fox, 1999). It may also allow an opportunity to
retrospectively evaluate the influence of dose on the success or side effects of the
treatment. Most importantly, this type of treatment planning process can be used to
evaluate different treatments and give an a priori evaluation of the overall effectiveness
of the treatment.
2.7 Radiobiological Considerations
Designing an optimal treatment for brachytherapy, or any other radiotherapy
treatment for that matter, requires a detailed knowledge of radiobiological principles.
Although animal studies and clinical trials provide the physical evidence of the efficacy
of a treatment, a radiobiological perspective is necessary in understanding the
fundamentals of any in vivo study. Radiation can inhibit restenosis because it kills cells
by direct ionization of DNA, or by the creation of free radicals, which can interact with
nearby water molecules (John et al., 2001; Mitchell et al., 2002). The free radicals and
reactive ions produced by indirect effects, or radiation deposited directly can alter the
purines and pyrimidines (bases) in DNA resulting in point mutations and cross-links, as
well as disruption in the integrity of the phosphodiester bonds which join the nucleotides
in each of the DNA strands. This can lead to double or single-stranded breaks in the
DNA, translocations, and chromosome aberrations in the form of dicentrics and rings, all
of which can potentially limit the proliferative potential of the cell eventually resulting in
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cell death (Hall, 1988, 1999; Mitchell, 2002). These ideas are illustrated in figures 2-6
and 2-7.
TARGET: DNA
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Figure 2-6. Mechanism of Damage of Ionizing Radiation
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Figure 2-7. Direct and Indirect Action of Ionizing Radiation
Several studies in the 1960's demonstrated that certain portions of the cell cycle
are more susceptible to radiation effects, with cells in G2 and mitosis stages of the cell
cycle being the most radiosensitive (Hall et al., 1988). Damage occurs more readily when
the chromosomes are greatly condensed in mitosis. This is important because tumor and
cancer cells, or rapidly proliferating cells, undergo division more often than normal cells,
and are therefore more susceptible to damage. This property is the foundation of why
radiation is so successful in treating cancer. Therefore, rapidly dividing cells in the
neointima are more susceptible to radiation and the reason why this treatment is
successful in treating restenosis (Mitchell, 2002).
Biological tissues have the ability to accumulate and repair radiation damage. In
terms of modeling the lesions to DNA, there are two main kinds of lesions: repairable
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lesions and irreversible lesions (Mitchell, 2002). A repairable lesion has a good
probability of being repaired or misrepaired by at least one biochemical repair pathway.
An irreversible lesion, on the other hand, has no chance of being repaired, and can be
further sub-divided into fatal lesions and non-lethal mutations, which eventually result in
cell death (Mitchell, 2002). Low levels of radiation can lead to a delay in cell division
from which the cell can gradually recover and continue to divide as normal. Higher doses
of radiation may inhibit cell division permanently, thus not allowing the cells to divide,
ultimately resulting in death.
Central to the subject of radiobiology is the linear quadratic formalism or LQ
model. Dose-response or dose-survival curves for all dose rates are fit to the linear
quadratic formalism, which expresses the surviving fraction (S) of cells as a function of
dose (D) (Dale, 1985; Brenner, 1997).
S =e-aD1
The constants a and P are characteristic of a given cell type and have units of Gy and
Gy 2 respectively. The ratio a/P is expressed in units of Gy and is of great clinical
significance because it is a measure of the fractionated sensitivity of a tissue (Dale,
1993). They are also measures of two separate cell kill processes, type A and B (Giap et
al., 1999). Type A damage is characterized by two critical targets (DNA strands) being
hit simultaneously by a single radiation event resulting in cell death without repair (Dale,
1985; Giap et al., 1999). Type A damage is directly related to the linear component of the
linear-quadratic formalism, ad. In Type B, which is related to Pd2 damage, each of the
two critical sites is hit in sequence by different radiation events. When one of the two
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critical sites is damaged, there is evidence of sublethal damage. Over a period of time, the
cell can either be killed by accumulation of sublethal damage or it can be repaired. At
lower doses, the linear component dominates, while at higher doses, the quadratic term
starts to dominate (Mitchell, 2002).
The LQ model is used for the radiobiological assessment of a particular radiation
therapy. The biological effects of radiation are dependent on the parameters BED and RE
which are derived from the LQ model, as they take into account a and R constants of a
given tissue, or more importantly the ratio of the two. Biological equivalent dose (or
(BED) (also referred to as ERD or extrapolated response dose), is a single-figure measure
of the biological effectiveness of a dosing strategy on a particular tissue (Dale 1985,
1993). The concept of BED is key in comparing different treatments, but the calculation
of BED is made through another fundamental LQ parameter RE, or relative effectiveness
per unit dose (Dale, 1985, 1993; Giap et al., 1999). RE is dimensionless and measures the
effectiveness of a given unit of dose to cause a specific biological endpoint taking into
account the dose rate and repair capability of the tissue (Giap et al., 1999). BED (units
are Gy) is equal to the product of RE and the absorbed dose at a specific point (Dale,
1985, 1993; Giap et al., 1999). Thus far, there is no radiobiological assessment of
radioactive stents employing the concepts of BED and RE for comparing dosing
strategies with different radioisotopes.
2.8 Target Tissue
There is yet to be a consensus as to what is the target tissue to be irradiated. In
addition, a tolerance dose for the artery wall has not been established. It had long been
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speculated that neointimal growth was the result of proliferation of smooth muscle cells
in the tunica media (Hehrlein et al., 1995). This fact has been challenged by the tunica
adventitia as the source of proliferating cells, in particular the adventitial myofibroblast,
which migrates through the media in to the arterial lumen (Scott et al., 1996; Wilcox et
al., 1996, 2002). The different layers of the artery wall and their respective thicknesses
are shown in Figure 2-8.
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Figure 2-8. Thickness of artery wall layers
If this in fact is the case, then an effective radiation dose needs to be delivered at least 1
to 2 mm from the artery lumen (Fox, 2002). Further studies on the cellular cascade of
events associated with restenosis present two main hypotheses. One points to the
myofibroblast as being the target cell of interest, while the other focuses on the
monocyte-derived macrophage (Rubin et al., 2002). The monocyte-derived macrophage
has received much attention because it is a key manufacturer of a number of cytokines
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and growth factors responsible for the activation and promotion of myofibroblast or
smooth muscle cell proliferation (Rubin et al., 1998, 2002). At present, most investigators
believe the target lies in the adventitia with either macrophages or myofibroblasts being
the cells responsible for triggering the complex biological processes that ultimately lead
to medial smooth muscle cell proliferation and restenosis (Wilcox et al., 1996, 2002; Fox,
2002; Rubin et al., 2002). This further illustrates the overall complexity of the restenosis
problem, and the interplay of factors that must come together in order to render any anti-
restenosis treatment successful. In general, for restenosis modeling purposes, it is correct
to deliver radiation up to 3 mm from the arterial lumen (Fox, 2002).
2.9 Dosimetry of Radioactive Stents
Dosimetric considerations in all forms of brachytherapy are extremely important.
In the case of the radioactive stent, the matter is further complicated by the fact that the
stent is a permanently implanted device. This implies a careful consideration of a
particular radioisotope's half-life, as well as the initial activity of the stent. The
dosimetric characterization of the radiation field in both longitudinal and radial
directions, of any brachytherapy source is generally the first step prior to animal and
clinical studies that might pave the way for future commercialization of a particular
treatment.
In conventional brachytherapy dose delivered to a target point is specified at a
distance of 1 cm from the source (Nath et al., 1999). Consequently a large volume of
experimental and theoretical dosimetry data is available for source to target distances of 1
cm or more and the dosimetry of both gamma and beta emitters is well established at
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these distances. In vascular brachytherapy, the distribution of radiation dose around the
source is difficult to measure because the sources have very small diameters and the dose
distribution must be determined very close to the source, usually less than 5mm (Amols,
1999a; Fox, 1999; Nath et al., 1999). At such small distances the dosimetry is
complicated due to the steep dose gradients, low energy secondary radiations and self-
shielding effects of the radioactive source. The uncertainties in dosimetry are larger for
low-energy beta-emitting sources than for gamma sources due to the limited range of the
beta particles and the effect of heterogeneities in the medium (Amols, 1999a; Nath et al.,
1999).
The near-filed dose distributions of a radioactive stent can be determined by both
theoretical and experimental methods. Theoretical calculations are obtained from dose
point kernel calculations and from Monte Carlo simulations. The dose point kernel
(DPK) describes the distribution of absorbed dose around point-isotropic sources of
electrons and beta particles in water (Berger, 1971; Prestwich, 1989; Cross, 1992). In
1995, Prestwich et al. presented the results of a dose distribution study around a uniform
cylinder of 32P using the DPK method. In this model, the source of radioactivity was
uniformly distributed on the two-dimensional surface of a cylinder. The stent can be
modeled as a cylinder, although it in fact possesses a quite intricate and detailed
geometry. The gridded architecture of a stent is an important consideration of these
dosimetric determinations as the radiation is expected to be higher in the proximity of the
struts than in the spaces in between struts. To overcome this problem and to elaborate on
the model presented by Prestwich et al. (1995), another group of researchers calculated
the near-field dose of a 3P stent using the dose point kernel and a cylindrical coordinate
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system to simulate the wire mesh geometry of the stent (Janicki et al., 1997). The dose
distribution generated by the beta particles emitted from the radioisotope was computed
at distances ranging from 0.1 to 3 mm from the stent surface. A later study by Janicki et
al. (1999) introduced a new model taking into account the scaling property of the dose
point kernel function which can be extended to a heterogeneous medium with a density
different to that of water. Because in a realistic artery the presence of plaque can allow
attenuation of the beta particles, incorporating plaque density in a theoretical model has
some advantageous effects.
Monte Carlo simulations have also been used by several groups of investigators to
study the dose distributions surrounding radioactive stents (Li et al., 1998; Reynaert et
al., 1999, 2001; Fox and Henson, 2000). Monte Carlo codes, in particular the MCNP
(Monte Carlo N-Particle Transport Code System), is a multimaterial, 3-D, arbitrary
geometry, electron/photon/neutron transport code developed at the Los Alamos National
Laboratory (Li et al., 1998). This type of theoretical simulation can be achieved by
specifying the specific energy assumed for the radioactive source, the architecture
assumed for the stent, the specific depth assumed for the radioactive species in the stent
material, and the inclusion or exclusion of nonhomogenous material or the absorption or
scatter of stent struts (Coffey and Duggan, 2002).
2.10 AAPM Task Group 60 Report
The AAPM (American Association of Physicists in Medicine) Task Group 60 has
developed a series of recommendations based on several early dosimetric studies for dose
specifications in intravascular brachytherapy (Nath et al., 1999). It is recommended to
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use 0.5 mm from the surface of the stent as the reference depth and a total treatment time
of 28 days as a common framework for the dose field characterization (Nath et al., 1999).
A time period of 28 days is reasonable because it falls within the time frame of restenosis
onset, namely the first few weeks to two months after stent placement. The desired
objective of the dosimetric characterization of a radioactive stent is to determine the 3D
dose rate per unit of activity around the stent deployed in an angioplasty balloon catheter,
as well as to demonstrate the circumferential and longitudinal uniformity of the dose
delivered by the stent (Nath et al., 1999). Furthermore, the AAPM recommends that the
three-dimensional dose distributions around the stent be carefully determined before
animal and clinical trials. The model described in this study will take into account the
recommendations of the AAPM, although it will be equipped to calculate the dose at a
depth less than 0.5 mm and times greater or less than 28 days. The results presented in
this work are for lifetime doses delivered by the stent under the assumption that the stent
is a permanent implant unless otherwise stated.
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CHAPTER 3
MATERIALS AND METHODS
This chapter provides an outline of the development of the radiation dosimetry
and radiobiological model that was used to calculate the 3D dose distribution and
radiobiological effectiveness of a radioactive stent. It includes the set of equations that
govern the dose point kernel convolution method, the calculation of beta and gamma dose
point kernels, and the equations of the radiobiological model. In addition, information on
the stent geometry that was used, as well as details on the algorithm using the dose point
kernel convolution and the different dose calculations that were done is also provided in
this section. This chapter closes with the validation of results obtained from the dose
point kernel convolution method to those obtained through Monte Carlo simulations.
3.1 Radiation Dosimetry Model
The radiation dosimetry model is based on the dose point kernel (DPK)
convolution. Several investigators have used the dose point kernel for calculation of 3D
dose distribution of radioactive stents (Prestwich, et al.., 1995; Duggan et al., 1998;
Janicki et al., 1997, 1999). The dosimetry model is equipped for the calculation of
absorbed dose at any specified point defined radially and longitudinally from the surface
of the stent. In addition to its versatility regarding stent geometries, it will also allow dose
calculation of stents with different radioisotopes or combinations of radioisotopes and
initial activities. In this project, the dosimetry of a 17Lu, 32P, 188Re, and 90Y stent was
determined as well as that of combinations of these radioisotopes.
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3.1.1 Dose Point Kernel Convolution
Absorbed dose due to any source can be computed by splitting the extended
source into a series of point sources and summing up the individual contributions
(Berger, 1971; Janicki et al., 1997). In other words, the dose at each target point in tissue
will receive contributions from each point source. The initial activity is distributed
uniformly over the surface or the volume of the stent. The stent is the source of radiation,
and is represented as a series of point sources defined by a set of coordinates (x,y,z). This
operation can be expressed in the form of a convolution integral as follows:
D(r,t)= S-x[1-exp(-2t)]xf DPK r-r ls, (1)
where D(r,t) is the absorbed dose at a particular point in space and time, AOis initial
activity of the stent uniformly distributed over the stent surface, A (h-1) is the decay
constant of the radionuclide, S is the total active stent surface area (mm 2), t (h) is the time
interval after stenting, DPK is the dose point kernel function for a specific radioisotope,
and r - r' is the distance (mm) between a source point on the stent and the source point
where the dose is calculated. The dose rate at any time t after stent implantation is
dependent on the initial activity and is given by:
b(t) = Doe-', (2)
where A0 is the initial dose rate given by:
Do(r)= x fDPK(r-r)s (3)
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The total absorbed dose at time t is obtained by integrating equation (2).
D(t) = tDoe-dt (4)
- Do
In the case of a radioactive stent that is inserted permanently in the patient, time t is equal
to infinity. The dose values obtained are the lifetime doses of the stent until complete
decay of the radioisotope. Therefore, Equation (4) is converted to:
D(r) = -- (5)
The source points, which are the coordinates defining the stent itself, are
designated as r' (mm)= (x', y', z'). The target points, or the points defining the artery
wall depth at which the dose is calculated, are defined by the coordinates r (mm)= (x, y,
z). The z coordinates will cover the length of the stent and extend 5 mm beyond the edges
of the stent at intervals of 0.125 mm. The x and y coordinates extend radially from the
surface of the stent up to a distance of 5 mm from the surface of the stent. Absorbed dose
was calculated at intervals of 0.125 mm. Dose values were calculated starting from 0.1
mm from the stent surface. The distance between source and target points is given by the
following equation:
r = (-x')2+ (y-y')2 + (z-z')2  (6)
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3.1.2 Dose Point Kernel
The dose point kernel (DPK) describes the spherically symmetrical dose-rate
distribution of absorbed dose around an isotropic source obtained from Monte Carlo
simulations of beta or gamma radiations in water (Berger 1971; Giap et al., 1995). The
DPK function K(r, r') defines the dose rate at a point r delivered by a point source of unit
cumulative activity located at r'. For radioisotopes having beta and gamma emissions, the
dose point kernel consists of two components. Therefore the absorbed dose in the target
tissue has contributions from both beta and gamma radiations. This additive expression
for DPK is as follows:
DPK(r, r')= DPK,(r, r')+DPK,(r, r'), (7)
where DPK, (r, r') and DPKg (r, r') are the DPK for the gamma and beta radiations
respectively. The following table illustrates the main properties of the radioisotopes used
in the radiation dosimetry model. Of note is the fact that 32P and 90Y emit pure beta
energy, therefore the dose delivered is given only by the convolution over the target
points of the beta DPK. On the other hand, even though '"Lu and 188Re decay by mainly
by beta emissions, they also emit a low energy gamma radiation and also have a gamma
DPK component contributing to the total dose.
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Table 3-1. Properties of Radioisotopes used in Radiation Dosimetry Model
Radio- Maximum Average
isotope Half-life Energy Energy Energy(MeV) (MeV)
beta 0.498 0.134
1Lu 6.734 d gamma 0.113 (6.4 %) NA
0.208 (11.0%)
beta 2.118 0.706
188Re 16.94 h gamma 0.155 (14.9%) NA0.633 (1.25%)
0.478 (1.01%)
3P 14.28 d beta 1.709 0.695
9Y 2.67 d beta 2.282 0.761
3.1.3 Beta Dose Point Kernel
Beta DPK of 32P, 188Re and 90Y were obtained from the tabulated data of Cross et
al. (1992). These data were derived from Monte Carlo radiation transport simulations of
beta particles in water considering the beta spectrum of different radioisotopes. The DPK
represents the dose expressed in units of nGy-cm2 as a function of a distance r (mm)
Bq - hr
emitted by an isotropic point source. Figures 3-1 through 3-3 show the DPK curves of
3P, 90Y and IsRe. For these radioisotopes, DPK data was fit to an analytical expression
shown in Table 3-2.
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Figure 3-1. Beta DPK of 32P
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Figure 3-3. Beta DPK of 1"Re
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Table 3-2. Functions and r2 values for DPK expressions of selected radioisotopes
Radio- Equation
isotope Value
32P DPK(r),, = -0.016r 5 +0.0866r 4 +1.8508r 3 -15.253r 2 +9.889r +104.6 0.9999
"Y DPK(r), = -0.0058r 5 +0.1258r4 -0.655r 3 -0.7175r 2 -5.0275r +101 0.9997
18Re DPK(r),q =0.0131r6 -0.3731r 5 +4.0461r4 -20.505r 3 +48.831r 2 -66.652r+126.89 0.9964
3.1.4 Dose Point Kernel of Beta Emissions of '"Lu
Since '"Lu is just recently being used in radiotherapy applications, there is not
readily available DPK data in published literature for this radioisotope. The DPK of the
beta emissions of 1"Lu was calculated by using the following equation:
NDPK(r,r') = x DPK(r,r', E ), (8)
where DPK(r, r'),6 is the DPK of the beta radiations, DPK(r, r'E,) is the DPK of the beta
particles of energy E;, N is the total number of electrons emitted by disintegration of the
radioisotope, and n,(E) is the number of particles of a particular energy E;. This method
makes use of DPK values for beta particles of specific energies over the energy spectrum
of '"Lu. The DPK of beta particles K(r, r'E), at different energies E has been calculated
by Cross et al. (1992) by means of Monte Carlo radiation transport simulations. The
calculation of the spectrum of beta emissions of 1"Lu (n, (E, )/ N) is shown in Appendix
A. The calculations for determining the DPK of beta emissions of 1"Lu are provided in
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Appendix B. Figure 3-4 shows the beta DPK for 17Lu. Because the fitting of the DPK
data of '7Lu to an analytical expression yielded a high error percentage, beta DPKs were
stored as a lookup table in the dosimetry model. The beta DPK for each distance r was
calculated by logarithmic linear interpolation according to the following equation:
DPK(r) =ln(DPK 1)- [ln(DPK1)-1n(DPK 2 )]x (dis -r)
dis -d s2  (
where r is the distance of interest between the source and target points, DPKj and DPK2
are the DPK values for distances dis and dis2 respectively, and DPK (r)is the dose point
kernel for the distance of interest.
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Figure 3-4. Beta DPK of '"Lu
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3.1.5 Dose Point Kernel of Gamma emissions of '"Lu and 188Re
Dose point kernel data of gamma emissions are not readily available in a
tabulated fashion like the beta DPK provided by Cross et al. (1992). Both 1 77Lu and '88Re
emit non-negligible gamma radiation that must be accounted for in the total dose
calculation.
Table 3-3. Beta and Gamma energies of 1"Lu and 188Re
Maximum Average
Isotope Half-life Energy Energy Energy
(MeV) (MeV)
beta 0.498 0.134
1"Lu 6.734 d gamma 0.208 (11.0%) NA
0.113 (6.4 %)
beta 2.118 0.706
Re 16.94 h gamma 0.155 (14.9%) NA0.633 (1.25%)
0.478 (1.01%)
Furhang et al. (1996) have derived a mathematical expression of photon or gamma dose
kernels for several radioisotopes, including 188Re. The gamma DPK was generated in
water for the full gamma emission spectrum of the radioisotope through Monte Carlo
simulations (Furhang et al., 1996). For the calculation of gamma DPK of 188Re, the
following expression was used:
DPK(r), = a -+ 1 +ao +al -r+a2 -r2 j e--"', (10),
where r is the distance in cm, and DPK is expressed in cGy/Bq -s . The coefficients for this
expression are listed in Table 3-4.
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Table 3-4. Coefficients of the gamma DPK expression of '"8 Re
2.162 x 10-12
a-2  1.444 X 10- 2
a_, 3.455 x 10- 3
ao 1.298 x 10~ 4
0.10739
m 5.197
Error. 1.2%
Table 3-5. Functions and r2 values for gamma DPK expressions of '88Re and 17 Lu
Radio- Equation
isotope
18 8  K(r) = 2.162 x10-1 3.455 x 10--3 +1.298x 10- 14 e-o.10 739 r + 1.444 10 _5.1971Re r r r r2 N/A
177Lu K(r)r =0.0071r 6 -0.0447r 5 +0.1107r 4 -0.1377r 3 +0.0896r 2 -0.0253r +0.0428 0.9669
'
77Lu is a relatively new in radiotherapy treatment and as a result was not among the
radioisotopes whose gamma DPK was calculated by Furhang et al., (1996). In this case
the gamma DPK of 177Lu was calculated by using the gamma energy tables of Luxton
and Jozsef (1999), which were calculated through EGS4 Monte Carlo simulations for
gamma rays with energies between 10 keV and 2 MeV. These tables present the dose of
a gamma ray of particular energy emitted in water as a function of distance radial
distance from a point source (Luxton and Jozsef, 1999). The dose for gamma emissions
of 0.208 MeV(11%) and 0.113 MeV (6.4%) was calculated using these tables and a
logarithmic linear interpolation according to equation 9. Dose is expressed in nGy-
cm2/Bq-hr. The total dose from the two gamma energies is obtained by multiplying each
dose value at a specific energy by its fraction and summing up the two components
according to the following equation:
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DPK(r), =(fQ x DPKI(r))+(f2 x DPK2 (r)) (11)
Refer to Appendix C for results of the interpolation calculation and the final gamma
DPK data. This data was plotted and fit to the analytical expression shown in table 3-5.
Figure 3-5 shows the curve of the gamma DPK of '7Lu.
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Figure 3-5. Gamma DPK of 17 Lu
3.2 Radiobiological Model
The main purpose of the radiobiological model is to compare the physical
absorbed dose at a specific target point with the biological equivalent dose at that same
point taking into account the initial dose rate, repair probability of the tissue, duration of
treatment and biological endpoint (a/0 ratio) (Dale, 1985, 1993; Giap et al., 1999). The
radiobiological impact of the different radioisotope distribution is assessed by means of
two main parameters, BED and RE. Biological equivalence dose (BED) and relative
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effectiveness per unit dose (RE) are the focus of the radiobiological model. BED is a
measure of the biological consequences to the tissue receiving a particular dose. RE
measures the effectiveness of a given dose. These parameters are derived from the
linear-quadratic (LQ) formalism, which expresses the surviving fraction (S) of cells as a
function of dose (D).
S = e-aD-l (12)
The constants a and p are characteristic of a given cell type and have units of Gy" and
Gy 2 respectively. BED and RE are related to the physical absorbed dose by the
following expression:
BED (Gy) = RE x (Absorbed dose) (13)
3.2.1 Relative Effectiveness per unit Dose for a Permanent Implant
For a permanently implanted exponentially decaying source such as treatment of
coronary artery disease with radioactive stents, the LQ parameter RE is represented by:
(RE 1+2R p, 1 -1(RE)=1
pc-A a _2A p+A_
=1+ 2a-2 (l P4- A) (14)
pu-A a 2A( + A)
which reduces to: RE =1+ < , (15)
,p+2 a
where DA is the initial dose rate delivered to the tissue and X is the radioactive decay
constant of the implanted radionuclide. p is the sublethal repair constant, which describes
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the probability for cells to repair the radiation damage per hour and is related to the repair
half-life T1,2 by p= ln 2/T1 2 . The value of the repair half-life to be used in this model is
taken from published literature (Brenner and Hall, 2001) and has been experimentally
determined to be 0.5 hours for smooth muscle cells. The a/ ratio for early-responding
vascular tissue has been estimated as 8 Gy (Brenner and Hall, 2001). This is assuming
that the cells in the arterial wall responsible for the neointimal hyperplasia component of
restenosis are rapidly proliferating cells and can be estimated more accurately as tumor or
cancer cells than normal tissue. A summary of the values used in the radiobiological
model is shown in Table 3-6. Included is also the values of X for each of the
radioisotopes, which was calculated according to X=1n2/t" 2, where t1 2 is the half-life of
the radioisotope.
Table 3-6. Summary of Values for Variables used in Radiobiological Model
a/(3 ratio 8 Gy
Repair half-life 0.5 hours
. (sublethal repair constant) 1.386 h-1
32P:0.00202 h-1
X (decay constant of the 9Y: 0.0108 h 1
radionuclide) '8 Re: 0.0409 W
17Lu: 0.00428 h-1
Dose rate varies for each point
Absorbed dose varies for each point
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3.2.2 RE for Implant Containing Two Different Radioisotopes
The dosimetry model will also be used to calculate the dose distribution of a stent
containing two radioisotopes, one in the center or body of the stent, and another in the
edges of the stent or a uniform distribution of a combination of radioisotopes. In this
case, equation (14) will not be adequate because it only takes into account the biological
effects of the dose rate and half-life of one radioisotope only, where in fact the two
radioisotopes might have important effects, particularly if the half-lives differ greatly.
For a permanent implant in which the dose is a result of a combination of two
radioisotopes as in the case of the hybrid stent, the following equation was used (Chen,
2003):
+oi o 2D014 2 (21 +'12 + 2pC)
RE=I+ x + ++22X+P 2 , (16)
a D01  Do2
/12
where D ] and D02 is the dose rate for isotopes 1 and 2 respectively, and X and X2 are
the decay constants. The biological equivalent dose or BED is calculated in the same
manner as that for a stent containing one radioisotope and is the product of RE and the
absorbed dose.
3.3 Stent Model
The stent design used in this research is an example of a stent geometry that can
be used for calculation of the dose distribution surrounding the stent. The stent (patent
No. 6,187,037) was designed by Bionucleonics Inc, of Miami, FL. Cartesian coordinates
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(x,y,z) are used in our model and arranged in a Microsoft Excel file and loaded into the
program. The file with these stent source coordinates can be found in Appendix D. The
dose calculation model described in this work can accommodate any set of coordinates
that define the geometry of the stent. The stent has deployed dimensions of 15.25 mm in
length and 4mm in diameter with a strut thickness of 0.1527mm (Satz, 2001). The stent is
divided into 1840 pieces, or strut points, which are considered the point sources in the
DPK convolution calculation. The detailed gridded architecture of the stent used in this
research project is shown in Figure 3-6. It represents a projection of the stent into the (0,
z) plane.
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Figure 3-6. Stent geometry and dimensions
The stent developed by Bionucleonics Inc., has mLu incorporated into a nickel-
titanium alloy which when subsequently activated, yields an entirely uniform dispersion
of the radioisotope, much more uniform than coating the alloy surface by ion
49
implantation, vacuum deposition or other deposition technique (Satz, 2001). '"Lu shows
an optimal combination of properties that make it very attractive in the preparation in this
type of stents, including a wide cross-section in barns, which facilitates activation in a
reactor and requires a shorter reaction time to achieve the preferred levels of
radioactivity. '7Lu has a half-life of 6.734 days with a maximum energy of 498 keV, an
average energy of 134 keV and gamma emissions of 113 keV (6.4%) and 208 keV
(11.0%) (Satz, 2001). The '7Lu stent is 0.1% by weight lutetium. This stent design will
be used for all other dose calculations with different radioisotopes. For radioisotopes
other than '7Lu, the radiation was assumed as being on the surface of the stent, not
embedded within the nickel-titanium alloy.
3.4 Algorithm for Radiation Dosimetry Model
The algorithm is written in Matlab 6.5 programming language (The MathWorks,
Inc., Natick, Massachusetts) and is based on the dose point kernel (DPK) convolution.
The DPK convolution method divides the extended source of radiation, in this case the
stent, into a series of point sources. The dose at a target point is made up of the
contributions of each of the individual point sources. For calculation purposes, the stent
will be represented by a set of contiguous transaxial slices. Figure 3-7 represents a slice
along the transaxial plane of the stent and the corresponding cross-section of stent struts.
Each slice corresponds to one value of z along the z-axis (length of stent), and contains
the strut point (x,y) for that value of z. The dose calculation algorithm calculates the dose
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delivered from each of the source point defining the stent architecture on a slice-by-slice
basis.
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Figure 3-7. Stent cross section at midplane (z = 0)
3.4.1 Dose Calculation Algorithm Flowchart
Each slice along the z axis of the stent depends on the coordinates x and y.
Therefore, each stent coordinates can be represented by the following notation: z(x,y),
where z is -7.75 mm to 7.75 mm at intervals of 0.125 mm. For each slice z there are 16
sets of (x,y) coordinates. Computation time was decreased by excluding the source points
at which distances between source and target points extended beyond the range of the
DPK for a particular radioisotope. Figure 3-8 shows a flow diagram of the algorithm for
the radiation dosimetry model developed in this project. A sample of the algorithm code
is provided in appendices E and F.
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INPUT: Stent source coordinates Definition of Target Coordinates
(xs, ys, zs) (xt, yt, zt)
j = L:nsource i ntarge
distance = j[xt(i)- xs(j)2 + yt(i)- ys(j)2 + [zt()- zs )]2
Distance
DPK Range
YES
Dose = DPK (distance)
NO
Dose (i) = SUM + Dose (i)
------- Next j
Next i
Figure 3-8. Diagram of Dose Calculation Algorithm
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3.4.2 Model Assumptions
The algorithm for calculation of dose distributions around radioactive stents is based on
the following assumptions:
1) Absorbed dose is calculated for stent with deployed dimensions of 4 mm in
diameter and 15.25 mm in length.
2) Medium (soft arterial tissue) is isotropic and homogeneous with attenuation
properties close to that of water. The presence of plaque is not accounted for.
3) Dose is symmetrical around the stent, so for calculation efficiency purposes, only
the dose in the first quadrant of the stent is calculated.
4) Absorbed dose is expressed per unit of activity in cGy/pCi. cGy describes the
dose delivered per gram of tissue. pCi is the unit of activity, where activity is a
measurement of the number of radioactive disintegrations or transformations an
amount of radioactive material undergoes in a given period of time.
5) Stent is a permanently implanted therefore the convolution equation is integrated
to time t = oo.
6) For '77Lu, source of radiation is embedded within the NiTi alloy. In this case, the
dose delivered to tissue is corrected by a self-attenuation factor described in
Section 3.4.3. For all other radioisotopes the source of radiation is simulated on
the stent surface as a coating.
3.4.3 Conversion of Units
The DPK data in the tables of Cross et al. (1992) are expressed in units of
nGy-cm 2/Bq-h. In our calculations, it was expressed in cGymm2/pCi-h. The conversion
of units was performed as follows:
nGy -cm 2  10-'cGy 37,000Bq 100mm 2 _ 0.37cGy -mm 2k = x x x (17
Bq -h nGy puCi cm2  paCih (17)
Therefore, to express the dose in units of cGymm 2/pCi-h, the dose values obtained were
multiplied by the conversion factor k = 0.37.
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3.4.4 Attenuation Correction Factor for Dose Point Kernel Calculation of 1"Lu
The 17Lu stent is made radioactive by a different manner altogether, one that has
the potential for a more uniform distribution of the radioisotope, leading to a more
uniform dose delivery to the artery wall. The lutetium is an integral part of the nickel-
titanium alloy prior to its activation. For this reason, a correction factor needs to be
introduced to account for the self-attenuation of the stent material. The self-attenuation
by uniform dispersion of the radioactive source in the stent material is given by the
following expression:
Actualdose = D x [- (P AX], (18)
where the percentage loss of energy due to attenuation of beta particles is given by
Ax, in which -- is the total stopping power( the sum of the collision and
T dc dc
radiative stopping powers) for NiTi alloy equal to 2.391 MeV-cm2/g (Berger et la, 2000),
T is the average beta emission energy equal to 0.134 MeV, and p is the density of the
NiTi alloy equal to 6.45 g/cm3.
The CSDA range (continuous slow down approximation) is a very close
approximation to the average path length traveled by a charged particle as it slows down
to rest (Attix, 1986, p. 1 80; Berger et al., 2000). The RCSDA of NiTi for beta particles with
an average energy of 0.134 MeV is 3.443 x 102 g/cm2 (Berger et al., 2000). This value,
divided by the density of NiTi results in the range expressed only in units of distance
0.0534 mm. This value was used to exclude those source points on the stent that have no
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contribution to the total dose at a particular target point. Assuming that the source of
radioactivity is a point source located in the center of the stent strut, then the distance
traveled by beta particles to the target point, which is equal to 0.0763 5, or half the stent
strut thickness, is greater than the CSDA range. For this reason the location of the point
source was assumed to be in the center of half of the strut width, as shown in Figure 3-8.
As a result, a quantity of 0.038175 mm, or one fourth the strut width was added to each x
and y coordinate defining the stent geometry in order to consider the point source in the
center of the stent. In equation 18, Ax is equal to 0.038175 mm. This is the only segment
that will be attenuated because the others are so out of range that none of the radiations
will make it to the target point. In addition, the dose is multiplied by a factor of 0.5 taking
into account the fact that the activity of half of the strut will have no contribution to the
dose whatsoever.
I- Ax= 0.03815 mm
Figure 3-9. Portion of stent strut with attenuation correction
The attenuation due to gamma absorption was also calculated according to the
exponential attenuation equation for gamma rays and x-rays (Attix, 1986, p.39). In this
case Ax is 0.1527 =0.076350 or half of the stent strut thickness, under the assumption
2
that the gamma radiation is emitted from the center of the stent strut.
attenuation = e-"P (19)
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P JN, + fA, (20)
P NiTi P) Ni Ti
where Nu and are the linear mass attenuation coefficients for Ni and Ti
respectively, which were obtained from the tables provided by Chantler et al. (2003). fN
and fn are the fractions of each material that contribute to the total composition of the
NiTi, which is 50% Ni and 50% Ti. The attenuation factors for both beta and gamma
energies will be multiplied by the calculated dose values to obtain the corrected dose
values due to the attenuation of the stent material. This was applied only in the case of
17 Lu.
3.5 Model Simulations
One of the aims of this study is to theoretically evaluate different radioisotopes as
potential candidates in a radioactive stent for the treatment and prevention of restenosis,
as well as for the prevention of edge restenosis. In addition to characterizing the 3D dose
distribution of 32p, 90 Y "'Re and 177Lu stents, combinations of these radioisotopes will
also be explored such as shown in table 3-7. The geometric distribution of radioisotopes
can be varied with ease. Two radioisotopes can be combined throughout the entire length
of the stent. The 3 mm at both ends of the stent were simulated to include a radioisotope
that is different from that in the center of the stent as shown in Figure 3-10. This also
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includes the "dumbbell effect" or the incorporation of higher activities of the radioactive
source at the stent ends.
200
150-
100-
50-
0-
Q -50
-100
-150
-200 I
-10 -8 -6 -4 -2 0 2 4 6 8 10
Z (mm)
Figure 3-10. Radioisotope distribution at stent edges
Table 3-7. Radioisotope Distribution of Stent Geometry
Stent Simulations Stent Center Stent Edges
1 177Lu + 32P 177Lu +32P
2 177Lu+9Y 177Lu+ Y
3 77Lu+ 188Re '77Lu+188Re
4 32P 32P
5 3 x Y
6 '88Re 3 x 8 8 Re
7 177Lu 3 x 1 77Lu
8 2P 188Re
9 32P 90Y
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3.6 Model Validation
The validation of the DPK convolution for dosimetry calculation of radioactive
stent was compared against the results obtained from Monte Carlo simulations using the
MCNP code. Monte Carlo simulations were done by Michael G. Stabin of Vanderbilt
University. The stent was simulated as a hollow cylinder with 32P embedded within the
volume of the cylinder. The dimensions of this cylinder are shown in Figure 3-11.
-A 0.96 mnm
z
x I
y 18.0 mm
0.6 mm -- I
Figure 3-11. Dimensions of 32P cylinder used in MCNP and DPK calculations
The dose was calculated at distances of 0.01, 0.2, 0.5, 0.7, 1.0, 2.0, and 4.0 mm
from the surface of the stent at z = 0 or the midplane of the stent. The Monte Carlo
simulation was done under the following assumptions:
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1) Cylinder is made of NiTi (50% Ni, 50% Ti).
2) The full beta energy spectrum of 32P was used.
3) Dose was calculated as dose per electron emitted from the whole stent, not per
unit, and was calculated for 3.7 x 10' dps at each emission point.
4) Dose is expressed in units of cGy/mCi-h.
5) Dose calculation included the production of secondary electrons and
bremssthralung.
6) The number of simulations yields a mean error of 6.1% in the calculations of the
dose at the specified points.
The radiation dose from a 32P cylinder was calculated at the same distances
described above using the DPK dosimetry model developed in this project. The cylinder
was defined by cylindrical coordinates with a radius of 0.48-1.08 mm. The radius was
divided to discrete intervals of 0.2 mm, the length in intervals of 0.115 mm from -9 to 9
mm, and the angle in intervals of 5 degrees, from 0 to 355 degrees. This is equivalent to
31,913 units of volume. The activity was 1 mCi per unit. To make this calculation
comparable to the Monte Carlo results, the issue of attenuation had to be addressed.
Unlike Monte Carlo simulations, the DPK convolution method relies on using average
values of attenuation. Therefore, in this type of calculation, the attenuation correction for
the dose delivered by 32P embedded within the volume of the NiTi cylinder relied on two
main points: a) the elimination of all those source points of the cylinder whose distance
traveled within the stent to the target point is greater than the CSDA range of the mean
energy of 32P in the NiTi material, and b) calculation and implementation of an
attenuation factor for beta particles as described in equation 18, section 3.4.3. First and
foremost, the CSDA range in mm was calculated for the mean beta energy of 32P
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traveling across a NiTi material. This calculation was done using the values shown in
Table 3-8.
Table 3-8. Stopping Power (dT/dx) and CSDA range for the mean beta energy of 32P
emissions in a NiTi alloy.
Energy (MeV) dT/dx (Mev-cm 3/g) CSDA Range (g/cm2 )
0.695 1.382 0.3942
The range, calculated as:
0.3942g/cm2
= 6.11lcm = 0.611mm,
6.45g/cm3
meaning that the width of the cylinder is greater than the range. The following
assumptions were made based on this result, and were included in the selection of source
coordinates defining the source components of the cylinder:
1) The angle was reduced to a range between -45* and 45*. This approximation is
justified because the mean distance within the stent source points to the target
points is greater than the CSDA range of 0.611 mm.
0.78 mm 45*
----------- X -----------
0.01 mm
-45*
Figure 3-12. Angle range defining contributing points to dose at target
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mean distance
within the stent 0.78mm - 0.012-mm = 0.77mm
2) Only those points in the z range from -0.23 mm to 0.23 mm contributed to the
radiation dose. This assumption is justified by the fact that most of the source
points outside of this range have distances within the stent greater than the CSDA
range.
3) Approximately only half of the source points in the range z E [- 0.23mm,0.23mm]
contributed to the radiation dose. The final dose values were thus multiplied by a
factor of 0.5.
1.08 mm -
Figure 3-13. Contributing points to dose at target for a segment along the
stent z axis
4) The dose was divided by 31,913 units of volume under the assumption that each
unit has 1 mCi of activity.
Attenuation correction for 32P particles embedded within the volume of the stent was
calculated according to:
1dT
AF=1---p Ax,
T dx
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where Ax is the mean distance from the source points included in the calculation to the
stent surface. It was approximated by:
Ax = d -r, (21)
where d is the mean distance from source to target points, which was calculated by the
code in Appendix F, and r is the distance from the surface of the stent to the target point.
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CHAPTER 4
RESULTS
Results presented are for the lifetime dose delivered by the stent under the
assumption that the stent is permanently implanted. Dose is expressed per unit of activity
as cGy/pCi. Radioactivity is assumed on the stent surface unless stated otherwise as in
the case of 'mLu. A target distance of 2.0 mm is taken as a reference point with
adventitial layer of the artery as the target tissue for prevention of cell proliferation due to
neointimal hyperplasia and negative vascular remodeling.
4.1 Dosimetry of a 3P stent
Figure 4-1 represents a 2D dosimetry plot for a stent coated with 32P as a function of
radial distances along the entire axis of the stent. The different curves are for doses at
different depths into the arterial wall. In the near-field or 0.1 mm from the surface of the
stent, the dose varies from 3000 to 4700 cGy/pCi at the stent strut wires to 1000 cGy/pCi
in the interstices between struts. At a distance of 1.0 mm, dose delivery is more
homogenous with a cumulative dose of~500 cGy/pCi.
Figures 4-2 to 4-5 represent 3D dose maps extending from -10 mm z 10 mm
at distances d = 0.1, 0.5, 1.0 and 2.0 mm from the stent surface. These plots are
projections over the stent in the (0, z) plane as shown in Figure 3-6 (Chapter 3). Shown is
the dose for a segment over the stent between 0 and 45 degrees. These plots provide a
clear view of the nonuniformity of the dose at very close distances to the stent. Evident is
also the fall-off of the dose at the edges of the stent at -- 8.0 and 8.0 mm on the z axis.
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Figure 4-1. 2D plot of dose distribution of a 3p stent
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Figure 4-2. 3D map of dose to tissue after total decay of a 3 P stent at 0.1 mm exterior to the
stent surface.
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Figure 4-3. 3D map of dose to tissue after total decay of a 32P stent at 0.5 mm exterior to the
stent surface.
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Figure 4-4. 3D map of dose to tissue after total decay of a 32P stent at 1.0 mm exterior to the
stent surface.
65
200 - - 50
0 
30 6 2 -4 -1
200 180 160 140 120 100 80 60 40 20
Figure 4-5. 3D map of dose to tissue after total decay of a 32P stent at 2.0 mm exterior to the
stent surface.
Figure 4-6 represents the dose as a function of radial distance up to 5 mm into the arterial
wall calculated at the stent midplane or z = 0. For 32P, the dose delivered at 0.1 mm is
4797 cGy/pCi, while at 1.0 mm it falls off by 88% to 531.84 cGy/pCi. At a target
distance of 2mm, the dose is 172.26 cGy/pCi, or 3.7% of the dose at 0.1 mm. The dose
delivered to the arterial wall at a fixed radial distance of 2.0mm along the axis of the stent
is shown in Figure 4-7 for half a stent from 0 to 12 mm. At the stent ends, the dose is
88.78 cGy/pCi or 51.54% of the dose at z = 0.
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Figure 4-6. The variation of dose with radial distance of a 32P stent
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Figure 4-7. The variation of dose with axial distance of a 32P stent
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4.2 Dosimetry of a '"Y stent
Figure 4-8 represents a 2D dosimetry plot for a stent coated with 9Y as a function
of increasing radial distance along the entire axis of the stent. The different curves are for
doses at different depths into the arterial wall. At 0.1 mm from the surface of the stent,
the dose varies from 900 to 600 cGy/pCi at close proximity to the stent strut wires to
-200 cGy/pCi in the areas between struts. At a distance of 1.0 mm, dose delivery is more
homogenous with a cumulative dose of -100 cGy/pCi. At 2.0 and 3.0 mm, the dose is
completely uniform, although it has fallen to less than 5% of the dose at 0.1 mm.
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Figure 4-8. 2D plot of dose distribution of a "Y stent
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Figures 4-9 to 4-5 represent 3D dose maps extending from -10 mm : z ; 10 mm at
distances d = 0.1, 0.5, 1.0 and 2.0 mm from the stent surface. These plots are projections
over the stent in the (0, z) plane shown in Figure 3-6 (Chapter 3). Shown is the dose for a
segment over the stent between 0 and 45 degrees of the total stent circumference. At a
distance of 0.1 mm, the effect of the stent wires is pronounced. This effect is reduced
significantly at distances of 1.0 and 2.0 mm as seen in Figures 4-11 and 4-12.
1200 10
Fiur 4-9 11,D ta of dos to tisu afe o e f d 'Yse-a . m xeirt h
s 1en 0 srface.0
8006 o ~ ~30
m- ttc400 
0 -
200- 4"" a
100
00
1000 900 800 700 600 500 400 300 200 100
Figure 4-9. 3D map of dose to tissue after total decay of a 90Y stent at 0.1 mm exterior to the
stent surface.
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Figure 4-10. 3D map of dose to tissue after total decay of a "Y stent at 0.5 mm exterior to
the stent surface.
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Figure 4-11. 3D map of dose to tissue after total decay of a 9Y stent at 1.0 mm exterior to
the stent surface.
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Figure 4-12. 3D map of dose to tissue after total decay of a 9Y stent at 2.0 mm exterior to
the stent surface.
Figure 4-13 represents the dose as a function of radial distance up to 5 mm into the
arterial wall calculated at the stent midplane or z = 0. For 90Y, the dose delivered at 0.1
mm is 888.81 cGy/pCi, while at 1.0 mm it falls by 85.42% to 129.60 cGy/pCi. At a
target distance of 2mm, the dose is 58.19 cGy/pCi, or 6.5% of the dose at 0.1 mm. The
dose delivered to the arterial wall at a fixed radial distance of 2.0 mm along the axis of
the stent is shown in Figure 4-14 for half a stent from 0 to 12 mm. At the stent ends, the
dose is 29.89 cGy/pCi or 51.38% of the dose at z = 0.
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Figure 4-13. The variation of dose with radial distance of a 9Y stent
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Figure 4-14. The variation of dose with axial distance of a 90Y stent
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4.3 Dosimetry of a '"Re stent
Figure 4-15 represents the 2D dosimetry plot for a stent coated with '88Re as a function of
increasing radial distance along the entire axis of the stent. The different curves are for
doses at different depths into the arterial wall. At 0.1 mm from the surface of the stent,
the dose varies from 290 to 195 cGy/pCi at close proximity to the stent strut wires down
to -60 cGy/ Ci in the areas between struts. At a distance of 1.0 mm, dose delivery is
more homogenous with a cumulative dose of -30 cGy/pCi. At 2.0 and 3.0 mm, the dose
is completely uniform, although it has fallen to about 6% of the dose at 0.1 mm.
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Figure 4-15. 2D plot of dose distribution of a '"Re stent
Figures 4-16 to 4-19 provide a view of 3D dose maps extending from -10 mm z 10
mm at distances d = 0.1, 0.5, 1.0 and 2.0 mm from the stent surface. These plots are
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projections over the stent in the (0, z) plane shown in Figure 3-6 (Chapter 3). Shown is
the dose for a segment over the stent between 0 and 45 degrees of the total stent
circumference. At a distance of 0.1 mm, the effect of the stent wires is very pronounced,
indicating the nonuniformity of dose. This effect is significantly reduced at distances of
1.0 and 2.0 mm as seen in Figures 4-18 and 4-19.
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Figure 4-16. 3D map of dose to tissue after total decay of a "8Re stent at 0.1 mm exterior to
the stent surface.
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Figure 4-17. 3D map of dose to tissue after total decay of a ' 8 Re stent at 0.5 mm exterior to
the stent surface.
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Figure 4-18. 3D map of dose to tissue after total decay of a 1*8Re stent at 1.0 mm exterior to
the stent surface.
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Figure 4-19. 3D map of dose to tissue after total decay of a 1 Re stent at 2.0 mm exterior to
the stent surface.
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Figure 4-20. The variation of dose with radial distance of a "8Re stent
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The dose delivered to the arterial wall at a fixed radial distance of 2.0mm along the axis
of the stent is shown in Figure 4-21 for half a stent from 0 to 12 mm. At the stent edge,
the dose is 7.6 cGy/ Ci or 53 % of the dose at z = 0. Figure 4-20 represents the dose
delivered by a '88Re stent as a function of radial distance up to 5 mm into the arterial wall
calculated at the stent midplane or z = 0. At 0.1 mm, the dose delivered is 289.75
cGy/pCi, while at 1.0 mm it falls by 88.35% to 33.76 cGy/pCi. At a target distance of
2mm, the dose is 14.30 cGy/pCi, or 4.9% of the dose at 0.1 mm.
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Figure 4-21. The variation of dose with axial distance for a "8 Re stent
'Re decays by both beta and gamma emissions. Although its highest energy is provided
by beta decay, it has gamma decay of 0.155 MeV at 14.9%, 0.633 MeV at 1.25% and
0.478 at 1.01%. The relative percentage of this gamma decay to the total dose delivered
by a '88Re stent as a function of radial distance is shown in Figure 4-22. The beta DPK of
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88Re has a maximum range of 8.7 mm, at which point the dose is composed of gamma
emissions entirely. At the target distance of 2 mm, gamma emissions contribute about a
20% to the total dose.
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Figure 4-22. Contribution of gamma energy to total dose of a 188Re stent
Figure 4-23 provides a view of the total dose as a function of radial distance and the
contributions of both beta and gamma emissions. From a distance of 4.0 mm the greatest
contribution is provided by the gamma emissions. Note that the dose from beta emissions
falls off more quickly than that of gamma emissions, which is of a much smaller
magnitude, but with a less steep dose gradient. Numerical values are presented in Table
4-1.
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Figure 4-23. Beta and gamma components of dose delivered by a 188Re stent
Table 4-1. Beta and gamma components of total dose of a ""8Re stent
Radial BETA GAMMA TOTAL DOSE
distance (mm) (cGy/ Ci) (cGy/pCi) (cGy/pCi)
0.1 259.68 30.07 289.75
0.5 54.81 8.19 63.00
1.0 28.61 5.14 33.76
1.5 17.65 3.82 21.47
2.0 11.28 3.02 14.30
2.5 7.22 2.48 9.70
3.0 4.56 2.08 6.64
3.5 2.83 1.77 4.61
4.0 1.72 1.54 3.26
4.5 1.04 1.34 2.38
5.0 0.62 1.19 1.80
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4.4 Self-Attenuation Correction Factor for DPK Calculation of a 177Lu stent
The 17Lu stent, unlike all others simulated in this work has the radioactivity
embedded within the volume of the stent. This required the calculation of an attenuation
correction factor of the beta and gamma emissions as they travel from the inside of the
material to the target distances. The self-attenuation factor for both beta and gamma
emissions was calculated according to equations 18 and 19 in (Chapter 3). Self-
attenuation factors were 0.28 for beta emissions and 0.991 for gamma emissions. The
final dose results obtained from the dosimetry model was then multiplied by these factors
for beta and gamma emissions respectively. Figure 4-24 shows a comparison of the dose
delivered from the midstent, or z = 0, to target points ranging from 0.1 to 5 mm from the
stent. The dose from the beta emissions is significantly attenuated with only 28% of the
dose reaching the target tissue. As the distance increases from the stent surface, the dose
from beta emissions becomes negligible and the dose is composed entirely of gamma
emissions. At these points the dose with and without attenuation correction is almost
identical, because for gamma energy the self-attenuation is negligible. Table 4-2 shows
numerical values of the components of the dose delivered by '77Lu at increasing radial
distances from the surface of the stent.
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Figure 4-24. Comparison of dose with and without attenuation correction for a 1"Lu stent.
Table 4-2. Comparison of dose with and without self-attenuation correction factors for dose
delivered by a m7 Lu stent.
Radial Beta (with Gamta Total (ithlds
Gam
distance Beta attenuation Gam wt. dose (wt
(mm) correction) attenuation attenuation
________correction) correction)
0.1 2,774.4 776.8 142.42 141.14 2,916.80 917.96
0.5 55.7 15.6 33.91 33.61 89.61 49.20
1.0 0.4914 0.1376 20.99 20.81 21.49 20.94
1.5 0.0123 0.0035 17.10 16.95 17.11 16.95
2.0 0.0000 0.0000 13.34 13.22 13.34 13.22
2.5 0.0000 0.0000 11.56 11.46 11.56 11.46
3.0 0.0000 0.0000 9.55 9.46 9.55 9.46
3.5 0.0000 0.0000 8.50 8.42 8.50 8.42
4.0 0.0000 0.0000 7.23 7.17 7.23 7.17
4.5 0.0000 0.0000 6.54 6.48 6.54 6.48
5.0 0.0000 0.0000 5.68 5.63 5.68 5.63
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4.5 Dosimetry of a 1"Lu stent
Figure 4-25 shows the 2D dose distribution of '"Lu emitting stent along the entire
axis of the stent with distances ranging from 0.1 to 2.0 mm from the stent surface. Due to
the steep dose gradient of '"Lu, the dose delivered at a distance of 0.1 mm ranges
between -900 cGy/pCi at points in close proximity to the stent struts and -50 cGy/pCi
in areas between the struts. As the distance from the stent increases, the dose uniformity
increases, although the dose delivered decreases dramatically up to insignificant values
with 1.4% of the dose at 0.1 mm, at a target distance of 2.0 mm into the artery wall.
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Figure 4-25. 2D plot of dose distribution of a 177Lu stent
Figures 4-26 to 4-29 provide a view of 3D dose maps extending from -10 mm z S 10
mm at distances d = 0.1, 0.5, 1.0 and 2.0 mm from the stent surface. These plots are
projections over the stent in the (0, z) plane shown in Figure 3-6 (Chapter 3). Shown is
the dose for a segment over the stent between 0 and 45 degrees of the total stent
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circumference. At a distance of 0.1 mm, the effect of the stent wires is very pronounced,
indicating the nonuniformity of dose. This effect is significantly reduced at distances of
1.0 and 2.0 mm as seen in Figures 4-28 and 4-29.
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Figure 4-26. 3D map of dose to tissue after total decay of a 1 7 Lu stent at 0.1 mm exterior to
the stent surface.
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Figure 4-27. 3D map of dose to tissue after total decay of a 1 77Lu stent at 0.5 mm exterior to
the stent surface.
83
001 - 0
-10 -8 -6 
-4 -2 0 2 4 6 8 10
Z (mm) 0
24 22 20 18 16 14 12 10 8 6
Figure 4-28. 3D map of dose to tissue after total decay of a 1 77Lu stent at 1.0 mm exterior to
the stent surface.
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Figure 4-29. 3D map of dose to tissue after total decay of a 177Lu stent at 2.0 mm exterior to
the stent surface.
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Figure 4-30 shows the variation of dose as a function of radial distance delivered by a
m7Lu calculated at stent midplane z = 0. A maximum dose of 917.96 cGy/pCi is
delivered at a distance of 0.1 mm from the stent, however it falls off steeply by 95% to
49.2 cGy/pCi at a distance of 0.5 mm. The high energy delivered at such short distances
is the result of the beta energy. At a target distance of 2 mm from the stent, the dose is
only 13.73 cGy/pCi, or 1.5% of the initial dose, and is composed entirely of gamma
energy.
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Figure 4-30. The variation of dose with radial distance of a 17 Lu stent
Figure 4-31 shows the variation of dose with axial displacement for a fixed radial
distance of 2.0 mm. The graph shows only half the stent as the dose distribution is
symmetrical on the negative z axis of the stent. The dose tends to drop gradually at the
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edges of the stent and beyond. At the stent edge, the dose is 8.1562 cGy/4Ci or 60% of
the dose at z = 0. The contribution to this dose is made solely by gamma emissions of
"Lu.
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Figure 4-31. The variation of dose with axial distance of a '"Lu stent
Like '8 8Re, 1l 7 Lu decays by both beta and gamma emissions. Figure 4-32 shows the
percentage of contribution of gamma energy to total dose delivered by the '77Lu as a
function of radial distance from the stent surface. At a radial distance greater than 1 mm
the contribution of gamma to total dose is 100%. Figure 4-33 shows the breakdown of the
dose into beta and gamma components. It is clear that the dose by beta energy falls off
significantly and makes very little contribution to the total dose at a radial distance
greater than 1.0 mm. Specific values are shown in Table 4-3.
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Figure 4-32. Contribution of gamma energy to total dose delivered by a 17 Lu stent.
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Figure 4-33. Beta and gamma components of dose delivered by a '"Lu stent
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Table 4-3. Beta and gamma components of total dose of a 1 7 7Lu stent
Radial BETA GAMMA TOTAL DOSE
distance (mm) (cGy/pCi) (cGy/ Ci) (cGy/ Ci)
0.1 776.83 141.14 917.96
0.5 15.59 33.61 49.20
1.0 0.31 22.08 22.40
1.5 0.0035 16.95 16.95
2.0 0.00 13.73 13.73
2.5 0.00 11.46 11.46
3.0 0.00 9.75 9.75
3.5 0.00 8.42 8.42
4.0 0.00 7.36 7.36
4.5 0.00 6.48 6.48
5.0 0.00 5.76 5.76
4.6 Dosimetry Comparison of 32P, 9Y, 18Re, and 7Lu stents
Figures 4-34 shows a comparison of the dose distribution of the four radioisotope stents
as a function of radial distance. Figure 4-35 represents the ratio of the dose at the point of
interest to the dose at the middle of the stent along the stents axis for a fixed radial
distance of 2.0 mm for each of the radioisotope stents.
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Figure 4-34. Comparison of radial dose distribution of four radioisotopes.
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Figure 4-35. Comparison of axial dose distribution of four radioisotopes
4.7 Radiobiological Modeling for 32P,Y, "Re, and 17Lu Stents
The purpose of the radiobiological model was to establish a comparison between
the physical absorbed dose and the biological equivalent dose (BED) at the same target
point. This was done by employing equations 13 and 15 (Chapter 3). Figures 4-36 to 4-39
represent this comparison taken as a function of radial distance from the stent midplane z
= 0 for 32P, 9Y, I"Re, and '"Lu stents respectively. In all cases, it is clear that the BED
is always higher than the physical dose. Tables 4-4 to 4-7 provide the values for dose
rate, physical absorbed dose, relative effectiveness (RE) and BED for a set of radial
distances ranging from 0.1 to 5.0 mm in intervals of 0.5 mm.
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4.7.1 Radiobiological Modeling of a 3p stent
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Figure 4-36. Comparison of BED and physical absorbed dose of a 32P stent
Table 4-4. Calculation of BED for a 32P stent at increasing radial distance
Radial Physical . Biological
distance Dose rate Absorbed Relative equivalent(cGy/h) dose cG Effectiveness dose
0.1 9.69 4,797.60 88.28 424,000
0.5 2.19 1,082.10 20.68 22,382
1.0 1.07 531.84 10.68 5,677.30
1.5 0.60516 299.58 6.45 1,932.30
2.0 0.34796 172.26 4.13 712.04
2.5 0.1971 97.58 2.78 270.78
3.0 0.10762 53.28 1.97 104.91
3.5 0.055711 27.58 1.50 41.42
4.0 0.02689 13.31 1.24 16.54
4.5 0.011789 5.84 1.11 6.46
5.0 0.0046097 2.28 1.04 2.38
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4.7.2 Radiobiological Modeling of a stent
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Figure 4-37. Comparison of BED and physical absorbed dose of a 9Y stent
Table 4-5. Calculation of BED for a 9Y stent at increasing radial distance
Radial 
.BooiaRdiae Dose rate Absorbed Relative Biological
(cGy/h) dose (cGy) Effectiveness equivalent(mm) dose
0.1 9.62 888.81 87.06 77,381.13
0.5 2.47 228.36 23.11 5,277.61
1.0 1.40 129.60 13.55 1,755.93
1.5 0.9209 85.11 9.24 786.44
2.0 0.6296 58.19 6.63 386.08
2.5 0.4359 40.29 4.90 197.43
3.0 0.3017 27.89 3.70 103.19
3.5 0.2074 19.17 2.86 54.74
4.0 0.1409 13.02 2.26 29.45
4.5 0.0945 8.73 1.85 16.11
5.0 0.0624 5.77 1.56 8.98
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4.7.3 Radiobiological Modeling of a 18Re stent
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Figure 4-38. Comparison of BED and physical absorbed dose of a "Re stent
Table 4-6. Calculation of BED for a '"Re stent at increasing radial distance
Radial . Biological
distnce Dose rate Absorbed Relative eqialn
(cGy/h) dose (cGy) Effectiveness dose(mm) dose
0.1 11.85 289.75 104.81 30369.83
0.5 2.57 63.00 23.57 1485.20
1.0 1.38 33.76 13.10 442.05
1.5 0.8782 21.47 8.69 186.65
2.0 0.5850 14.30 6.12 87.60
2.5 0.3966 9.70 4.47 43.38
3.0 0.2717 6.64 3.38 22.45
3.5 0.1884 4.61 2.65 12.21
4.0 0.1334 3.26 2.17 7.07
4.5 0.0974 2.38 1.85 4.41
5.0 0.0738 1.80 1.65 2.97
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4.7.4 Radiobiological Modeling of a 1'Lu stent
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Figure 4-39. Comparison of BED and physical absorbed dose of a 1"Lu stent
Table 4-7. Calculation of BED for a '"Lu stent at increasing radial distance
Radial Dose rate Absorbed Relative Biological
distance (cGy/h) dose (cGy) Effectiveness equivalent
mm dose
0.1 3.95 917.96 36.49 33,495.70
0.5 0.21 49.20 2.90 142.79
1.0 0.10 22.40 1.87 41.79
1.5 0.07 16.95 1.66 28.06
2.0 0.06 13.73 1.53 21.02
2.5 0.05 11.46 1.44 16.53
3.0 0.04 9.75 1.38 13.43
3.5 0.04 8.42 1.33 11.17
4.0 0.03 7.36 1.28 9.45
4.5 0.03 6.48 1.25 8.11
5.0 0.02 5.76 1.22 7.04
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The rate at which the dose is delivered is a very important factor in IVBT. Figure 4-40
shows a comparison of the dose rates of the four radioisotope stents. The curves represent
the initial dose rate as a function of radial distance from the stent midplane z = 0. This is
important in the resulting BED for each of the radioisotopes.
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Figure 4-40. Variation of dose rate with radial distance for 32P, 9Y, 1"Re, and 17"Lu stents
BED serves an important function in comparing different treatments. Table 4-8 shows the
calculation of BED for 32P, 9Y, 1s8Re and m7Lu stents delivered to the same target point
of 2.0 mm into the arterial wall. The third column represents the value of the dose at 2
mm, while the fourth column is the activity required for each to reach a therapeutically
significant dose of 2000 cGy or 20 Gy. This calculation of BED shows how for a same
physical dose, the BED can vary greatly, with that of '8 8Re being 20 times the value of
BED of 32P.
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Table 4-8. Calculation of BED of each radioisotope for the same physical dose of 20 Gy
Physical
Absorbed Dose
Radio- Abobd Activity Ds
. Half-life Dose Rate RE BEDisotope at 2 mm ( Ci) (cGy/h)
(cGy/pCi)
3P 14.28 d 172.26 11.6 4.036 37.35 74,631
90Y 2.67 d 58.19 34.4 21.66 194.83 390,010
188Re 16.94 h 14.30 139.8 81.781 717.42 1,434,500
'
77Lu 6.734 d 13.73 145.7 8.601 78.33 156,685
4.8 Combinations of Isotopes within the Same Stent
The following results describe the dosimetry of a radioactive stent containing two
radioisotopes. Figures 4-41, 4-43, and 4-45 show the 2D dose distribution of a 1 77Lu stent
combined with 32P, 90Y and 188Re respectively along the entire axis of the stent with
distances ranging from 0.1 to 2.0 mm from the stent surface. Figures 4-42, 4-44 and 4-46
represent a comparison of the physical absorbed dose and the biological equivalent dose
(BED) for each of the combinations with 177Lu at increasing radial distance from the
stents midplane. Tables 4-9 to 4-11 present the results of the radiobiological modeling
according to equation 16 (Chapter 3). The values of RE and BED are for the effects of the
combined radioisotopes.
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4.8.1 Uniform distribution of 17 Lu and 32P
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Figure 4-41. 2D plot of dose from a combined 17 Lu and 32P stent
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Figure 4-42. Comparison of BED and physical absorbed dose of a combined '"Lu and 32P
stent.
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Table 4-9. Calculation of BED for a combined 1"Lu and 3 2P stent at increasing radial
distance
Radial Dose Dose Total Absorbed Biological
distance rtdoe dose Reaie equivalent(mm) (cGy/h) (cGy/h) rate Effectiveness dose(mm) 17Lu 32P (cGy/h) (cGy) dose
0.1 3.947 9.691 13.638 5,715.60 118.07 675,000.00
0.5 0.212 2.186 2.397 1,131.30 22.24 25,158.00
1.0 0.096 1.074 1.171 554.23 11.38 6,308.20
1.5 0.073 0.605 0.678 316.53 6.99 2,211.50
2.0 0.059 0.348 0.407 185.99 4.57 850.04
2.5 0.049 0.197 0.246 109.03 3.14 342.61
3.0 0.042 0.108 0.150 63.03 2.29 144.05
3.5 0.036 0.056 0.092 36.00 1.78 64.07
4.0 0.032 0.027 0.059 20.67 1.49 30.83
4.5 0.028 0.012 0.040 12.32 1.33 16.44
5.0 0.025 0.005 0.029 8.04 1.25 10.07
4.8.2 Uniform Distribution of 177Lu and Y
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Figure 4-43. 2D plot of dose distribution of a combined 1"Lu and 9Y stent
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Figure 4-44. Comparison of BED and physical absorbed dose of a combined ""Lu and 9Y
stent.
Table 4-10. Calculation of BED for a combined 1"7 Lu and 90Y stent at increasing radial
distance
Dose Dose TotalRadial rate te dose Absorbed . Biological
distance dose Eetive equivalent(cGy/h) (cGy/h) rate Effectiveness(mm) 1'"Lu 9Y (cGy/h) (cGy) dose
0.1 3.947 9.617 13.564 1,806.80 111.22 201,000
0.5 0.212 2.471 2.682 277.56 24.00 6,660.80
1.0 0.0963 1.4023 1.4986 152.00 13.94 2,118.20
1.5 0.0729 0.9209 0.9937 102.06 9.54 973.77
2.0 0.0590 0.6296 0.6887 71.92 6.89 495.30
2.5 0.0493 0.4359 0.4852 51.74 5.12 264.92
3.0 0.0419 0.3017 0.3437 37.64 3.90 146.65
3.5 0.0362 0.2074 0.2436 27.59 3.03 83.73
4.0 0.0316 0.1409 0.1726 20.38 2.43 49.48
4.5 0.0279 0.0945 0.1224 15.22 2.00 30.47
5.0 0.0248 0.0624 0.0872 11.53 1.71 19.69
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4.8.3 Uniform distribution of 177Lu and 18Re
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Figure 4-45. 2D plot of dose distribution of a combined 177Lu and '"Re stent
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Figure 4-46. Comparison of BED and physical absorbed dose of a combined 177Lu and 1Re
stent.
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Table 4-11. Calculation of BED for a combined 17 Lu and 188Re stent at increasing radial
distance
Dose Dose TotalRadial rate rate dose Absorbed Relative Biological
distance (cGy/h) (cGy/h) rate Effectiveness equivalent
(mm) 177 Lu 18 e cG /h) (cGy) dose
0.1 3.95 11.85 15.80 1,207.70 83.30 101,000
0.5 0.21 2.58 2.79 112.20 18.33 2,056.20
1.0 0.096 1.381 1.477 56.15 10.48 588.27
1.5 0.073 0.878 0.951 38.42 6.90 264.99
2.0 0.059 0.585 0.644 28.03 4.84 135.74
2.5 0.049 0.397 0.446 21.15 3.56 75.26
3.0 0.042 0.272 0.314 16.40 2.73 44.83
3.5 0.036 0.188 0.225 13.03 2.21 28.74
4.0 0.032 0.133 0.165 10.62 1.87 19.83
4.5 0.028 0.097 0.125 8.86 1.65 14.65
5.0 0.025 0.074 0.099 7.56 1.51 11.45
4.9 Modification of Radioisotope Distribution at Stent Edges
The problem of edge restenosis is the results of underdosing at the stent edges as a result
of excessive barotraumas during the angioplasty procedure as well as the radiation dose
fall-off at the edges. Figures 4-7, 4-14, 4-21 and 4-31 show that the dose at the stent
edges is roughly 50% of that in the center of the stent for 32P, 9 0Y , "'Re and 1"Lu
respectively. The dosimetry model developed in this work was used to modify the
radioactivity at the stent edges in order to increase the dose to greater than 50%. This
modification was done at the 3 mm proximal and distal segments along the z axis of the
stent.
4.9.1 Different radioisotopes at stent edges
One alternative is that of combining different radioisotopes at the stent edges. The
simulated stents consisted of uniform 32P with added "'Re and 90Y at 3 mm in the edges.
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These isotopes were chosen because of their higher energy compared to 32P alone. Figure
4-47 shows this comparison as a function of axial distance from the stent midplane at a
fixed radial distance of 2 mm. Figure 4-48 shows the same information but with the
values normalized at the stent edge of 7.625 mm in order to observe the dose gradient
extending beyond the stent edge. The effect of incorporating different radioisotopes at the
stent edges can be further amplified by increasing the activity of the radioisotopes at the
stent edges. Figure 4-49 shows the results of increasing the activity of 18 Re and 9Y to 10
pCi at the stent edges. For a 32P stent, the dose at the edge is 52% of that in the center.
For the stent with uniform 32P with 10 pCi of 188Re at the edges, the dose at the edges is
83% higher than the dose at the stent center. In the case of 9Y, the dose at the edges is
168% higher than the dose at the center.
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Figure 4-47. Comparison of a 32P stent with 188Re and 9Y at stent edges
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Figure 4-48. Comparison of a 32p stent with '"Re and "Y at stent edges normalized to the
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Figure 4-49. Comparison of a 32p stent with 10x the activity of ""Re and "0Y at stent edges
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4.9.2 Increase of activity at stent edges ("dumbbell effect")
Another way of increasing the dose at the stent edges was by increasing the activity of at
the edges of the same radioisotope in order to achieve the "dumbbell effect". For 32P,
90Y, '8 8Re and '"Lu stents the activity at the stent edges was increased by an order of
three. Therefore the stent edges had 3 Ci of activity.
4.9.2.1 3P stent with 3x the activity at the stent edges
Figure 4-50 shows the 2D dose distribution of a 3P stent with weighted activity at the
edges (3 mm) along the entire axis of the stent with distances ranging from 0.1 to 2.0 mm
from the stent surface. The dose is higher at the stent ends compared to the stent center.
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Figure 4-50. 2D plot of dose distribution of a 32P stent with 3x the activity on the stent edges.
Figure 4-51 shows a comparison of a uniform 32P stent with a 3P stent with 3 times the
activity at the edges. The graph shows the curves as the ratio of the dose at a particular
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point to the dose at the stent center for a fixed radial distance of 2 mm. At the stent edge,
the dose delivered by the stent with the weighted activity is 150% of the dose at the stent
center, compared to 50/o with a uniform 32P stent.
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Figure 4-51. Comparison of dose as a function of axial distance from a uniform 32P stent
and one with 3x the activity at the stent edges.
Table 4-12. Dose calculation of a 3 2P stent with variation in activity at stent edges
Radial Position Along Stent Axis
Distance
from Stent Stent Stent Stent 1.0 mm 2.0 mm 3.0 mm
frSu ent Center Edge Distal Distal distalSurface
0.5mmP 1,082.00 573.24 177.33 58.30 17.50
_ .5_mm_ 3 x P 1,086.80 1,689.50 525.11 173.87 52.45
1.0mmP 531.79 276.52 121.52 13.47 13.47
.3 x :P 535.42 806.28 359.27 40.36 40.36
2.0mmP 154.04 79.38 43.19 18.11 5.86
2. mm 3 x _ _P 155.53 227.93 127.31 54.01 17.58
3 x "P indicates nonuniform activity (three times the activity at the stent edges)
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Table 4-12 shows the dose delivered from a uniform 32P stent and one with 3 times the
activity at the stent edges for radial distances of 0.5, 1 and 2 mm from the surface of the
stent. The values of dose are taken for points at the stent center, or midplane, at the stent
edge, and 1, 2 and 3 mm distal to the edge of the stent.
4.9.2.2. 9Y stent with 3x the activity at the stent edges
Figure 4-52 shows the 2D dose distribution of a 9Y stent with weighted activity at the
edges along the entire axis of the stent with distances ranging from 0.1 to 2.0 mm from
the stent surface.
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Figure 4-52. 2D plot of dose distribution of a "Y stent with 3x the activity at the stents edges
Figure 4-53 shows a comparison of a uniform 90Y stent with a 90Y stent with 3 times the
activity at the edges. The graph shows the curves as the ratio of the dose at a particular
point to the dose at the stent center for a fixed radial distance of 2 mm. At the stent edge,
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the dose delivered by the stent with the weighted activity is 130% of the dose at the stent
center, compared to 50% with a uniform 9Y stent.
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Figure 4-53. Comparison of dose as a function of axial distance from a uniform 9Y stent
and a "Y stent with 3 times the activity at the stent edges.
Table 4-13 shows the dose delivered from a uniform 90Y stent and one with 3 times the
activity at the stent edges for radial distances of 0.5, 1 and 2 mm from the surface of the
stent. The values of dose are taken for points at the stent center, or midplane, at the stent
edge, and 1, 2 and 3 mm distal to the stent edge.
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Table 4-13 . Dose calculation of a "Y stent with variation in activity at stent edges
Radial Position Along Stent Axis
Distance
from Stent Stent Stent Stent 1.0 mm 2.0 mm 3.0 mm
Surface Center Edge Distal Distal distal
05Y 228.34 120.19 47.21 21.78 10.34
.5mm 3 x Y 237.90 341.30 132.88 61.64 29.57
10Y 129.59 67.06 35.77 17.85 8.70
.mm 3 x Y 137.75 184.92 99.83 50.36 24.83
20mmY 58.19 29.90 19.07 10.77 5.59
2.__mm_3 x _Y 63.66 79.19 52.23 30.12 15.84
3 x Y indicates nonuniform activity (three times the activity at the stent edges)
4.9.2.31 8Re stent with 3x the activity at the stent edges
Figure 4-54 shows the 2D dose distribution of a 188Re stent with weighted activity at the
edges along the entire axis of the stent with distances ranging from 0.1 to 2.0 mm from
the stent surface.
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Figure 4-54. 2D plot of dose distribution of a 
188Re stent with 3x the activity at the stent
edges.
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Figure 4-55 shows a comparison of a uniform '88Re stent with a 188Re stent with 3 times
the activity at the edges. The graph shows the curves as the ratio of the dose at a
particular point to the dose at the stent center for a fixed radial distance of 2 mm. At the
stent edge, the dose delivered by the stent with the weighted activity is 125% of the dose
at the stent center, compared to 50% with a uniform Re stent.
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Figure 4-55. Comparison of dose as a function of axial distance from a uniform 188Re stent
and a 1"Re stent with 3 times the activity at the stent edges.
Table 4-14 shows the dose delivered from a uniform 'Re stent and one with 3 times the
activity at the stent edges for radial distances of 0.5, 1 and 2 mm from the surface of the
stent. The values of dose are taken for points at the stent center, or midplane, at the stent
edge, and 1, 2 and 3 mm distal to the stent edge.
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Table 4-14. Dose calculation of a 'Re stent with variation in activity at stent edges
Radial Position Along Stent Axis
DistanceDrstance Stent Stent Stent 1.0 mm 2.0 mm 3.0 mmfrom Stent Center Edge Distal Distal DistalSurface ____
0.5 mm Re 63.00 33.52 12.30 5.50 2.66
3 x Re 65.45 95.84 34.45 15.04 7.00
1.0 mm Re 33.76 17.74 9.21 2.30 1.28
3 x _Re 35.95 49.13 25.43 5.98 3.12
20 mmRe 14.30 7.59 4.86 2.83 1.632.__mm_ 3 x Re 15.98 19.91 12.86 7.33 4.06
3 x 'Re indicates nonuniform activity (three times the activity at the stent edges)
4.9.2.4. "7 Lu with 3x the activity at the stent edges
Figure 4-56 shows the 2D dose distribution of a 17Lu stent with weighted activity at the
edges along the entire axis of the stent with distances ranging from 0.1 to 2.0 mm from
the stent surface.
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Figure 4-56. 2D plot of dose distribution of a 177Lu emitting stent with 3x the activity at the
stent ends.
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Figure 4-57 shows a comparison of a uniform 1"Lu stent with a 1"Lu stent with 3 times
the activity at the edges. The graph shows the curves as the ratio of the dose at a
particular point to the dose at the stent center for a fixed radial distance of 2 mm. At the
stent edge, the dose delivered by the stent with the weighted activity is 67% of the dose at
the stent center, compared to 50% with a uniform Lu stent.
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Figure 4-57. Comparison of dose as a function of axial distance from a uniform "7Lu stent
and a 17"Lu stent with 3 times the activity at the stent edges.
Table 4-15 shows the dose delivered from a uniform 177LU stent and one with 3 times the
activity at the stent edges for radial distances of 0.5, 1 and 2 mm from the surface of the
stent. The values of dose are taken for points at the stent center, or midplane, at the stent
edge, and 1, 2 and 3 mm distal to the stent edge.
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Table 4-15. Dose calculation of a 17 Lu stent with variation in activity at stent edges
Radial Position Along Stent Axis
Distance
from Stent Stent Stent Stent 1.0 mm 2.0 mm 3.0 mm
Surface Center Edge Distal Distal Distal
0.5 mm Lu 49.10 27.66 10.05 6.74 4.97
3 x Lu 55.29 74.43 23.62 15.05 10.73
1.0 mm Lu 21.71 12.47 8.57 6.16 4.67
3 x Lu 27.55 29.42 19.51 13.52 9.96
2.0 Lu 13.50 8.14 6.50 5.13 4.10
n 3 x Lu 18.66 17.48 13.94 10.85 8.51
3 x 'Lu indicates nonuniform activity (three times the activity at the stent edges)
4.10. Validation of DPK convolution method with Monte Carlo simulation of a 3P
Cylinder
The validation of the DPK convolution used in the radiation dosimetry model was done
for the dose emitted by a cylinder of 32P as a function of radial distance from the surface
of the cylinder. Table 4-16 summarizes the parameters that were needed for the
calculation of the attenuation correction factor AF for the radioactivity of the 32P within
the volume of the cylinder.
Table 4-16. Tabulated parameters for calculation of attenuation correction factor for 32P
cylinder used in validation of DPK convolution.
1 dT
r (mm) d (mm) Ax (mm) -p-Ax AF
T dx
0.01 0.489 0.479 0.609 0.391
0.2 0.629 0.429 0.55 0.45
0.5 0.888 0.388 0.494 0.506
0.7 1.07 0.37 0.471 0.529
1.0 1.36 0.36 0.458 0.542
2.0 2.33 0.33 0.4201 0.5799
4.0 4.32 0.32 0.407 0.593
The Monte Carlo simulation of the 32P cylinder was done by Dr. Michael Stabin of
Vanderbilt University. Table 4-17 shows the dose values at specific target points obtained
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from Monte Carlo and DPK methods as well as the % error. This data is plotted in
Figure 4-58.
Table 4-17. Comparison between Monte Carlo and DPK dose values for increasing radial
distance.
r (mm) Monte Carlo DPK % Error
0.01 10,400 10,699.7 2.88
0.2 6,000 6,297.9 4.96
0.5 3,680 3,276.4 10.97
0.7 2,580 2,276.6 11.76
1.0 1,900 1,907.3 0.38
2.0 514 371.4 27.74
4.0 35.2 27.8 21.02
100000
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. 100001 
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- 1000
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Figure 4-58. Monte Carlo versus DPK convolution method for dose calculation as a function
of radial distance from surface of cylinder.
The dose emitted from a 32P stent was also compared to the dose calculated by Janicki et
al. (1997), which was also based on a DPK convolution model. The dose was calculated
for increasing radial distance r up to 2 mm from the surface of the stent. The stent used
by Janicki et al. (1997) was a Palmaz-Schatz stent with expanded dimensions of 5 mm in
diameter and 13 mm in length. The sample stent used in the radiation dosimetry model
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developed in this work had deployed dimensions of 4 mm in diameter and 15 mm in
length. Dose was calculated for stents with an initial activity of 1 4Ci cumulated over a
one half-life time interval of 14.28 days for 32P. Figure 4-59 shows the comparison of the
radial dose distribution curves obtained from the DPK radiation dosimetry model
developed in this work and the results presented by Janicki et al. (1997). Table 4-18
provides tabulated values of these results.
3000.00 
-t-- DPK Radiation Dosimetry Model
2500.00 - -- Janicid et al. (1997)
a 2000.00
0 1500.00
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Figure 4-59. Comparison of DPK radiation dosimetry model with published results (Jancki
et al. (1997)).
Table 4-18. Dose at increasing radial distance for DPK radiation dosimetry model and
published results from Janicki et al. (1997)
r (mm) DPK Radiation Janicki et al. % Error
Dosimetry Model (1997) %o
0.1 2,398.82 2,520 4.81
0.25 994.47 1,350 26.34
0.5 541.03 600 9.83
1.0 265.92 300 11.36
2.0 86.13 100 13.87
113
CHAPTER 5
DISCUSSION
The results from the DPK radiation dosimetry model of the 32 p 90y 188Re and
17Lu stents reveal several important findings. These radioisotopes are commonly used in
IVBT, with the exception of '77Lu, and are examples of the different radioisotopes that
can be used in the radiation dosimetry model. Relevant to all is the nonuniformity of the
dose at close proximity to the stent struts. There is a great variation of the dose at areas
immediately adjacent to the struts and that between the struts, resulting in the peaks and
valleys of the curves at distances of 0.1 mm shown in Figures 4-1, 4-8, 4-15 and 4-25.
This effect is also evident in the 3D dose maps for each of the stents. At distances of 1-2
mm from the stent surface, the dose distribution becomes more homogenous, although
falling to very low, almost negligible doses. It is believed that a dose in the range of 15-
30 Gy is significant in the treatment and prevention of neointimal hyperplasia. Dose is
expressed per unit of activity so to obtain a desired dose it is necessary to multiply by a
factor of activity. However, to deliver dose in this range to the adventitial layer at a depth
of 2 mm into the arterial wall, the dose at closer proximities to the stent surface will be
massive.
This pronounced nonuniformity of dose at such close distances is more evident
with 47Lu than with other isotopes investigated, and quite unfavorable. Because the beta
energy of '7Lu is so low and falls off so steeply to negligible doses at -2.0 mm, the dose
at distances greater than 2.0 mm results mostly from gamma emissions. The dose from
gamma energy is very low, and not enough to produce any significant effect on its own.
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The lutetium is embedded within the volume of the stent and a self-attenuation
correction factor of 0.28 was calculated for the beta emissions of this radioisotope. The
self-attenuation correction factor for gamma emissions was 0.991. This means that only
28% of the beta emissions will reach the target point, while most of the gamma energy
will be accounted for. Furthermore, in the presence of plaque, the dose will be attenuated
even further. This is not the most favorable radioisotope for IVBT, even less so for
incorporation into the NiTi alloy of the stent.
The radiation dosimetry model also allows the modification of dose distribution at
the stent edges. The problem of edge restenosis has prompted the investigation of other
alternatives within the radioactive stent. One such alternative is the increase of activity at
the stent ends. As can be seen from the results obtained for the uniform stents, the dose at
the stent ends is roughly 50% of that at the center of the stent. This is because the center
of the stent receives dose from the center as well as from the stent segment on either side.
At the stent ends, the dose is delivered by only half of a stent, as there is no source of
radiation in the areas proximal and distal from the stent ends. Figures 4-50, 4-52, 4-54,
and 4-6 illustrate 2D axial dose plots for 32P, 90Y, "'Re and '7 7Lu stents respectively with
3 times the activity at the stent ends. This did increase the percentage of the dose at the
stent ends compared to the dose in the center of the stent as well as for 3 mm distal to the
stent edges. However, the dose at the stent ends and beyond will never be the same as
that in the center because of the dose fall-off particularly in the case of beta emitters.
Even though clinical trials using these modifications have given unsatisfactory results,
self-expanding radioactive stents, as well as radioactive angioplasty balloons could help
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improve these efforts by reducing barotraumas at the stent edges (Serruys and Kay, 2000;
Hehrlein and Fischell, 2002).
Along with increasing the activity at the stent ends, different radioisotopes were
also simulated. A uniform 32P stent was reinforced with 90Y and '88Re. The selection of
these radioisotopes at the stent edges was based on their higher energy. Figures 4-46 and
4-47 show the results of this simulation and reveal that the dose is slightly increased at
the stent ends. This effect is amplified by increasing the activity of 90Y and '88Re yielding
162% and 83% higher dose at the ends respectively. The dosimetry of the 17Lu stent
established in this work has demonstrated that 17Lu is a poor candidate for IVBT due to
its rapid fall-off dose and extremely low beta energy that is almost entirely attenuated
when incorporated into the metal alloy of the stent. As previously stated, the gamma
energy of '"Lu is attenuated by only 0.01%, and at distances greater than 2 mm from the
stent, the dose is composed in its entirety of gamma emissions. Figure 4-35 shows a
comparison of the axial dose distribution of the 32p, 90y, 1Re and 177Lu calculated at a
fixed radial distance of 2 mm from the surface of the stent and measured as the ratio of
the dose to the dose at the center of the stent. Of the four radioisotopes, '"Lu has the
smoothest dose fall-off at the stent edges, with over 60% of the dose at the center at the
edge of the stent, compared to values of 50% and below for the other radioisotopes. At
this distance, the smoothness of the curve of 17Lu is a result of the gamma emissions.
The low gamma energy of mLu produces a smooth reduction in the dose fall-off at the
edges of the stent. This effect, which could in theory reduce the candy wrapper effect,
makes '"Lu a potentially useful candidate for use at the stent edges.
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The concept of BED is very important in radiotherapy treatment planning and is
widely used in the treatment of cancerous tumors (Dale, 1985,1993; Giap et al., 1999).
BED is more complete than physical absorbed dose in that it takes into account the repair
capability of the tissue, half-life and dose rate, all of which are not included in the
physical dose. Even though establishing a treatment based on BED is difficult due to
limited experimental data, it is physiologically more relevant. The results of the
radiobiological model for the four radioactive stents modeled in this project reveal that
the BED is much higher than the physical absorbed dose, ranging from 100 times higher
in the case of 188Re to 36 times higher in the case of '"Lu. This can be explained by the
much higher energy and shorter half-life of 188Re. Furthermore, it is interesting to note
that the relative effectiveness (RE) and hence the BED vary greatly as a function of radial
distance. At a smaller radial distance, the dose rate is much higher, resulting in a higher
value of RE. At a distance of 5.0 mm, the dose rate has decreased significantly and RE is
close to unity, therefore there is not much difference between the physical absorbed dose
and the BED. Table 4-8 offers an interesting analysis of BED for the same physical dose
delivered by the four radioisotope stents. The underlying premise is that for the same
physical dose delivered by different radioisotopes, the biological equivalent dose BED is
much different, because of the difference in dose rates, and half-lives of the
radioisotopes. These results illustrate the importance of this type of calculation and
provide an insight on the actual effect of this dose on the tissue. The goal is to irradiate
target tissue without causing significant damage to healthy tissue.
In the case of IVBT, the concept of BED may be even more important. Unlike the
treatment of cancer, where the interest is in irradiating and killing the tumor, in restenosis
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it is only necessary to irradiate a given population of cells so as to limit their proliferative
potential. Also, the range of target tissue is very small, only in the order of a few
millimeters thick. In the case of cancer, a higher BED is more favorable. In IVBT
applications, this is not as clear. Radiotherapy treatments are not an exact science. Even
today, dose prescription is done rather empirically. Because there is a lack of information
in the subject of BED related to IVBT and restenosis, the theoretical calculation of BED
is not widely used. It is not clear up to what point is a high BED desirable, and what are
the dose thresholds for BED that would prove effective in the prevention of restenosis.
The practical consequences of BED are unknown and worthy of further experimental
investigation.
An attempt was made in this work to investigate the radiobiological effects of the
uniform combination of radioisotopes in one stent. Figures 4-41, 4-43 and 4-45 show the
dose distribution of a ' 7Lu stent combined with 32P, 90Y and 188Re respectively. This
results in an increase in the total dose than what would be delivered by 1 7Lu alone. A
radiobiological modeling was done for each case as well, and is illustrated in figures 4-
42, 4-44 and 4-46. Similar to the simulation of a one-radioisotope stent, the BED is
greater than the physical dose. The dose rate is also increased. Unfortunately, the
advantage of incorporating more than one radioisotope in a stent is unknown and the
radiobiological data obtained from this analysis does not provide much enlightenment.
The use of multiple radioisotopes in a permanent implant has been used in radioactive
seeds for use in head and neck cancer and prostate carcinomas. For tumors containing
both fast growing and slow growing cells, the use of different radioisotopes with different
half-lives is advantageous (Chen et al., 2003). The details of the radiobiology and cellular
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kinetics in IVBT is not as clear, and therefore, conclusions that are made in the use of
radiation for treatment of cancer cannot be extended to IVBT with the same conviction.
This area is worthy of further experimental study. Nevertheless, the DPK radiation
dosimetry model has demonstrated to have the versatility of allowing the calculation of
dose and radiobiological equivalent dose of a stent containing more than one radioisotope
with similar ease and dexterity.
The validation of the DPK convolution method was done for the dose emitted
from a cylinder of 32P as a function of radial distance from the midplane of the cylinder
and compared to the results obtained from a Monte Carlo simulation done by Dr. Michael
Stabin of Vanderbilt University. Figure 4-57 shows that the curves for DPK and Monte
Carlo are in close agreement. The percentage error between the two ranges between
2.88% at the points closest to the surface of the cylinder to 21.02% at the furthest
distance of 4.0 mm. The error is greater at larger distances because the number of
radiations reaching the target point is considerably less. In addition there is a statistical
difference between the dose calculated from DPK and Monte Carlo methods, as the DPK
relies on the CSDA range and Monte Carlo follows the trajectory of each individual
electron and its respective attenuation along path length. Nevertheless, the correlation
between the two methods is most important at smaller distances, which are of greatest
significance in IVBT dosimetry.
In addition, the results of the DPK convolution method used in the radiation
dosimetry model in this work was also compared with the results of a paper published by
Janicki et al. (1997) which calculated dosimetry of a 32P Palmaz-Schatz stent using the
DPK. Figure 4-58 shows the comparison of these two methods for increasing radial
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distance calculated from the center of the stent. Dose was calculated from stents with an
initial activity of 1 Ci cumulated at one half life interval of 14.28 days for 32P. Table 4-
18 provides the tabulated data of these results. This table, as well as figure 4-58, shows
that the dose values obtained in the radiation dosimetry model developed in this work are
comparable to those obtained by Janicki et al. (1997). The error percentage between the
two can be explained by the different stent geometries and stent dimensions that were
used in each respective dose calculation. Additionally, the surface area or surface area
units in the convolution equation represented by the number of stent struts or coordinates
could be quite different for each stent.
The use of the dose point kernel is attractive because it is relatively simple to
accommodate different stent geometries, radioisotopes and activities, a task that is more
difficult and time consuming with Monte Carlo simulations. The calculation of dose
distribution of a radioactive stent in this project revealed fast computation times of less
than 15 minutes. Determination of the dose distribution around a radioactive source
simply requires inputting radiation source coordinates, initial activity, and the analytical
expression for a specific DPK, or a lookup table. Even the combination of isotopes is
done quickly and easily. Even though the Monte Carlo method can be very accurate, it is
generally not used for radiotherapy treatment planning because of the amount of time
required. Instead, most dose calculations rely on the use of tabulated data or dose point
kernel tables generated from Monte Carlo radiation transport simulations in water to
perform a very fast and generally accurate assessment of the dose distribution.
Monte Carlo simulations do hold some advantages over DPK methods. Monte
Carlo simulations can take into account different densities and materials, such as the
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presence of plaque to simulate more closely a realistic diseased artery. With DPK, this
becomes much more difficult, as the DPK describes the dose emitted by an isotropic
point source in water. However, calculations have been done using a scaling factor of
DPK that takes into account different densities such as that of plaque surrounding an
artery (Janicki et al., 1999).
The most important disadvantage of the DPK convolution method relevant in this
study is the problem of self-attenuation when radioactive material is embedded within the
NiTi material of the stent, such as the case of the 17Lu stent. In this case, the lutetium is
an integral part of the nickel-titanium alloy prior to its activation; therefore problems of
leaching, flaking or peeling of the radioactive coatings of the stent are essentially
eliminated (Satz, 2001). As a result, a more uniform distribution of the dose is expected.
However, attenuation is a big problem with beta particle irradiation, particularly in the
case of '7Lu, which has a very low energy and range. It is recommended that if a stent is
to be made in this manner that the radioactive material is of much higher beta energy, or a
low gamma energy, so that it is still capable of delivering significant dose to the target
tissue without being completely attenuated within the stent. In the case of '"Lu, only
28% of the dose from the beta energy is actually delivered to the target tissue. Even by
increasing the activity of '"Lu, the dose still would not be optimal, as there would have
to be an enormous dose at close proximity to the stent struts in order to deliver a
therapeutically significant dose to tissue at a target distance of 2 mm. Furthermore,
increasing the initial activity would also prove problematic since the cost of irradiation
would increase significantly, and there is a limit as to how much the stent can be
activated. The attenuation factor calculated in this work was based on approximations
121
and average values. This issue of attenuation correction could be more exact and tractable
through Monte Carlo simulations.
Calculation of the dose within a specified volume is a standard means employed
by radiation oncologists/radiation physicists for planning brachytherapy treatments (Fox,
1999). These dose calculation methods provide clinicians with a tool to make pre-
treatment evaluations of the dose distribution and customize the treatment for the
individual patient. Treatment planning in IVBT poses some difficulty because the
distances of interest are so small. In conventional brachytherapy applications, distances
are usually in a much greater range. Furthermore, there are many uncertainties related to
the optimal dose, radiation source, activity, and target tissue to be irradiated. In vascular
brachytherapy, the use of dose calculation methods for pre-treatment evaluation is not
widely carried out.
Even though radioactive stents have had their share of problems, particularly edge
effects, IVBT is considered a promising and effective anti-restenosis therapy (Kuntz and
Baim, 2000; Sims et al., 2002; Fox, 2002). In 2002, IVBT was the standard of care for
the treatment of in-stent restenosis, and is currently in practice in over 500 catheterization
labs in the United States (Waksman, 2002b). Catheter-based systems such as the Guidant
GalileoTM, Cordis CheckmateTM and Novoste Beta-CathTM systems are all implemented
clinically with much success. The radioactive stent as a delivery platform does need
much improvement, but a device that is so efficient in inhibiting in-stent neointimal
hyperplasia, with such a low incidence of thrombosis and simple in terms of delivery
technique should not be abandoned (Colombo, 2000).
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Improvement of stent design is a viable option, as well as a radioactive stent
specifically tailored for radiation delivery. Stents with fewer, thicker struts make poor
radiation delivery systems because of the accentuated difference of dose delivery
between the areas adjacent to the struts and the areas between the struts (Amols, 1999b).
This can be improved by decreasing stent strut thickness, increasing the number of struts,
and placing them closer together in order to deliver a more uniform dose at closer
proximities to the stent. It is possible to incorporate radiation considerations into stent
design but perhaps not without compromising mechanical properties. A stent with more
struts placed closer together could inhibit re-endothelialization that is an important
healing process necessary to minimize stent thrombosis. Nevertheless, it is questionable
if such a stent design would comply with the mechanical properties of the stent.
Radioisotope selection could also further improve the dose delivery of radioactive
stents. Some uncertainty exists as to whether 32P, the most commonly used radioisotope
in radioactive stents, which has a maximum energy of 1.71 MeV, provides sufficient
penetration to deliver adequate amounts of radiation to the media and adventitia (Amols,
1999a). Doses from all radioactive sources decrease by at least 30-50% per millimeter,
with the dose being very high near the source, but rapidly decreasing with increasing
distance. The dose fall-off rate exceeds 70% per millimeter for 32P (Amols, 1999a) If an
adequate dose is delivered to the media, the adventitia will receive a negligible dose. On
the other hand, for an adequate dose to be delivered to the adventitia, the dose to the
intima may be excessive (Amols, 1999a; Fischell et al., 2000). Other radioisotopes such
as positron emitter 48V, and gamma emitters 103Pd and 131Cs have received some attention
as candidates for use in radioactive stents (Hehrlein and Fischell, 2002). However, these
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gamma emitters are of relatively low energies and would require higher activities to
deliver therapeutically effective doses. There also exists the concern of irradiating healthy
tissue as a result of the more penetrating gamma rays. Still, there is uncertainty as to the
optimal activity of the radioisotope, dose and dose rate to be delivered to the tissue, as
well as the half-life that best matches the growth rates of the tissues involved in
neointimal hyperplasia and restenosis.
Drug-eluting stents have been acclaimed by many to be one of the greatest
breakthroughs in interventional cardiology (Waksman, 2002a; Indolfi et al., 2003). With
the advent of drug-eluting stent technology and the reported lower restenosis rates, it
would appear that the future of intravascular brachytherapy (IVBT) would be in jeopardy,
particularly in the case of radioactive stents. Despite the fact that radioactive stents need
much improvement, IVBT of a catheter-based nature is used clinically with much
success. After redilatation of in-stent restenosis, brachytherapy reduces the risk of
subsequent recurrence by over 50% (Teirstein and King, 2003). While IVBT has proven
to be an effective treatment in cases of in-stent restenosis, its fate in the drug-eluting stent
world appears to be uncertain.
At present, there is sufficient data from numerous trials including SCORES,
ELUTES, FIM, RAVEL, SIRIUS, TAXUS I, and TAXUS II to convincingly indicate the
promise and effectiveness of drug-eluting stents in reducing restenosis rates to single
digit percentages. A target lesion restenosis rate of only 5.5% was observed in the Boston
Scientific TAXUS II trial with a slow-release paclitaxel stent. In the Cordis SIRIUS trial
where sirolimus-eluting stents were compared to bare stents, restenosis of the target
lesion was observed in only 8.9% of treated patients compared with 36.6% of placebo
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patients (Teirstein and King, 2003). Moreover, the Cordis CYPHER drug-eluting stent
received FDA approval in April 2003, and the Boston Scientific TAXUS drug-eluting
stent has been given an expedited review status by the FDA (Endovascular Today,
May/June 2003).
Despite the enthusiasm surrounding drug-eluting stents, the technology is still not
perfect. The overall success of drug-eluting stents relies on inconsistent results between
animal and clinical trials. The animal models have generally yielded positive results,
although it is important to note that the atherosclerotic and healing processes in animals
and humans are quite different, with the healing process in humans being much longer
and complex. In addition, cases of edge restenosis in drug eluting stents, as well as
thrombosis, polymer-induced inflammation, drug-leaching and toxicity, nonabsorbable
polymers, and late stent malapposition have been reported (Waksman, 2002a, Indolfi et
al., 2003). Late malapposition, or separation of the stent from the vessel wall, has been
observed in both the RAVEL and the multi-center SIRIUS BX Velocity sirolimus coated
stent trials in a small cohort of patients that were subject to intravascular ultrasound
analysis (Indolfi et al., 2003). Other problems could emerge in the long-term results of
clinical trials.
A major shortcoming of drug-eluting stents is the cost. At present, drug-eluting
stents are costly, which might have a negative impact on their widespread applicability
(Waksman, 2002a). Each drug-eluting stent costs more than twice as much as a bare
metal stent. In Europe, where drug-eluting stents have been approved since 2002, the use
of drug-eluting stents ranged between 5 and 10% of cases, mainly for economic reasons.
Adequate reimbursement could also be a problem (Waksman, 2002a). For hospitals
125
receiving a budget on drug-eluting stents, not all patients and all lesions can be treated
with this technology.
Clinical trials have confirmed the benefit and efficacy of IVBT in treatment of in-
stent restenosis lesions of varying lengths and vessel diameters, native artery and
aortocoronary saphenous vein graft targets, bifurcation lesions, and/or the presence of
diabetes (Waksman and Weinberger, 2003). Recent trials have provided excellent-quality
data supporting the effectiveness of y-radiation for the treatment of saphenous vein graft
in-stent restenosis, superficial femoral artery obstructions, and diseased dialysis grafts.
Results from the SVG BRITE (Saphenous Vein Graft Beta Radiation to Prevent In-Stent
Restenosis) study with the use of a 32P source train are encouraging, with a 0% restenosis
rate (Waskman, 2002b). In the majority of clinical trials, drug-eluting stents have been
used mostly for smaller and simpler lesions. In the SIRIUS study, a 35% restenosis rate
was reported in insulin-dependent diabetic patients, despite the sirolimus-eluting stent.
Similarly, rates between 16 and 18% were observed in patients with long lesions and
small vessels (Waksman, 2002a). The risk of restenosis is much higher in longer and
complex lesions, and the initial data on drug-eluting stents is not very encouraging with
higher rates of restenosis in this group of patients (Massat, 2002; Waksman, 2002a;
Yajnik et al., 2003). Additionally, there exists no data regarding the effectiveness of
drug-eluting stents for saphenous vein graft stenoses (Yajnik et al., 2003).
It is the opinion of some experts that drug-eluting stents will more than double the
current number of patients undergoing stent implantation to approximately 2 million a
year by 2005 (Yajnik et al., 2003). If this is the case, even a very small rate of failure
such as 5% will translate into a considerable number of candidates for IVBT, up to
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100,000 per year, even in a drug-eluting stent era (Yajnik et al., 2003). Even though drug-
eluting stents might become the treatment of choice for in-stent restenosis, restenotic
lesions in a more difficult subset of patients with diabetes, long lesions and smaller
vessels, and restenosis in peripheral vessels will likely benefit from IVBT therapy.
Intravascular brachytherapy should not be dismissed completely as it has proven to be an
effective means of treating restenosis and may be needed for the treatment of in-stent
restenosis due to drug-eluting stent failures (Waksman, 2002a). A randomized study of
IVBT vs. drug-eluting stents in peripheral and more complex lesions is warranted and
might provide more conclusive information on this subject.
Experimental work using radiochromic film as well as complete Monte Carlo
simulations is recommended for further characterization of the '77Lu stent. In addition,
the calculation of self-attenuation correction factor by experimental means might also be
useful and could be a more accurate than theoretical approximations. This is specifically
significant for the cases in which the radioisotope is embedded within the volume of the
stent. The design of the experiment would consist of measuring the stent activity in a
radioisotope calibrator. This activity would be for the radiations emitted from the whole
stent and designated as Asa, or the activity of the self-attenuated radiations. The stent
would then be pulverized and its activity measured in a beta liquid scintillator with a
photomultiplier tube, and corrected for the time decay. This activity, Ao, is the actual
activity of the stent. The self-attenuation correction factor would be given by the quotient
of the two measured activities or AsA/Ao. Once determined, this self-attenuation
correction factor would be multiplied by the dose calculated from the stent. This is the
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experimental method used by NIST (National Institute of Standards and Technology) for
determining the activity of any material.
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CHAPTER 6
CONCLUSIONS
The DPK method developed in this work proved to be a fast, easy and versatile
way to estimate the 3D distribution of the dose emitted from radioactive stents. The
radiation dosimetry model developed in this work has the versatility to accommodate
different radioisotopes, stent geometries and activities. This model has fast computation
times of 15 minutes or less per simulation. It characterized the dose at different distances
into the target tissue in both radial and axial directions. The dosimetry of 32 p 9 0y 188Re
and '77Lu was investigated. Of the four, 32P delivers the highest dose, while 90Y 188Re
and '7Lu require high levels of activity to deliver a significant therapeutic dose in the
range of 15-30 Gy. At very short distances from the stent, the dose is highly nonuniform.
This nonuniformity decreases with increasing distance, although the dose falls off
significantly.
Two different kinds of stents were simulated in this study. The radioactivity was
assumed on the stent surface for 32P, 90Y and 1'8 Re. In the case of 17Lu, the radioactivity
was embedded within the volume of the stent. This required the calculation of self-
attenuation correction factors for both beta and gamma emissions of '7Lu. The total dose
delivered by 1'Lu was attenuated by 72% for beta emissions and 0.9 % for gamma
emissions. Even though the gamma emissions were hardly attenuated, the energy is too
low to be significant. In addition, the self-attenuation of beta particles by the stent when
the '7Lu is incorporated into the alloy, make this radioisotope a poor candidate for
intravascular brachytherapy. For a radioactive stent in which the radioactive material is
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an integral part of the metal alloy of the stent, a radioisotope with a much higher energy
should be used for a significant dose to be delivered to the target tissue. The main
limitation of the DPK model is the calculation of the self-attenuation of the beta
emissions when the radioisotope is incorporated into the volume of the stent. This
particular case could require the experimental determination of a self-attenuation factor.
The rapid fall-off dose of beta particles of radioisotopes used in this work results
in the dose at the stent edges being about fifty percent less than the dose at the center of
the stent. The low energy of the beta emissions does not allow adequate delivery of
radiation dose to the critical targets. Nevertheless, the low gamma energy of 177
produces a smooth reduction in the dose at the edges of the stent compared to the other
radioisotopes studied. This effect, which in theory could reduce the candy wrapper effect,
makes 17Lu a potentially useful radioisotope to be incorporated at the edges of the stent.
This also implies that the use of a gamma emitter at the stent edges could also be
favorable.
A radiobiological assessment provides interesting insights on the dose delivered at
a particular target point by different radioisotopes. It was shown that for the same
physical dose delivered by 32P, 90y, "'Re and 17Lu stents, the BED is quite different.
Physical absorbed dose does not say much about the quality and characteristics of the
dose. However, BED takes into account the rate at which the dose is delivered, the half-
life of the radioisotope and the repair capability of the tissue. BED can be up to 100 times
higher than physical absorbed dose. Results of the radiobiological model demonstrated
that the same physical dose delivered by different radioisotopes could produce
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significantly different biological effects. The practical consequence of this effect is
unknown and is worthy of further experimental investigation.
The dosimetry and radiobiological models developed in this work serve as a tool
to characterize the dosimetry of a radioactive stent, and give an idea of the
radiobiological effect. This type of theoretical dose calculation can be useful for the
development of new stent designs in efforts to improve the radioactive stent technology,
and in the planning of animal studies and clinical trials.
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APPENDIX A
Determination of the Spectrum of Beta Emissions of 17 Lu
139
The beta spectrum of "7Lu was determined according to the formalism of
Dillman et al. (1969) and Prestwich et al. (1989). The disintegration of 17 Lu includes
three beta emissions (Table A.1).
Table A.1. Nuclear Properties of 177Lu
Atomic Mass 177
Atomic Number 71
Beta Decay 0.498 MeV (79%)
0.385 MeV (9.1%)
0.177 MeV (12%)
Gamma Decay 0.208 MeV (11%)
1.113 MeV (6.4%)
For each emission an individual spectrum was calculated by using the following
equation (Prestwich et al., 1989):
n(E ) = CF (Z, W, )PW(EM - E,)2'
where Ei is the energy bin, n(E) is the relative number of beta emissions corresponding
to the energy Ei. EM is the maximum energy of the beta emission.
W, = E; +moc 2 -V 0,
in which moc 2 is the electron rest mass expressed in energy units (0.511 MeV) and V, is
the screened potential, given by:
1,131IZI41
V = = 0.0092 MeV,
a
where Z is the atomic number of daughter nucleus (Z = 72) and a is the fine structure
constant (a = 1/137) (Evans, p. 601, 1982).
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Pi is the screened momentum given by :
P = W, -moc 4 .
F(Z,Wi) is the Fermi function (Evans, p.548, 1982) expressed by:
F(Z,W)= FN(Z,W)x F2
in which F2 is given by:
a2Z2w2+(w 
-1) s
4 '
FN(ZW)= 
-2Xv
aZw;
17i
2'7
moc
P
moc
and S= 1-a 2Z 2 -1 =-0.1492.
C is a correction factor (Prestwich et al., 1989) given by:
C =1+ j(Z -50)+ b[Z -5012 x (i - e-vi)
where a= 4.05x10-4
b=2.23x10-5
k=1.26.
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For calculating the beta spectrum, the maximum energy was divided into 100 energy
bins. The relative number of emissions was determined for the average energy of each
energy bin. Tables A.2, A.3 and A.4 show the calculations for each beta disintegration of
'
77Lu. The graphs of the beta spectra are shown in Figures A.1, A.2 and A.3.
Table A.2. Spectrum calculation and distribution of the beta emission with maximum
energy of 0.498 MeV (79%)
Energy
number E (MeV) W P w I v F, F2  C n(E)
0 0.00249 511.0 3.20 1.0000 0.0063 84.0067 527.8307 1.2119 1.0197 0.02998
1 0.00747 511.1 9.04 1.0002 0.0177 29.7039 186.6355 1.2118 1.0197 0.02938
2 0.01245 514.3 57.77 1.0064 0.1131 4.6779 29.3923 1.2076 1.0169 0.02897
3 0.01743 519.2 92.11 1.0161 0.1803 2.9625 18.6140 1.2011 0.9953 0.02816
4 0.02241 524.2 117.0 1.0259 0.2289 2.3554 14.7993 1.1948 0.9673 0.02718
5 0.02739 529.2 137.6 1.0356 0.2692 2.0216 12.7019 1.1887 0.9399 0.02622
6 0.03237 534.2 155.6 1.0454 0.3046 1.8038 11.3337 1.1828 0.9146 0.02532
7 0.03735 539.2 172.0 1.0551 0.3365 1.6478 10.3541 1.1771 0.8918 0.02450
8 0.04233 544.1 187.0 1.0648 0.3659 1.5294 9.6101 1.1715 0.8713 0.02374
9 0.04731 549.1 201.0 1.0746 0.3934 1.4356 9.0215 1.1661 0.8526 0.02304
10 0.05229 554.1 214.2 1.0843 0.4193 1.3592 8.5418 1.1608 0.8358 0.02239
11 0.05727 559.1 226.8 1.0941 0.4439 1.2954 8.1418 1.1556 0.8204 0.02178
12 0.06225 564.1 238.8 1.1038 0.4674 1.2412 7.8021 1.1506 0.8063 0.02121
13 0.06723 569.0 250.4 1.1136 0.4899 1.1945 7.5094 1.1456 0.7933 0.02067
14 0.07221 574.0 261.5 1.1233 0.5117 1.1537 7.2541 1.1408 0.7814 0.02016
15 0.07719 579.0 272.2 1.1331 0.5328 1.1177 7.0291 1.1361 0.7703 0.01968
16 0.08217 584.0 282.7 1.1428 0.5532 1.0857 6.8292 1.1316 0.7601 0.01921
17 0.08715 589.0 292.8 1.1526 0.5730 1.0570 6.6501 1.1271 0.7505 0.01876
18 0.09213 593.9 302.7 1.1623 0.5924 1.0311 6.4887 1.1227 0.7416 0.01833
19 0.09711 598.9 312.4 1.1720 0.6113 1.0076 6.3424 1.1184 0.7332 0.01792
20 0.10209 603.9 321.8 1.1818 0.6298 0.9862 6.2091 1.1142 0.7254 0.01752
21 0.10707 608.9 331.1 1.1915 0.6479 0.9665 6.0870 1.1101 0.7180 0.01713
22 0.11205 613.9 340.1 1.2013 0.6656 0.9485 5.9747 1.1060 0.7111 0.01675
23 0.11703 618.8 349.1 1.2110 0.6831 0.9317 5.8712 1.1021 0.7045 0.01637
24 0.12201 623.8 357.8 1.2208 0.7002 0.9163 5.7753 1.0982 0.6983 0.01601
25 0.12699 628.8 366.4 1.2305 0.7171 0.9019 5.6863 1.0944 0.6924 0.01566
26 0.13197 633.8 374.9 1.2403 0.7337 0.8884 5.6034 1.0907 0.6868 0.01531
27 0.13695 638.8 383.3 1.2500 0.7500 0.8759 5.5260 1.0870 0.6815 0.01497
28 0.14193 643.7 391.5 1.2598 0.7662 0.8641 5.4535 1.0834 0.6765 0.01463
29 0.14691 648.7 399.6 1.2695 0.7821 0.8531 5.3855 1.0798 0.6716 0.01430
30 0.15189 653.7 407.7 1.2792 0.7978 0.8427 5.3216 1.0763 0.6671 0.01398
31 0.15687 658.7 415.6 1.2890 0.8133 0.8329 5.2614 1.0729 0.6627 0.01365
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32 0.16185 663.7 423.5 1.2987 0.8287 0.8237 5.2046 1.0696 0.6585 0.01334
33 0.16683 668.6 431.2 1.3085 0.8439 0.8149 5.1509 1.0662 0.6545 0.01302
34 0.17181 673.6 438.9 1.3182 0.8589 0.8066 5.1001 1.0630 0.6506 0.01271
35 0.17679 678.6 446.5 1.3280 0.8738 0.7987 5.0519 1.0598 0.6470 0.01241
36 0.18177 683.6 454.0 1.3377 0.8885 0.7912 5.0062 1.0566 0.6434 0.01210
37 0.18675 688.6 461.5 1.3475 0.9031 0.7841 4.9627 1.0535 0.6400 0.01180
38 0.19173 693.5 468.9 1.3572 0.9176 0.7773 4.9213 1.0505 0.6368 0.01151
39 0.19671 698.5 476.2 1.3670 0.9320 0.7708 4.8818 1.0474 0.6336 0.01121
40 0.20169 703.5 483.5 1.3767 0.9462 0.7647 4.8442 1.0445 0.6306 0.01092
41 0.20667 708.5 490.7 1.3864 0.9603 0.7587 4.8082 1.0415 0.6277 0.01063
42 0.21165 713.5 497.9 1.3962 0.9744 0.7531 4.7738 1.0387 0.6249 0.01034
43 0.21663 718.4 505.0 1.4059 0.9883 0.7477 4.7409 1.0358 0.6222 0.01006
44 0.22161 723.4 512.1 1.4157 1.0021 0.7425 4.7094 1.0330 0.6196 0.00977
45 0.22659 728.4 519.1 1.4254 1.0158 0.7375 4.6792 1.0302 0.6171 0.00949
46 0.23157 733.4 526.0 1.4352 1.0294 0.7327 4.6502 1.0275 0.6146 0.00921
47 0.23655 738.4 533.0 1.4449 1.0430 0.7281 4.6224 1.0248 0.6123 0.00894
48 0.24153 743.3 539.8 1.4547 1.0564 0.7237 4.5956 1.0222 0.6100 0.00867
49 0.24651 748.3 546.7 1.4644 1.0698 0.7194 4.5698 1.0196 0.6078 0.00840
50 0.25149 753.3 553.5 1.4742 1.0831 0.7153 4.5451 1.0170 0.6056 0.00813
51 0.25647 758.3 560.2 1.4839 1.0963 0.7113 4.5212 1.0144 0.6036 0.00786
52 0.26145 763.3 567.0 1.4937 1.1095 0.7075 4.4982 1.0119 0.6016 0.00760
53 0.26643 768.2 573.6 1.5034 1.1226 0.7038 4.4760 1.0094 0.5996 0.00734
54 0.27141 773.2 580.3 1.5131 1.1356 0.7003 4.4546 1.0069 0.5977 0.00708
55 0.27639 778.2 586.9 1.5229 1.1486 0.6968 4.4340 1.0045 0.5959 0.00682
56 0.28137 783.2 593.5 1.5326 1.1614 0.6935 4.4140 1.0021 0.5941 0.00657
57 0.28635 788.2 600.1 1.5424 1.1743 0.6903 4.3947 0.9997 0.5924 0.00632
58 0.29133 793.1 606.6 1.5521 1.1871 0.6872 4.3760 0.9974 0.5907 0.00607
59 0.29631 798.1 613.1 1.5619 1.1998 0.6842 4.3579 0.9951 0.5891 0.00583
60 0.30129 803.1 619.5 1.5716 1.2124 0.6812 4.3405 0.9928 0.5875 0.00558
61 0.30627 808.1 626.0 1.5814 1.2250 0.6784 4.3235 0.9905 0.5860 0.00535
62 0.31125 813.1 632.4 1.5911 1.2376 0.6757 4.3071 0.9883 0.5845 0.00511
63 0.31623 818.0 638.8 1.6009 1.2501 0.6730 4.2912 0.9861 0.5830 0.00488
64 0.32121 823.0 645.2 1.6106 1.2625 0.6704 4.2758 0.9839 0.5816 0.00465
65 0.32619 828.0 651.5 1.6203 1.2750 0.6679 4.2608 0.9817 0.5802 0.00443
66 0.33117 833.0 657.8 1.6301 1.2873 0.6655 4.2462 0.9796 0.5788 0.00421
67 0.33615 838.0 664.1 1.6398 1.2996 0.6631 4.2321 0.9774 0.5775 0.00399
68 0.34113 842.9 670.4 1.6496 1.3119 0.6608 4.2184 0.9753 0.5762 0.00378
69 0.34611 847.9 676.6 1.6593 1.3241 0.6586 4.2051 0.9733 0.5750 0.00357
70 0.35109 852.9 682.9 1.6691 1.3363 0.6564 4.1921 0.9712 0.5738 0.00336
71 0.35607 857.9 689.1 1.6788 1.3485 0.6543 4.1795 0.9692 0.5726 0.00316
72 0.36105 862.9 695.3 1.6886 1.3606 0.6522 4.1673 0.9672 0.5714 0.00297
73 0.36603 867.8 701.4 1.6983 1.3727 0.6502 4.1553 0.9652 0.5703 0.00278
74 0.37101 872.8 707.6 1.7081 1.3847 0.6483 4.1437 0.9632 0.5692 0.00259
75 0.37599 877.8 713.7 1.7178 1.3967 0.6464 4.1324 0.9613 0.5681 0.00241
76 0.38097 882.8 719.8 1.7275 1.4087 0.6445 4.1214 0.9593 0.5670 0.00224
77 0.38595 887.8 725.9 1.7373 1.4206 0.6427 4.1106 0.9574 0.5660 0.00207
78 0.39093 892.7 732.0 1.7470 1.4325 0.6409 4.1002 0.9555 0.5650 0.00190
79 0.39591 897.7 738.1 1.7568 1.4444 0.6392 4.0900 0.9536 0.5640 0.00174
80 0.40089 902.7 744.1 1.7665 1.4562 0.6375 4.0800 0.9518 0.5630 0.00159
143
81 0.40587 907.7 750.2 1.7763 1.4680 0.6359 4.0703 0.9499 0.5621 0.00144
82 0.41085 912.7 756.2 1.7860 1.4798 0.6343 4.0609 0.9481 0.5612 0.00130
83 0.41583 917.6 762.2 1.7958 1.4916 0.6327 4.0516 0.9463 0.5603 0.00116
84 0.42081 922.6 768.2 1.8055 1.5033 0.6312 4.0426 0.9445 0.5594 0.00103
85 0.42579 927.6 774.2 1.8153 1.5150 0.6297 4.0338 0.9427 0.5585 0.00091
86 0.43077 932.6 780.1 1.8250 1.5266 0.6283 4.0252 0.9410 0.5577 0.00080
87 0.43575 937.6 786.1 1.8347 1.5383 0.6268 4.0168 0.9392 0.5568 0.00069
88 0.44073 942.5 792.0 1.8445 1.5499 0.6254 4.0085 0.9375 0.5560 0.00059
89 0.44571 947.5 797.9 1.8542 1.5615 0.6241 4.0005 0.9358 0.5552 0.00049
90 0.45069 952.5 803.8 1.8640 1.5730 0.6228 3.9927 0.9341 0.5544 0.00041
91 0.45567 957.5 809.7 1.8737 1.5846 0.6215 3.9850 0.9324 0.5537 0.00033
92 0.46065 962.5 815.6 1.8835 1.5961 0.6202 3.9775 0.9307 0.5529 0.00026
93 0.46563 967.4 821.5 1.8932 1.6076 0.6189 3.9701 0.9291 0.5522 0.00019
94 0.47061 972.4 827.3 1.9030 1.6190 0.6177 3.9629 0.9275 0.5515 0.00014
95 0.47559 977.4 833.2 1.9127 1.6305 0.6165 3.9559 0.9258 0.5508 0.000095
96 0.48057 982.4 839.0 1.9225 1.6419 0.6153 3.9490 0.9242 0.5501 0.000058
97 0.48555 987.4 844.8 1.9322 1.6533 0.6142 3.9423 0.9226 0.5494 0.000030
98 0.49053 992.3 850.7 1.9419 1.6647 0.6131 3.9357 0.9210 0.5487 0.000011
99 0.49551 997.3 856.5 1.9517 1.6760 0.6120 3.9292 0.9195 0.5481 0.000001
Figure A.1 Beta Spectrum of '"Lu with Maximum Energy of 0.498 MeV (79%)
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Table A.3. Spectrum calculation and distribution of the beta emission with maximum
energy of 0.385 MeV (9.1%)
Energy
bin
number E (MeV) W P w v F. F2  C n(E)
0 0.00249 511.0 3.20 1.0000 0.0063 84.0067 527.8307 1.2119 1.0197 0.03951
1 0.00747 511.1 9.04 1.0002 0.0177 29.7039 186.6355 1.2118 1.0197 0.03849
2 0.01245 514.3 57.77 1.0064 0.1131 4.6779 29.3923 1.2076 1.0169 0.03772
3 0.01743 519.2 92.11 1.0161 0.1803 2.9625 18.6140 1.2011 0.9953 0.03644
4 0.02241 524.2 117.0 1.0259 0.2289 2.3554 14.7993 1.1948 0.9673 0.03494
5 0.02739 529.2 137.6 1.0356 0.2692 2.0216 12.7019 1.1887 0.9399 0.03349
6 0.03237 534.2 155.6 1.0454 0.3046 1.8038 11.3337 1.1828 0.9146 0.03213
7 0.03735 539.2 172.0 1.0551 0.3365 1.6478 10.3541 1.1771 0.8918 0.03087
8 0.04233 544.1 187.0 1.0648 0.3659 1.5294 9.6101 1.1715 0.8713 0.02970
9 0.04731 549.1 201.0 1.0746 0.3934 1.4356 9.0215 1.1661 0.8526 0.02862
10 0.05229 554.1 214.2 1.0843 0.4193 1.3592 8.5418 1.1608 0.8358 0.02760
11 0.05727 559.1 226.8 1.0941 0.4439 1.2954 8.1418 1.1556 0.8204 0.02665
12 0.06225 564.1 238.8 1.1038 0.4674 1.2412 7.8021 1.1506 0.8063 0.02575
13 0.06723 569.0 250.4 1.1136 0.4899 1.1945 7.5094 1.1456 0.7933 0.02489
14 0.07221 574.0 261.5 1.1233 0.5117 1.1537 7.2541 1.1408 0.7814 0.02407
15 0.07719 579.0 272.2 1.1331 0.5328 1.1177 7.0291 1.1361 0.7703 0.02329
16 0.08217 584.0 282.7 1.1428 0.5532 1.0857 6.8292 1.1316 0.7601 0.02254
17 0.08715 589.0 292.8 1.1526 0.5730 1.0570 6.6501 1.1271 0.7505 0.02182
18 0.09213 593.9 302.7 1.1623 0.5924 1.0311 6.4887 1.1227 0.7416 0.02112
19 0.09711 598.9 312.4 1.1720 0.6113 1.0076 6.3424 1.1184 0.7332 0.02045
20 0.10209 603.9 321.8 1.1818 0.6298 0.9862 6.2091 1.1142 0.7254 0.01979
21 0.10707 608.9 331.1 1.1915 0.6479 0.9665 6.0870 1.1101 0.7180 0.01916
22 0.11205 613.9 340.1 1.2013 0.6656 0.9485 5.9747 1.1060 0.7111 0.01854
23 0.11703 618.8 349.1 1.2110 0.6831 0.9317 5.8712 1.1021 0.7045 0.01793
24 0.12201 623.8 357.8 1.2208 0.7002 0.9163 5.7753 1.0982 0.6983 0.01734
25 0.12699 628.8 366.4 1.2305 0.7171 0.9019 5.6863 1.0944 0.6924 0.01676
26 0.13197 633.8 374.9 1.2403 0.7337 0.8884 5.6034 1.0907 0.6868 0.01620
27 0.13695 638.8 383.3 1.2500 0.7500 0.8759 5.5260 1.0870 0.6815 0.01564
28 0.14193 643.7 391.5 1.2598 0.7662 0.8641 5.4535 1.0834 0.6765 0.01510
29 0.14691 648.7 399.6 1.2695 0.7821 0.8531 5.3855 1.0798 0.6716 0.01456
30 0.15189 653.7 407.7 1.2792 0.7978 0.8427 5.3216 1.0763 0.6671 0.01404
31 0.15687 658.7 415.6 1.2890 0.8133 0.8329 5.2614 1.0729 0.6627 0.01352
32 0.16185 663.7 423.5 1.2987 0.8287 0.8237 5.2046 1.0696 0.6585 0.01302
33 0.16683 668.6 431.2 1.3085 0.8439 0.8149 5.1509 1.0662 0.6545 0.01252
34 0.17181 673.6 438.9 1.3182 0.8589 0.8066 5.1001 1.0630 0.6506 0.01203
35 0.17679 678.6 446.5 1.3280 0.8738 0.7987 5.0519 1.0598 0.6470 0.01155
36 0.18177 683.6 454.0 1.3377 0.8885 0.7912 5.0062 1.0566 0.6434 0.01108
37 0.18675 688.6 461.5 1.3475 0.9031 0.7841 4.9627 1.0535 0.6400 0.01061
38 0.19173 693.5 468.9 1.3572 0.9176 0.7773 4.9213 1.0505 0.6368 0.01015
39 0.19671 698.5 476.2 1.3670 0.9320 0.7708 4.8818 1.0474 0.6336 0.00970
40 0.20169 703.5 483.5 1.3767 0.9462 0.7647 4.8442 1.0445 0.6306 0.00926
41 0.20667 708.5 490.7 1.3864 0.9603 0.7587 4.8082 1.0415 0.6277 0.00883
42 0.21165 713.5 497.9 1.3962 0.9744 0.7531 4.7738 1.0387 0.6249 0.00840
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43 0.21663 718.4 505.0 1.4059 0.9883 0.7477 4.7409 1.0358 0.6222 0.00798
44 0.22161 723.4 512.1 1.4157 1.0021 0.7425 4.7094 1.0330 0.6196 0.00757
45 0.22659 728.4 519.1 1.4254 1.0158 0.7375 4.6792 1.0302 0.6171 0.00717
46 0.23157 733.4 526.0 1.4352 1.0294 0.7327 4.6502 1.0275 0.6146 0.00678
47 0.23655 738.4 533.0 1.4449 1.0430 0.7281 4.6224 1.0248 0.6123 0.00639
48 0.24153 743.3 539.8 1.4547 1.0564 0.7237 4.5956 1.0222 0.6100 0.00602
49 0.24651 748.3 546.7 1.4644 1.0698 0.7194 4.5698 1.0196 0.6078 0.00565
50 0.25149 753.3 553.5 1.4742 1.0831 0.7153 4.5451 1.0170 0.6056 0.00529
51 0.25647 758.3 560.2 1.4839 1.0963 0.7113 4.5212 1.0144 0.6036 0.00494
52 0.26145 763.3 567.0 1.4937 1.1095 0.7075 4.4982 1.0119 0.6016 0.00460
53 0.26643 768.2 573.6 1.5034 1.1226 0.7038 4.4760 1.0094 0.5996 0.00427
54 0.27141 773.2 580.3 1.5131 1.1356 0.7003 4.4546 1.0069 0.5977 0.00395
55 0.27639 778.2 586.9 1.5229 1.1486 0.6968 4.4340 1.0045 0.5959 0.00364
56 0.28137 783.2 593.5 1.5326 1.1614 0.6935 4.4140 1.0021 0.5941 0.00334
57 0.28635 788.2 600.1 1.5424 1.1743 0.6903 4.3947 0.9997 0.5924 0.00305
58 0.29133 793.1 606.6 1.5521 1.1871 0.6872 4.3760 0.9974 0.5907 0.00278
59 0.29631 798.1 613.1 1.5619 1.1998 0.6842 4.3579 0.9951 0.5891 0.00251
60 0.30129 803.1 619.5 1.5716 1.2124 0.6812 4.3405 0.9928 0.5875 0.00225
61 0.30627 808.1 626.0 1.5814 1.2250 0.6784 4.3235 0.9905 0.5860 0.00201
62 0.31125 813.1 632.4 1.5911 1.2376 0.6757 4.3071 0.9883 0.5845 0.00178
63 0.31623 818.0 638.8 1.6009 1.2501 0.6730 4.2912 0.9861 0.5830 0.00156
64 0.32121 823.0 645.2 1.6106 1.2625 0.6704 4.2758 0.9839 0.5816 0.00135
65 0.32619 828.0 651.5 1.6203 1.2750 0.6679 4.2608 0.9817 0.5802 0.00116
66 0.33117 833.0 657.8 1.6301 1.2873 0.6655 4.2462 0.9796 0.5788 0.00098
67 0.33615 838.0 664.1 1.6398 1.2996 0.6631 4.2321 0.9774 0.5775 0.00082
68 0.34113 842.9 670.4 1.6496 1.3119 0.6608 4.2184 0.9753 0.5762 0.00066
69 0.34611 847.9 676.6 1.6593 1.3241 0.6586 4.2051 0.9733 0.5750 0.00053
70 0.35109 852.9 682.9 1.6691 1.3363 0.6564 4.1921 0.9712 0.5738 0.00040
71 0.35607 857.9 689.1 1.6788 1.3485 0.6543 4.1795 0.9692 0.5726 0.00030
72 0.36105 862.9 695.3 1.6886 1.3606 0.6522 4.1673 0.9672 0.5714 0.00021
73 0.36603 867.8 701.4 1.6983 1.3727 0.6502 4.1553 0.9652 0.5703 0.00013
74 0.37101 872.8 707.6 1.7081 1.3847 0.6483 4.1437 0.9632 0.5692 7.3E-05
75 0.37599 877.8 713.7 1.7178 1.3967 0.6464 4.1324 0.9613 0.5681 3.2E-05
76 0.38097 882.8 719.8 1.7275 1.4087 0.6445 4.1214 0.9593 0.5670 7.1E-06
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Figure A.2 Beta Spectrum of 177Lu with Maximum Energy of 0.385 MeV (9.1%)
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Table A.4. Spectrum calculation and distribution of the beta emission with maximum
energy of 0.177 MeV (12.0%)
Energy
number E (MeV) W P w rl v F. F2  C n(E)
0 0.00249 511.0 3.20 1.0000 0.0063 84.0067 527.8307 1.2119 1.0197 0.08591
1 0.00747 511.1 9.04 1.0002 0.0177 29.7039 186.6355 1.2118 1.0197 0.08109
2 0.01245 514.3 57.77 1.0064 0.1131 4.6779 29.3923 1.2076 1.0169 0.07687
3 0.01743 519.2 92.11 1.0161 0.1803 2.9625 18.6140 1.2011 0.9953 0.07174
4 0.02241 524.2 117.0 1.0259 0.2289 2.3554 14.7993 1.1948 0.9673 0.06635
5 0.02739 529.2 137.6 1.0356 0.2692 2.0216 12.7019 1.1887 0.9399 0.06122
6 0.03237 534.2 155.6 1.0454 0.3046 1.8038 11.3337 1.1828 0.9146 0.05645
7 0.03735 539.2 172.0 1.0551 0.3365 1.6478 10.3541 1.1771 0.8918 0.05203
8 0.04233 544.1 187.0 1.0648 0.3659 1.5294 9.6101 1.1715 0.8713 0.04791
9 0.04731 549.1 201.0 1.0746 0.3934 1.4356 9.0215 1.1661 0.8526 0.04408
10 0.05229 554.1 214.2 1.0843 0.4193 1.3592 8.5418 1.1608 0.8358 0.04050
11 0.05727 559.1 226.8 1.0941 0.4439 1.2954 8.1418 1.1556 0.8204 0.03714
12 0.06225 564.1 238.8 1.1038 0.4674 1.2412 7.8021 1.1506 0.8063 0.03399
13 0.06723 569.0 250.4 1.1136 0.4899 1.1945 7.5094 1.1456 0.7933 0.03102
14 0.07221 574.0 261.5 1.1233 0.5117 1.1537 7.2541 1.1408 0.7814 0.02822
15 0.07719 579.0 272.2 1.1331 0.5328 1.1177 7.0291 1.1361 0.7703 0.02557
16 0.08217 584.0 282.7 1.1428 0.5532 1.0857 6.8292 1.1316 0.7601 0.02308
17 0.08715 589.0 292.8 1.1526 0.5730 1.0570 6.6501 1.1271 0.7505 0.02073
18 0.09213 593.9 302.7 1.1623 0.5924 1.0311 6.4887 1.1227 0.7416 0.01852
19 0.09711 598.9 312.4 1.1720 0.6113 1.0076 6.3424 1.1184 0.7332 0.01644
20 0.10209 603.9 321.8 1.1818 0.6298 0.9862 6.2091 1.1142 0.7254 0.01449
21 0.10707 608.9 331.1 1.1915 0.6479 0.9665 6.0870 1.1101 0.7180 0.01266
22 0.11205 613.9 340.1 1.2013 0.6656 0.9485 5.9747 1.1060 0.7111 0.01096
23 0.11703 618.8 349.1 1.2110 0.6831 0.9317 5.8712 1.1021 0.7045 0.00937
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24 0.12201 623.8 357.8 1.2208 0.7002 0.9163 5.7753 1.0982 0.6983 0.00791
25 0.12699 628.8 366.4 1.2305 0.7171 0.9019 5.6863 1.0944 0.6924 0.00657
26 0.13197 633.8 374.9 1.2403 0.7337 0.8884 5.6034 1.0907 0.6868 0.00535
27 0.13695 638.8 383.3 1.2500 0.7500 0.8759 5.5260 1.0870 0.6815 0.00426
28 0.14193 643.7 391.5 1.2598 0.7662 0.8641 5.4535 1.0834 0.6765 0.00328
29 0.14691 648.7 399.6 1.2695 0.7821 0.8531 5.3855 1.0798 0.6716 0.00243
30 0.15189 653.7 407.7 1.2792 0.7978 0.8427 5.3216 1.0763 0.6671 0.00170
31 0.15687 658.7 415.6 1.2890 0.8133 0.8329 5.2614 1.0729 0.6627 0.00110
32 0.16185 663.7 423.5 1.2987 0.8287 0.8237 5.2046 1.0696 0.6585 0.00063
33 0.16683 668.6 431.2 1.3085 0.8439 0.8149 5.1509 1.0662 0.6545 0.00028
34 0.17181 673.6 438.9 1.3182 0.8589 0.8066 5.1001 1.0630 0.6506 7.4E-05
35 0.17679 678.6 446.5 1.3280 0.8738 0.7987 5.0519 1.0598 0.6470 1.2E-07
Figure A.3 Beta Spectrum of '"Lu with Maximum Energy of 0.177 MeV (12.0%)
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The complete spectrum including the three beta emissions was determined by
adding the individual contributions of each beta emission according to the following
equation:
n(E,) =0.79n, (E, )+ 0.091n2 (E,)+ 0.12n3 (E,)
where nf(E), n2(E) and n3(E) correspond to the spectrum emissions of the maximum
energies of 0.498 MeV, 0.385 MeV and 0.177 MeV respectively. Table A.5 shows the
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numerical data of the complete beta energy spectrum of '77Lu. Figure A.4 shows the
graph of the complete spectrum.
Table A.5. Complete beta energy spectrum of 17 Lu
E Me n(E)
0.00249 0.03759
0.00747 0.03645
0.01245 0.03554
0.01743 0.03417
0.02241 0.03261
0.02739 0.03111
0.03237 0.02970
0.03735 0.02841
0.04233 0.02721
0.04731 0.02610
0.05229 0.02506
0.05727 0.02409
0.06225 0.02318
0.06723 0.02232
0.07221 0.02150
0.07719 0.02073
0.08217 0.02000
0.08715 0.01930
0.09213 0.01863
0.09711 0.01799
0.10209 0.01738
0.10707 0.01679
0.11205 0.01623
0.11703 0.01569
0.12201 0.01518
0.12699 0.01468
0.13197 0.01421
0.13695 0.01376
0.14193 0.01333
0.14691 0.01291
0.15189 0.01252
0.15687 0.01215
0.16185 0.01180
0.16683 0.01146
0.17181 0.01115
0.17679 0.01085
0.18177 0.01057
0.18675 0.01029
0.19173 0.01001
149
E (MeV) n(E)
0.19671 0.00974
0.20169 0.00947
0.20667 0.00920
0.21165 0.00893
0.21663 0.00867
0.22161 0.00841
0.22659 0.00815
0.23157 0.00790
0.23655 0.00764
0.24153 0.00739
0.24651 0.00715
0.25149 0.00690
0.25647 0.00666
0.26145 0.00642
0.26643 0.00618
0.27141 0.00595
0.27639 0.00572
0.28137 0.00549
0.28635 0.00527
0.29133 0.00505
0.29631 0.00483
0.30129 0.00462
0.30627 0.00441
0.31125 0.00420
0.31623 0.00400
0.32121 0.00380
0.32619 0.00360
0.33117 0.00341
0.33615 0.00323
0.34113 0.00304
0.34611 0.00287
0.35109 0.00269
0.35607 0.00253
0.36105 0.00236
0.36603 0.00221
0.37101 0.00205
0.37599 0.00191
0.38097 0.00177
0.38595 0.00163
0.39093 0.00150
0.39591 0.00138
0.40089 0.00125
0.40587 0.00114
0.41085 0.00103
0.41583 0.00092
0.42081 0.00082
0.42579 0.00072
0.43077 0.00063
150
E (MeV n(E)
0.43575 0.00054
0.44073 0.00046
0.44571 0.00039
0.45069 0.00032
0.45567 0.00026
0.46065 0.00020
0.46563 0.00015
0.47061 0.00011
0.47559 0.00007
0.48057 0.00005
0.48555 0.00002
0.49053 0.00001
0.49551 0.00000
Figure A.4 Beta Energy Spectrum of 17 Lu
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APPENDIX B
Calculation of Beta Dose Point Kernel of mL
152
The DPK for 177Lu was calculated according to equation 9 (Chapter 3, p. ). The
DPK of beta particles was derived from the dimensionless dose distribution
j(r/R, E)tabulated by Cross et al. (1992), where:
j(r/R, E)= 4npr 2 x DPK(r, E)x R/E ,
in which p is the density of water equal to 1 g/cm 2, r2 is the distance from the point source
to the target point and R is the range of beta particles in water for a specific energy E.
The DPK was calculated from the following equation:
DPK(r,E)= r/R, x E
41rpr2R E
The range R was determined from the beta range tables in water (Attix, Appendix E,
p.575, 1986). DPK was determined at intervals of 25 keV. Those values of j(r,E) or range
R, which were not available in the tables, were calculated by logarithmic linear
interpolation. Table B-1 shows the contribution to the DPK of each energy bin at
intervals of 25 keV. Table B-2 shows the value of the DPK of 177Lu at distances ranging
up to 2 mm.
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Table B-1. Contribution of each energy bin to DPK of'77Lu for distances ranging from
0.01 to 0.2 cm
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Table B-2. Beta DPK of "Lu
nGy-cm 2/
r (cm) MeV/g nGy/Bq-h Bq-h
0 212.51
0.01 1465.6 845240.8 84.52408
0.015 802.7 462933.1 104.16
0.02 356.63 205675.7 82.27026
0.025 198.5 114478.9 71.54933
0.03 111.83 64494.6 58.04514
0.035 69.1 39851.35 48.81791
0.04 41.9 24164.57 38.66331
0.045 29.3 16897.9 34.21824
0.05 20.9 12053.45 30.13362
0.055 15.2 8766.144 26.51759
0.06 11.11 6407.359 23.06649
0.065 7.52 4336.934 18.32355
0.07 5.18 2987.41 14.63831
0.075 3.39 1955.081 10.99733
0.08 2.36 1361.059 8.710779
0.085 1.63 940.0536 6.791887
0.09 1.064 613.6301 4.970404
0.095 0.606 349.4923 3.154168
0.1 0.29 167.2488 1.672488
0.125 0.0356 20.53123 0.320801
0.15 0.00245 1.412964 0.031792
0.175 0.00028 0.161482 0.004945
0.2 0.00004 0.023069 0.000923
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Appendix C
Calculation of Gamma DPK of '"Lu
156
Tables C-1 and C-2 present the results of the logarithmic linear interpolation that was
done to obtain the DPK values for gamma emissions of '7Lu with energies of .208 MeV
and 0.113 MeV for a given distance d. The interpolation was done using the values
provided in the tables by Luxton and Jozsef (1999). Table C-3 provides the final DPK of
17Lu obtain by summing up the DPK for both energies multiplied by the fraction of
emissions according to equation 11 (Chapter 3).
Table C-1. Dose to water per gamma ray emission from a point source (nGycm 2/Bq-hr) for
gamma energy 0.208 MeV (11.0%)
d(cm) 0.200 0.250 0.208dc) MeV MeV MeV
0.05 0.2852 0.3648 0.296657
0.1 0.28 0.3629 0.291863
0.2 0.2736 0.357 0.285499
0.24 0.2743 0.3545 0.285791
0.3 0.2693 0.3626 0.282428
0.4 0.2779 0.3699 0.290911
0.5 0.2719 0.361 0.284515
0.6 0.2803 0.3598 0.291725
0.8 0.2811 0.363 0.292838
0.9 0.2861 0.3648 0.297443
1 0.286 0.364 0.297251
1.11 0.2883 0.3688 0.299886
1.2 0.2875 0.3745 0.299922
1.5 0.2925 0.3706 0.303788
2 0.2985 0.3763 0.30977
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Table C-2. Dose to water per gamma ray emission from a point source (nGycm 2/Bq-hr) for
gamma energy 0.113 MeV (6.4%)
d(cm) 0.100 0.125 0.113dm) MeV MeV MeV
0.05 0.126 0.1559 0.140753
0.1 0.1231 0.1514 0.137085
0.2 0.1226 0.1519 0.137052
0.24 0.1206 0.1584 0.138969
0.3 0.1226 0.1563 0.139102
0.4 0.1244 0.161 0.142254
0.5 0.1223 0.1602 0.140731
0.6 0.1344 0.1574 0.145906
0.8 0.1313 0.1671 0.148838
0.9 0.1344 0.1675 0.150702
1.0 0.1347 0.1674 0.150817
1.11 0.1367 0.1708 0.153484
1.2 0.1371 0.175 0.155653
1.5 0.1418 0.1786 0.159876
2.0 0.152 0.1823 0.167068
Table C-3. Gamma DPK of 17 Lu
DPK
d(cm) (nGy-cm 2/Bq-hr)
0.05 0.041818
0.1 0.041053
0.2 0.040348
0.24 0.040503
0.3 0.040139
0.4 0.041279
0.5 0.040474
0.6 0.041603
0.8 0.041914
0.9 0.042542
1 0.042528
1.11 0.04299
1.2 0.043133
1.5 0.043831
2 0.044953
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APPENDIX D
Stent Coordinates
159
The following table provides the set of Cartesian coordinates of the stent
geometry that was used as the radiation source in this project. The stent at 15.5 mm in
length consists of four repeating segments that are joined together to obtain a stent of
this specific desired length. Table C.1 shows the set of (x,y,z) coordinates for this
segment, which are equivalent to one fourth of the total length of the stent.
Table D-1 Stent Coordinates
1.9439 0.1321 -7.6250
X Y Z 0.1834 1.9221 -7.5000
0.0000 2.0026 -7.7500 1.2625 1.4641 -7.5000
1.4161 1.4161 -7.7500 -1.2625 1.4641 -7.5000
-1.4161 1.4161 -7.7500 -0.1834 1.9221 -7.5000
0.0000 2.0026 -7.7500 -1.9221 0.1834 -7.5000
-2.0026 0.0000 -7.7500 -1.4641 1.2625 -7.5000
-1.4161 1.4161 -7.7500 -1.4641 -1.2625 -7.5000
-1.4161 -1.4161 -7.7500 -1.9221 -0.1834 -7.5000
-2.0026 0.0000 -7.7500 -0.1834 -1.9221 -7.5000
0.0000 -2.0026 -7.7500 -1.2625 -1.4641 -7.5000
-1.4161 -1.4161 -7.7500 1.2625 -1.4641 -7.5000
1.4161 -1.4161 -7.7500 0.1834 -1.9221 -7.5000
0.0000 -2.0026 -7.7500 1.9221 -0.1834 -7.5000
2.0026 0.0000 -7.7500 1.4641 -1.2625 -7.5000
1.4161 -1.4161 -7.7500 1.4641 1.2625 -7.5000
1.4161 1.4161 -7.7500 1.9221 0.1834 -7.5000
2.0026 0.0000 -7.7500 0.2320 1.9015 -7.3750
0.1321 1.9439 -7.6250 1.2139 1.4847 -7.3750
1.3139 1.4423 -7.6250 -1.2139 1.4847 -7.3750
-1.3139 1.4423 -7.6250 -0.2320 1.9015 -7.3750
-0.1321 1.9439 -7.6250 -1.9015 0.2320 -7.3750
-1.9439 0.1321 -7.6250 -1.4847 1.2139 -7.3750
-1.4423 1.3139 -7.6250 -1.4847 -1.2139 -7.3750
-1.4423 -1.3139 -7.6250 -1.9015 -0.2320 -7.3750
-1.9439 -0.1321 -7.6250 -0.2320 -1.9015 -7.3750
-0.1321 -1.9439 -7.6250 -1.2139 -1.4847 -7.3750
-1.3139 -1.4423 -7.6250 1.2139 -1.4847 -7.3750
1.3139 -1.4423 -7.6250 0.2320 -1.9015 -7.3750
0.1321 -1.9439 -7.6250 1.9015 -0.2320 -7.3750
1.9439 -0.1321 -7.6250 1.4847 -1.2139 -7.3750
1.4423 -1.3139 -7.6250 1.4847 1.2139 -7.3750
1.4423 1.3139 -7.6250 1.9015 0.2320 -7.3750
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0.2777 1.8821 -7.2500 1.8469 0.3607 -7.0000
1.1682 1.5041 -7.2500 0.3981 1.8310 -6.8750
-1.1682 1.5041 -7.2500 1.0478 1.5552 -6.8750
-0.2777 1.8821 -7.2500 
-1.0478 1.5552 -6.8750
-1.8821 0.2777 -7.2500 
-0.3981 1.8310 -6.8750
-1.5041 1.1682 -7.2500 
-1.8310 0.3981 -6.8750
-1.5041 -1.1682 -7.2500 
-1.5552 1.0478 -6.8750
-1.8821 -0.2777 -7.2500 
-1.5552 -1.0478 -6.8750
-0.2777 -1.8821 -7.2500 
-1.8310 -0.3981 -6.8750
-1.1682 -1.5041 -7.2500 
-0.3981 -1.8310 -6.8750
1.1682 -1.5041 -7.2500 -1.0478 -1.5552 -6.8750
0.2777 -1.8821 -7.2500 1.0478 -1.5552 -6.8750
1.8821 -0.2777 -7.2500 0.3981 -1.8310 -6.8750
1.5041 -1.1682 -7.2500 1.8310 -0.3981 -6.8750
1.5041 1.1682 -7.2500 1.5552 -1.0478 -6.8750
1.8821 0.2777 -7.2500 1.5552 1.0478 -6.8750
0.3206 1.8639 -7.1250 1.8130 0.3981 -6.8750
1.1254 1.5523 -7.1250 0.4330 1.8162 -6.7500
-1.1254 1.5223 -7.1250 1.0130 1.5700 -6.7500
-0.3206 1.8639 -7.1250 -1.0130 1.5700 -6.7500
-1.8639 0.3206 -7.1250 -0.4330 1.8162 -6.7500
-1.5223 1.1254 -7.1250 -1.8162 0.4330 -6.7500
-1.5523 -1.1254 -7.1250 -1.5700 1.0130 -6.7500
-1.8639 -0.3206 -7.1250 -1.5700 -1.0130 -6.7500
-0.3206 -1.8639 -7.1250 -1.8162 -0.4330 -6.7500
-1.1254 -1.5223 -7.1250 -0.4330 -1.8162 -6.7500
1.1254 -1.5523 -7.1250 -1.0130 -1.5700 -6.7500
0.3206 -1.8639 -7.1250 1.0130 -1.5700 -6.7500
1.8639 -0.3206 -7.1250 0.4330 -1.8162 -6.7500
1.5223 -1.1254 -7.1250 1.8162 -0.4330 -6.7500
1.5223 1.1254 -7.1250 1.5700 -1.0130 -6.7500
1.8639 0.3206 -7.1250 1.5700 1.0130 -6.7500
0.3607 1.8469 -7.0000 1.8162 0.4330 -6.7500
1.0852 1.5393 -7.0000 0.4652 1.8025 -6.6250
-1.0852 1.5393 -7.0000 0.9807 1.5837 -6.6250
-0.3607 1.8469 -7.0000 -0.9807 1.5837 -6.6250
-1.8469 0.3607 -7.0000 -0.4652 1.8025 -6.6250
-1.5393 1.0852 -7.0000 -1.8025 0.4652 -6.6250
-1.5393 -1.0852 -7.0000 -1.5837 0.9807 -6.6250
-1.8469 -0.3607 -7.0000 -1.5837 -0.9807 -6.6250
-0.3607 -1.8469 -7.0000 -1.8025 -0.4652 -6.6250
-1.0852 -1.5393 -7.0000 -0.4652 -1.8025 -6.6250
1.0852 -1.5393 -7.0000 -0.9807 -1.5837 -6.6250
0.3607 -1.8469 -7.0000 0.9807 -1.5837 -6.6250
1.8469 -0.3607 -7.0000 0.4652 -1.8025 -6.6250
1.5393 -1.0852 -7.0000 1.8025 -0.4652 -6.6250
1.5393 1.0852 -7.0000 1.5837 -0.9807 -6.6250
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1.5837 0.9807 -6.6250 1.6187 -0.8982 -6.2500
1.8025 0.4652 -6.6250 1.6187 0.8982 -6.2500
0.4949 1.7899 -6.5000 1.7675 0.5477 -6.2500
0.9511 1.5963 -6.5000 0.7922 1.6638 -6.1250
-0.9511 1.5963 -6.5000 0.6538 1.7225 -6.1250
-0.4949 1.7899 -6.5000 
-0.7922 1.6638 -6.1250
-1.7899 0.4949 -6.5000 
-0.6538 1.7225 -6.1250
-1.5963 0.9511 -6.5000 
-1.7225 0.6538 -6.1250
-1.5963 -0.9511 -6.5000 
-1.6638 0.7922 -6.1250
-1.7899 -0.4949 -6.5000 -1.6638 -0.7922 -6.1250
-0.4949 -1.7899 -6.5000 -1.7225 -0.6538 -6.1250
-0.9511 -1.5963 -6.5000 -0.6538 -1.7225 -6.1250
0.9511 -1.5963 -6.5000 -0.7922 -1.6638 -6.1250
0.4949 -1.7899 -6.5000 0.7922 -1.6638 -6.1250
1.7899 -0.4949 -6.5000 0.6538 -1.7225 -6.1250
1.5963 -0.9511 -6.5000 1.7225 -0.6538 -6.1250
1.5963 0.9511 -6.5000 1.6638 -0.7922 -6.1250
1.7899 0.4949 -6.5000 1.6638 0.7922 -6.1250
0.5221 1.7784 -6.3750 1.7225 0.6538 -6.1250
0.9239 1.6078 -6.3750 0.7464 1.6832 -6.0000
-0.9239 1.6078 -6.3750 -1.6832 0.7464 -6.0000
-0.5221 1.7784 -6.3750 -0.7464 -1.6832 -6.0000
-1.7784 0.5221 -6.3750 1.6832 -0.7464 -6.0000
-1.6078 0.9239 -6.3750 0.7271 1.6913 -5.8750
-1.6078 -0.9239 -6.3750 -1.6913 0.7271 -5.8750
-1.7784 -0.5221 -6.3750 -0.7271 -1.6913 -5.8750
-0.5221 -1.7784 -6.3750 1.6913 -0.7271 -5.8750
-0.9239 -1.6078 -6.3750 0.7464 1.6832 -5.7500
0.9329 -1.6078 -6.3750 -1.6832 0.7464 -5.7500
0.5221 -1.7784 -6.3750 -0.7464 -1.6832 -5.7500
1.7784 -0.5221 -6.3750 1.6832 -0.7464 -5.7500
1.6078 -0.9239 -6.3750 0.6538 1.7225 -5.6250
1.6078 0.9329 -6.3750 0.7922 1.6638 -5.6250
1.7784 0.5221 -6.3750 -0.7922 1.6638 -5.6250
0.5477 1.7675 -6.2500 -0.6538 1.7225 -5.6250
0.8982 1.6187 -6.2500 -1.7225 0.6538 -5.6250
-0.8982 1.6187 -6.2500 -1.6638 0.7922 -5.6250
-0.5477 1.7675 -6.2500 -1.6638 -0.7922 -5.6250
-1.7675 0.5477 -6.2500 -1.7225 -0.6538 -5.6250
-1.6187 0.8982 -6.2500 -0.6538 -1.7225 -5.6250
-1.6187 -0.8982 -6.2500 -0.7922 -1.6638 -5.6250
-1.7675 -0.5477 -6.2500 0.7922 -1.6638 -5.6250
-0.5477 -1.7675 -6.2500 0.6538 -1.7225 -5.6250
-0.8982 -1.6187 -6.2500 1.7225 -0.6538 -5.6250
0.8982 -1.6187 -6.2500 1.6638 -0.7922 -5.6250
0.5477 -1.7675 -6.2500 1.6638 0.7922 -5.6250
1.7675 -0.5477 -6.2500 1.7225 0.6538 -5.6250
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0.5477 1.7675 -5.5000 1.7899 0.4949 -5.2500
0.8982 1.6187 -5.5000 0.4652 1.8025 -5.1250
-0.8982 1.6187 -5.5000 0.9807 1.5837 -5.1250
-0.5477 1.7675 -5.5000 
-0.9807 1.5837 -5.1250
-1.7675 0.5477 -5.5000 -0.4652 1.8025 -5.1250
-1.6187 0.8982 -5.5000 
-1.8025 0.4652 -5.1250
-1.6187 -0.8982 -5.5000 -1.5837 0.9807 -5.1250
-1.7675 -0.5477 -5.5000 -1.5837 -0.9807 -5.1250
-0.5477 -1.7675 -5.5000 -1.8025 -0.4652 -5.1250
-0.8982 -1.6187 -5.5000 -0.4652 -1.8025 -5.1250
0.8982 -1.6187 -5.5000 -0.9807 -1.5837 -5.1250
0.5477 -1.7675 -5.5000 0.9807 -1.5837 -5.1250
1.7675 -0.5477 -5.5000 0.4652 -1.8025 -5.1250
1.6187 -0.8982 -5.5000 1.8025 -0.4652 -5.1250
1.6187 0.8982 -5.5000 1.5837 -0.9807 -5.1250
1.7675 0.5477 -5.5000 1.5837 0.9807 -5.1250
0.5221 1.7784 -5.3750 1.8025 0.4652 -5.1250
0.9239 1.6078 -5.3750 0.4330 1.8162 -5.0000
-0.9239 1.6078 -5.3750 1.0130 1.5700 -5.0000
-0.5221 1.7784 -5.3750 -1.0130 1.5700 -5.0000
-1.7784 0.5221 -5.3750 -0.4330 1.8162 -5.0000
-1.6078 0.9239 -5.3750 -1.8162 0.4330 -5.0000
-1.6078 -0.9239 -5.3750 -1.5700 1.0130 -5.0000
-1.7784 -0.5221 -5.3750 -1.5700 -1.0130 -5.0000
-0.5221 -1.7784 -5.3750 -1.8162 -0.4330 -5.0000
-0.9239 -1.6078 -5.3750 -0.4330 -1.8162 -5.0000
0.9329 -1.6078 -5.3750 -1.0130 -1.5700 -5.0000
0.5221 -1.7784 -5.3750 1.0130 -1.5700 -5.0000
1.7784 -0.5221 -5.3750 0.4330 -1.8162 -5.0000
1.6078 -0.9239 -5.3750 1.8162 -0.4330 -5.0000
1.6078 0.9329 -5.3750 1.5700 -1.0130 -5.0000
1.7784 0.5221 -5.3750 1.5700 1.0130 -5.0000
0.4949 1.7899 -5.2500 1.8162 0.4330 -5.0000
0.9511 1.5963 -5.2500 0.3981 1.8310 -4.8750
-0.9511 1.5963 -5.2500 1.0478 1.5552 -4.8750
-0.4949 1.7899 -5.2500 -1.0478 1.5552 -4.8750
-1.7899 0.4949 -5.2500 -0.3981 1.8310 -4.8750
-1.5963 0.9511 -5.2500 -1.8310 0.3981 -4.8750
-1.5963 -0.9511 -5.2500 -1.5552 1.0478 -4.8750
-1.7899 -0.4949 -5.2500 -1.5552 -1.0478 -4.8750
-0.4949 -1.7899 -5.2500 -1.8310 -0.3981 -4.8750
-0.9511 -1.5963 -5.2500 -0.3981 -1.8310 -4.8750
0.9511 -1.5963 -5.2500 -1.0478 -1.5552 -4.8750
0.4949 -1.7899 -5.2500 1.0478 -1.5552 -4.8750
1.7899 -0.4949 -5.2500 0.3981 -1.8310 -4.8750
1.5963 -0.9511 -5.2500 1.8310 -0.3981 -4.8750
1.5963 0.9511 -5.2500 1.5552 -1.0478 -4.8750
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1.5552 1.0478 -4.8750 1.5041 -1.1682 -4.5000
1.8310 0.3981 -4.8750 1.5041 1.1682 -4.5000
0.3607 1.8469 -4.7500 1.8821 0.2777 -4.5000
1.0852 1.5393 -4.7500 0.2320 1.9015 -4.3750
-1.0852 1.5393 -4.7500 1.2139 1.4847 -4.3750
-0.3607 1.8469 -4.7500 
-1.2139 1.4847 -4.3750
-1.8469 0.3607 -4.7500 
-0.2320 1.9015 -4.3750
-1.5393 1.0852 -4.7500 
-1.9015 0.2320 -4.3750
-1.5393 -1.0852 -4.7500 
-1.4847 1.2139 -4.3750
-1.8469 -0.3607 -4.7500 
-1.4847 -1.2139 -4.3750
-0.3607 -1.8469 -4.7500 
-1.9015 -0.2320 -4.3750
-1.0852 -1.5393 -4.7500 -0.2320 -1.9015 -4.3750
1.0852 -1.5393 -4.7500 -1.2139 -1.4847 -4.3750
0.3607 -1.8469 -4.7500 1.2139 -1.4847 -4.3750
1.8469 -0.3607 -4.7500 0.2320 -1.9015 -4.3750
1.5393 -1.0852 -4.7500 1.9015 -0.2320 -4.3750
1.5393 1.0852 -4.7500 1.4847 -1.2139 -4.3750
1.8469 0.3607 -4.7500 1.4847 1.2139 -4.3750
0.3206 1.8639 -4.6250 1.9015 0.2320 -4.3750
1.1254 1.5523 -4.6250 0.1834 1.9221 -4.2500
-1.1254 1.5223 -4.6250 1.2625 1.4641 -4.2500
-0.3206 1.8639 -4.6250 -1.2625 1.4641 -4.2500
-1.8639 0.3206 -4.6250 -0.1834 1.9221 -4.2500
-1.5223 1.1254 -4.6250 -1.9221 0.1834 -4.2500
-1.5523 -1.1254 -4.6250 -1.4641 1.2625 -4.2500
-1.8639 -0.3206 -4.6250 -1.4641 -1.2625 -4.2500
-0.3206 -1.8639 -4.6250 -1.9221 -0.1834 -4.2500
-1.1254 -1.5223 -4.6250 -0.1834 -1.9221 -4.2500
1.1254 -1.5523 -4.6250 -1.2625 -1.4641 -4.2500
0.3206 -1.8639 -4.6250 1.2625 -1.4641 -4.2500
1.8639 -0.3206 -4.6250 0.1834 -1.9221 -4.2500
1.5223 -1.1254 -4.6250 1.9221 -0.1834 -4.2500
1.5223 1.1254 -4.6250 1.4641 -1.2625 -4.2500
1.8639 0.3206 -4.6250 1.4641 1.2625 -4.2500
0.2777 1.8821 -4.5000 1.9221 0.1834 -4.2500
1.1682 1.5041 -4.5000 0.1321 1.9439 -4.1250
-1.1682 1.5041 -4.5000 1.3139 1.4423 -4.1250
-0.2777 1.8821 -4.5000 -1.3139 1.4423 -4.1250
-1.8821 0.2777 -4.5000 -0.1321 1.9439 -4.1250
-1.5041 1.1682 -4.5000 -1.9439 0.1321 -4.1250
-1.5041 -1.1682 -4.5000 -1.4423 1.3139 -4.1250
-1.8821 -0.2777 -4.5000 -1.4423 -1.3139 -4.1250
-0.2777 -1.8821 -4.5000 -1.9439 -0.1321 -4.1250
-1.1682 -1.5041 -4.5000 -0.1321 -1.9439 -4.1250
1.1682 -1.5041 -4.5000 -1.3139 -1.4423 -4.1250
0.2777 -1.8821 -4.5000 1.3139 -1.4423 -4.1250
1.8821 -0.2777 -4.5000 0.1321 -1.9439 -4.1250
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1.9439 
-0.1321 
-4.1250
1.4423 
-1.3139 
-4.1250
1.4423 1.3139 
-4.1250
1.9439 0.1321 
-4.1250
0.0000 2.0026 
-4.0000
1.4161 1.4161 -4.0000
-1.4161 1.4161 -4.0000
0.0000 2.0026 
-4.0000
-2.0026 0.0000 -4.0000
-1.4161 1.4161 -4.0000
-1.4161 -1.4161 -4.0000
-2.0026 0.0000 -4.0000
0.0000 -2.0026 -4.0000
-1.4161 -1.4161 -4.0000
1.4161 -1.4161 -4.0000
0.0000 -2.0026 -4.0000
2.0026 0.0000 -4.0000
1.4161 -1.4161 -4.0000
1.4161 1.4161 -4.0000
2.0026 0.0000 -4.0000
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APPENDIX E
Code for Dose Calculation of a Radioactive Stent
with One Radioisotope
166
Part A. represents the code for the calculation of the dose surrounding a stent
coated with a pure beta emitter such as 32P. Part B shows the code of a beta and
gamma emitter such as 1mLu. Note that the final dose is given by the sum of the dose
given by both beta and gamma DPK. Both beta and gamma components are
multiplied by their respective attenuation factors.
A.
% DOSE CALCULATION ALGORITHM FOR RADIOACTIVE STENTS
% DOSE POINT KERNEL CONVOLUTION
% Author: Maria Alejandra Caceres
% Date: May 1, 2003
clear
close all
% Input Source Points
% Source points are the coordinates defining the geometry of the stent and are this
algorithm's INPUT
% The coordinates are Cartesian coordinates (x,y,z) and are in a Microsoft Excel
format
% Can include option to select only several slices for a certain radioisotope
tic
xlsread source;
source=ans;
xs=source(:,1);
ys=source(:,2);
zs=source(:,3);
% Target points are defined in the First Quadrant Only (for computation
efficiency purposes).
% The assumption therefore is that the dose is symmetrical in all quadrants.
% Loop to find x and y target points
a=1;
for z=-12:0.2:12;
for y=0:0.2:5;
for x=2.1026:0.2:5.1026;
target(a,:,:,)=[a x y z];
a=a+1;
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end
end
end
xt=target(:,2);
yt=target(:,3);
zt=target(:,4);
% Dose calculation
% P-32 tl/2= 14.28 days(342.72 hours)
% lambda=ln 2/t(1/2)
% Initial Activity = 37 kBq = 1 microCi
nsource=size(xs);
ntarget=size(xt);
sumdose=zeros(ntarget); % allocate empty matrix to store dose values
for I=1:ntarget;
for j=1:nsource;
dis=sqrt((xt(i)-xsoj))^2+(yt(i)-ysOj))^2+(zt(i)-zs(j))^2);
if dis <= 6.68
DPK=((-0.0161. *(dis.^5))+(0.0866. *(dis.^4))+(1.8508.*(dis.^3))-
(15.253. *(dis.^2))+(9.889. *dis)+104.6)./dis.^2;
'warning off MATLAB:divideByZero'
sumdose(i)=sumdose(i)+DPK;
end
end
end
dose=sumdose.*(0.37/(0.00202*1840)); %unit conversion factor
DOSE=[xt yt zt dose];
% PLOT for dose along stent axis for different depths
B.
% DOSE CALCULATION ALGORITHM FOR RADIOACTIVE STENTS Lu-177
% DOSE POINT KERNEL CONVOLUTION for both BETA and GAMMA
energies
% Author: Maria Alejandra Caceres
% Date: June 1, 2003
clear
close all
% Input Source Points
168
% Source points are the coordinates defining the geometry of the stent and is this
algorithm's INPUT
% The coordinates are Cartesian coordinates (x,y,z) and are in a Microsoft Excel
format
% Can include option to select only several slices for a certain radioisotope
tic
xlsread source2;
source2=ans;
xs=source2(:, 1);
ys=source2(:,2);
zs=source2(:,3);
xlsread lu177;
lu 177=ans;
r=1u177(:,1);
dpk=lu177(:,2);
% Target Points
% Target points are defined in the First Quadrant Only (for computation
efficiency purposes)
% The assumption therefore is that the dose is symmetrical in all quadrants.
% Loop to find x and y target points
a=1;
for z=0;
for y=0;
for x=2.10407 7 5 :0.1: 7 .10407 7 5 ;
target(a,:,:,:)=[a x y z];
a=a+1;
end
end
end
xt=target(:,2);
yt=target(:,3);
zt=target(:,4);
% Dose calculation using Lu-177
% Lu-177 t11/2= 6.734 days=161.61 6 0 hours
% lambda-ln 2/t(1/2)=0.693/161.6160=0.0043
% Initial Activity = 37 kBq = 1 microCi
% # of struts=1840
% unit conversion factor, k=0.37
nsource=size(xs);
ntarget=size(xt);
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sumdosel=zeros(ntarget); % allocate empty matrix to store dose values
%BETA DPK
for i=1 :ntarget;
for j=1 :nsource;
dis 1=sqrt((xt(i)-xsoj))^2+(yt(i)-ysoj))^2+(zt(i)-zsoj))^2);
if disl <= 2.0
DPKB=interp 1 (r,dpk,disl,'linear');
'warning off MATLAB:divideByZero';
DPKB=DPKB./dis 1.^2;
sumdosel (i)=sumdose 1(i)+DPKB;
end
end
end
beta=sumdosel.*(0.37/(0.0043*1840))*0.28; %unit conversion factor
nsource=size(xs);
ntarget=size(xt);
sumdose2=zeros(ntarget); % allocate empty matrix to store dose values
%GAMMA DPK
for i=1:ntarget;
for j=1:nsource;
dis2=sqrt((xt(i)-xs(j))^2+(yt(i)-ys0j))^2+(zt(i)-zs(j))^2);
dis2=dis2./10;
DPKG = ((0.007.*(dis2.^6))-(0.0447.*(dis2.^5))+(0.1107.*(dis2.^4))-
(0.1377. *(dis2.^3))+(0.0896. *(dis2.^2))-(0.0253. *(dis2))+0.0428)./dis2.^2;
'warning off MATLAB :divideByZero';
sumdose2(i)=sumdose2(i)+DPKG;
end
end
gamma=sumdose2.*(0.37/(0.0043*1840))*0.991; %unit conversion factor
dose=beta+gamma;
DOSE=[xt yt zt dose];
doserate=dose. *(0.0043);
RE=1+doserate./((1.386+0.0043)*0.08);
BED=dose. *RE;
table=[dose BED];
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% PLOT for dose along stent axis for different depths
I=zt(1:26: size(zt)); m=dose(1:26: size (xt));n=dose(2:26: size (xt));o=dose(3 :26:size
(xt));p=dose(6:26:size (xt)); q=dose(11:26:size (xt));
plot(l,m,'b-', l,n,'r-', l,o,'m-', l,p,'y-', l,q,'g-')
grid on
xlabel('Z(mm)')
ylabel('Dose (cGy/uCi)')
title ('Dose along stent axis')
legend('O.1mm', '0.3 mm', '0.5 mm', '1.0 mm', '2.0 mm')
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APPENDIX F
Code for Dose Calculation of a Radioactive Stent
with Two Radioisotopes
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% DOSE CALCULATION ALGORITHM FOR HYRBID (More than one
radioisotope) RADIOACTIVE STENT
% DOSE POINT KERNEL CONVOLUTION
% Author: Maria Alejandra Caceres
% Date: May 21, 2003
clear
close all
% Input Source Points
% Source points are the coordinates defining the geometry of the stent and is this
algorithm's INPUT
% The coordinates are Cartesian coordinates (x,y,z) and are in a Microsoft Excel
format
% Can include option to select only several slices for a certain radioisotope
tic
xlsread source;
source=ans;
% Selection of slices of source for a specific radioisotope
%Selection of slices corresponding to the body of the stent
s1=source(461:1380,:,:,:);
%Selection of slices corresponding to the stent edges
s2=[source(1:460,:,:, :);source(1381:1840,:,:,:)];
xsl=sl(:,1);
ysl=sl (:,2);
zsl=s(:,3);
xs2=s2(:,1);
ys2=s2(:,2);
zs2=s2(:,3);
% Target Points
% Target points are defined in the First Quadrant Only (for computation
efficiency purposes)
% The assumption therefore is that the dose is symmetrical in all quadrants.
% Loop to find x,y,z target points
a=1;
for z=-10:0.2:10;
for y=0:0.2:5;
for x=2.1026:0.2:5.1026;
target(a,:,:,:)=[a x y z];
a=a+1;
end
end
end
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xt=target(:,2);
yt=target(:,3);
zt=target(:,4);
%Dose Point Kernel Convolution
ns1=size(xs 1);
ntarget=size(xt);
sumdosel=zeros(ntarget); % allocate empty matrix to store dose values
%Isotope in body of the stent (P-32)
for i=1:ntarget;
for j=1:nsl;
dis I =sqrt((xt(i)-xs 1(j))^2+(yt(i)-ys1(j))^2+(zt(i)-zs1 (j))^2);
if disi < 6.5
DPK1=((0.009. *(disl .^6))-(0.2008. *(dis1.^5))+(1.5189. *(dis1.^4))-
(3.2879. *(dis 1.^3))-(6.8498. *(disl .^2))+(4.7765. *dis1)+105.12)./disl .^2;
%'warning off MATLAB :divideByZero'
sumdose 1(i)=sumdosel (i)+DPK1;
end
end
end
r=sumdose 1. *(0.2);
ns2=size(xs2);
ntarget=size(xt);
sumdose2=zeros(ntarget);
%Isotope in stent edges (Y-90)
for i=1:ntarget;
for k=1:ns2;
dis2=sqrt((xt(i)-xs2(k))^2+(yt(i)-ys2(k))^2+(zt(i)-zs2(k))^2);
if dis2 < 8.0
DPK2= ((0.001.*(dis2.^6))-(0.0331.*(dis2.^5))+(0.4201.*(dis2.^4))-
(2.1246. *(dis2.^3))+(2.6294. *(dis2.^2))-(7.8638. *dis2)+101.4)./dis2.^2;
sumdose2(i)=sumdose2(i)+DPK2;
end
end
end
q=sumdose2. *(3.72* 10^-2);
sumdose=r+q;
DOSE=[xt yt zt sumdose];
%Plot 1: Dose along stent axis at different radial distances from stent edge
figure;
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c=zt(1:416: size(xt)); b=sumdose(1:416: size (sumdose));d=sumdose(2:4 16: size(sumdose));e=sumdose(3 :416: size (sumdose));f=sumdose(6:416:size (sumdose));
g=r( 1:416:size (sumdose));
plot(c,b,'b-', c,d,'r-', c,e,'m-', c,f,'y-', c,g,'g-')
grid on
xlabel('Z(mm)')
ylabel('Dose (cGy)')
title ('Dose along stent axis')
legend('0.1mm', '0.3 mm', '0.5 mm', '1.0 mm', '2.0 mm')
%Plot 2: Dose as a function of radial distance calculated at three
%stent planes: a)z=0, b)z=4 c)z=8
figure;
z1=0.1:0.2:3.1;
a=sumdose(20801:20816);
b=sumdose(29121:29136);
c=sumdose(3 7025:37040);
plot(zl,a,'b-s', zl,b,'r-.', zl,c,'g-x')
grid on
xlabel('distance (mm)')
ylabel('Dose (cGy)')
title('Dose as a function of radial distance at different z planes')
legend ('z=0 mm', 'z=4 mm', 'z=8 mm')
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APPENDIX G
Code for Calculation of Biological Equivalent Dose (BED)
for Radioactive Stents with One Radioisotope
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% Radiobiological Model for P-32 stent
% Author: Maria Alejandra Caceres
% Date: May 25, 2003
% Repair half-time is 0.5 hours (30 min.)
% alpha/beta ratio is 8 Gy
% lambda is 0.00202 h"1
% repair half-life of tissue u=1.38 h-1
clear
close all
tic
load dose;
%Dose rate is equal to total dose x decay constant (hours)
doserate=dose. *(0.00202);
% Relative effectiveness per unit dose (RE)
RE=1 +doserate./((1.386+0.00202)*0.08);
%Calculation of Biological Equivalent Dose
BED=dose. *RE;
table=[dose BED];
toc
t=toc
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APPENDIX H
Code for Calculation of Biological Equivalent Dose (BED)
for Radioactive Stents with Two Radioisotopes
178
% Radiobiological Model for stent containing two radioisotopes
% Author: Maria Alejandra Caceres
% Date: May 25, 2003
% Repair half-time is 0.5 hours (30 min.)
% alpha/beta ratio is 8 Gy (.08 cGy)
clear
close all
tic
load dose;
%Dose rate is equal to total dose x decay constant of radioisotope(hours)
r=DOSE(:,4);
%a=dose from isotope1 (P-32)
%b=dose from isotope2 (Lu-177)
%L1=decay constant of P-32
%L2=decay constant of Lu-177
%P-32
doserate=a. *(0.00202);
%Lu-177
doseratel=b. *(0.00428);
u=1.386
L1=0.00202
L2=0.00428
%Relative effectiveness per unit dose
RE=1 +(0.08 *((doseratel .^2./(L 1. *(L[ +u)))+(doserate2.^2./(L2. *(L2+u)))+(2*(dosera
tel. *doserate2. *(L1+L2+2. *u))./((L1+L2). *(L1+u). *(L2+u)))./((doseratel ./L1)+(dose
rate2./L2)))
%Calculation for Biologically Equivalent Dose
BED=r. *RE;
table=[r BED];
toc
t=toc
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